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9:30 a.m.
1010-03 Gender and Regional Variation in Quality of Care for 
Ischemic Heart Disease in a Large Canadian Cohort
Beth L. Abramson, Sherryn Rambihar, Liisa Jaakkimainen, Naushaba Degani, Gladys 
Honein, Nahid Azad, Moira Kapral, Arlene Bierman, Li Ka Shing Knowledge Institute of 
St. Michael’s Hospital, Toronto, ON, Canada, University of Toronto, Toronto, ON, Canada
Background: Gender disparities in access and quality of care post acute myocardial 
infarction (AMI) are well documented. The POWER (Project to Develop an Ontario Women’s 
Health Evidence-Based Report Card) study is developing an evidence-based tool to improve 
quality and reduce disparities in care. We sought to assess whether gender, age and regional 
differences in performance existed on widely used indicators for AMI care.
Methods: Hospitalizations, physician claims and drug beneﬁt data were used to evaluate 
post AMI quality indicators in the Ontario population 65+ years including care by 
cardiologist in hospital, prescriptions for beta blockers, ACE inhibitors and/or ARBs and 
statins one year post discharge, and angiography within 3 months post AMI. Sex and age 
(65-79 years vs 80+ years) stratiﬁed rates were calculated at the provincial and Local 
Health Integration Network levels (LHIN).
Results: 9,882 patients were hospitalized with AMI during 2005/06. Of these, 7,961 were 
alive one year post-discharge and medication use was assessed. Men and women had 
similar rates of beta blocker and ACE/ARB use. However women were signiﬁcantly less 
likely to use statins (71.5% vs 77.8%), undergo angiography post-AMI (36.0% vs 46.8%), 
and to receive care from a cardiologist. Differences persisted after age-adjustment.
The very old (80+ years) were less likely to see a cardiologist (32.4% vs 41.4%), ﬁll 
prescriptions for beta blockers, ACE/ARBs (69.5% vs 75.9%) and statins (67.1% vs 
79.5%), or to undergo angiography within 3 months post AMI (22.5% vs 57.0%) than 
those age 65-79.There was signiﬁcant regional variation in care, for example in medication 
prescription patterns across LHINs. Angiography rates post AMI ranged from a 40%-68%. 
The magnitude of sex and age differences in performance varied across LHINs.
Conclusions: Women were less likely then men post AMI to be cared for by a cardiologist, 
receive statins or coronary angiography, but equally as likely to receive beta-blockers and 
ACE/ARBS. Age and regional differences in performance were also identiﬁed. Routine 
sex and age stratiﬁed assessment of performance indicators can be used to identify and 
target persistent disparities in quality of care.
9:30 a.m.
1010-04 The Prevalence of Regular Aspirin Use for the Primary 
Prevention of Coronary Heart Disease: The Multiethnic 
Study of Atherosclerosis
Daniel R. Sanchez, Ana V. Diez Roux, Erin D. Michos, Roger S. Blumenthal, Pamela J. 
Schreiner, Gregory L. Burke, Karol Watson, University of California at Los Angeles, Los 
Angeles, CA
Background: In 2002 the American Heart Association (AHA) recommended aspirin 
for the primary prevention of coronary heart disease (CHD) for individuals who have 
a 10-year cardiovascular risk of q10%. Few studies have analyzed and compared the 
prevalence of aspirin use for the primary prevention of CHD before and after publication 
of the AHA guidelines.
Methods: We examined regular aspirin use in 2106 high-risk White, Black, Hispanic, and 
Chinese individuals without cardiovascular disease in a population-based cohort from 
2000-2002 and 1955 individuals from the same cohort in 2005-2007. Regular aspirin use 
was deﬁned as using aspirin q3 days per week on a regular basis, presumably for primary 
prevention of CHD. High-risk was deﬁned as a 10-year CHD risk of q10% as determined 
by the Framingham risk score.
Results: In 2000-2002, 26% of the cohort were regular aspirin users. There was no 
difference in aspirin use between men (26%) and women (29%) (P = 0.24). Whites (38%) 
were more likely to use aspirin than Blacks (23%), Hispanics (15%), or Chinese (16%) (P
< 0.0005). In multivariate analyses, Blacks (OR 0.65, 95% CI 0.49-0.85), Hispanics (OR 
0.45, 95% CI 0.32-0.65), and Chinese (OR 0.37, 95% CI 0.24-0.59) were all less likely 
than Whites to use aspirin. In 2005-2007, 41% of the cohort were regular aspirin users. 
There was still no difference in aspirin use between men (41%) and women (42%) (P = 
0.61) and racial/ethnic disparities persisted. Whites (52%) continued to use aspirin more 
than Blacks (37%), Hispanics (33%), and Chinese (23%) (P < 0.0005). In multivariate 
analyses, Blacks (OR 0.61, 95% CI 0.48-0.77), Hispanics (OR 0.61, 95% CI 0.46-0.82), 
and Chinese (OR 0.34, 95% CI 0.23-0.50) were all still less likely than Whites to use 
aspirin. Multivariate analyses were adjusted for age, gender, diabetes, insurance, income, 
education, and site of enrollment.
Conclusions: Aspirin use for the primary prevention of CHD has increased since publication 
of the AHA guidelines. However, it is signiﬁcantly underutilized in this multi-ethnic, mostly 
insured cohort of high-risk patients. Efforts should be made to address racial/ethnic disparities 
in regular aspirin use and raise awareness of the current AHA guidelines.
9:30 a.m.
1010-05 Return to Work in Patients With Stable Multivessel 
Coronary Disease, Who Underwent to On-Pump Versus 
Off-Pump Surgery
Celia Nogueira, Myrthes Takiuti, Priscyla Girardi, Teryo Nakano, Fernando Costa, Miguel 
Moretti, Felipe Paulitsch, Cibele Garzillo, Neuza Lopes, Noedir Stolf, Whady Hueb, 
Heart Institute University of Sao Paulo, Sao Paulo, Brazil
Background: Coronary artery bypass graft surgery (CABG) is effective in relieving angina 
and restoring life expectancy in patients with coronary artery disease. Off-pump surgery 
may improve quality of life and consequently patients might return the work earlier. We 
analyzed return to work in patients who underwent on-pump and off-pump surgery.
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9:30 a.m.
1010-01 Multidisciplinary Discharge Protocol Reduces Long-
Term Outcomes in Acute Coronary Syndromes
M. Zubair Jafar, Zia Rab, Lisa Pedevillano, Dannyaal Moin, David Weinreich, Asma 
Siddiqui, Daniel Odea, Hudson Valley Heart Center, poughkeepsie, NY
Background:Despite ample data , patients who present with acute coronary syndrome (acs 
) are not treated according to published guidelines. We hypothesized that a multidisciplinary 
protocol mandated approach to ACS would result in a reduction in long term cardiac events.
Methods:. An aggressive guidelines based mandated protocol was begun in 2006 for all 
patients being discharged with a diagnosis of acs. Pts were required to be d/c on ASA, 
Plavix, Beta blockers, ACE inhibitors, high dose statins(unless medically contraindicated) 
as well as instructed on smoking cessation and cardiac rehab. We retrospectively 
compared 304 consecutive patients (pre) that were discharged prior to initiation of the 
protocol to 354 pts(post) that were discharged after initiation. The primary endpoint was 
death, mi or revascularization @ 1 year.
Results:. An aggressive guidelines based mandated protocol was begun in 2006 for all 
patients being discharged with a diagnosis of acs. Pts were required to be d/c on ASA, 
Plavix, Beta blockers, ACE inhibitors, high dose statins(unless medically contraindicated) 
as well as instructed on smoking cessation and cardiac rehab. We retrospectively 
compared 304 consecutive patients (pre) that were discharged prior to initiation of the 
protocol to 354 pts(post) that were discharged after initiation. The primary endpoint was 
death, mi or revascularization @ 1 year. There was no difference between the pre and 
post group with regards to Age(71.4 vs 71.8 p=ns), diabetes(41.5 vs. 43.2 p=ns), prior 
mi(46.5 vs. 51.6 p=ns) prior ptca(17.5 vs. 21.6 p=ns) or cabg(18.5 vs. 21.1 p=ns). In 
addition the in hospital management was similar between the two groups:ptca(44.7 
vs. 42.5 p=ns) cabg(10.1 vs. 12.5 p= ns) and medical therapy(45.2 vs. 45.0 p=ns). The 
discharge ASA rate increased from 84% to 99%; B blocker use increased from 88% to 
99%, ACE inhibitor increased from 73.8% to 95% and plavix use increased from 80.2% to 
94.5%. The one year combined endpoint of death ,mi and revascularization was reduced 
from 14.9%(pre) to 9.0%(post) (p=.023).
Conclusions:A protocol mandated multidisciplinary approach increases compliance with 
guidelines and results in decreased cardiac event rates @ 1 year
9:30 a.m.
1010-02 Inﬂuence of Transfer-In Rates on Quality of Care and 
Outcomes at Receiving Hospitals in Patients With Non-
ST-Elevation Acute Coronary Syndromes
Rajendra H. Mehta, Anita Y. Chen, Eric D. Peterson, Matthew T. Roe, Duke Clinical 
Research Institute, Durham, NC
Background: Patients (pts) with non-ST-elevation MI (NSTEMI) are frequently transferred 
to tertiary hospitals for revascularization from hospitals lacking such capabilities. Given that 
pts who undergo invasive cardiac procedures are younger and have fewer comorbidities 
compared with pts managed medically, the relative proportion of transfer-in pts at tertiary 
hospitals may inﬂuence comparisons of quality and guidelines adherence.
Methods: We evaluated 142,092 NSTEMI pts treated at 396 revascularization capable 
sites in CRUSADE (2001-2006). Transfer-in pts were included if they arrived at the 
receiving hospital <24 hrs of their ﬁrst hospital presentation. Hospitals were categorized 
into 3 groups based upon the transfer-in rates (low, intermediate and high) and 
compared treatments among eligible pts (acute and discharge medications given Class I 
recommendations in the ACC/AHA guidelines) and hospital outcomes.
Results: Acute and discharge composite adherence scores improved and mortality 
decreased with increasing proportion of transfer-in pts, both among transferred as well as 
directly admitted pts (table).
Conclusions: The proportion of NSTEMI pts transferred into tertiary hospitals appears 
to be associated with a higher quality of care of both pts transferred and directly admitted 
to these hospitals. Whether these ﬁndings are the result of the concentration of lower-
risk pts at high transfer-in hospitals or improved care processes resulting in better care 
requires further study.
Hospital Tertiles Based onTransfer-in Rates and Composite Adherence Scores 
and Outcomes
Transfer-in Patients Number of Patients
Acute
Adherence
Score (%)
Discharge
Adherence
Score (%)
In-hospital
Mortality 
(%)
Hospitals with low transfer-in rates (0-9.4%) 1350 80.9 83.4 2.9
Hospitals with intermediate transfer-in 
rates (>9.4%-26.5%) 8827 83.5 83.1 3.2
Hospitals with High transfer-in rates 
(>26.5%-77.7%) 23848 84.8 84.2 3.1
Directly Admitted Patients
Hospitals with low transfer-in rates 
(0-9.4%) 32800 76.4 78.4 4.5
Hospitals with intermediate transfer-in 
rates (>9.4%-26.5%) 42217 78.3 78.4 4.3
Hospitals with High transfer-in rates 
(>26.5%-77.7%) 33050 80.3 81.3 4.1
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Methods: Patients with multivessel coronary disease, preserved ventricular function, and 
stable angina were randomized to on-pump and off-pump surgery. Baseline characteristics 
were similar among patients randomized to both strategies. Quality of life was measured 
with SF-36 Questionnaire. Patients were interviewed before the procedure, and 6 months 
and 12 months after surgery.
Results: Of 202 patients randomized between January 2002 and November 2006, 107 
underwent on-pump and 95 underwent off-pump surgery. Of those in the off-pump group, 
a signiﬁcant reduction occurred in the duration of surgery (4.08h vs. 5.04h, p<0.001), 
hospital stay (7.35 days vs. 10.07 days, p<0.001), need of a ventilator (7.44h vs. 10.08h, 
p<0.001), ICU (1.73 days vs. 2.06 days, p<0.001), and need of a blood transfusion 
(31.65% vs. 61.87%, p<0.001). In the on-pump group, 65.3% returned to work; in the 
off-pump group, 75.5 returned to work (p = 0.285). Both groups showed improvement in 
functional and physical capacity. Conclusion: The return to work was very early in the 
off-pump group. CABG produced an improvement in quality of life independently of the 
operative strategy.
9:30 a.m.
1010-06 ECG Detection Of Murine Chagasic Cardiomyopathy
Cade T. Lawrence, Christopher S. Eickhoff, John E. Sagartz, Leesa A. Bryant, Simil S. 
Gala, Michelle Bierig, Arthur J. Labovitz, Daniel F. Hoft, St. Louis University, St . Louis, MO
Background: Chagas disease, caused by T. cruzi, is a common cause of infectious 
myocarditis. Recent clinical treatment trials and vaccine studies indicate that chagasic 
immunopathology is directed against the parasite and not self-antigens. Therefore, 
vaccines may protect against disease progression. Certain combinations of mouse and 
parasite strains produce signiﬁcant histopathology and can be used for safety analyses of 
new vaccination strategies. The goals of this study were to determine: 1) if the development 
of Chagasic cardiomyopathy in the murine model could be identiﬁed by ECG, and 2) 
whether Chagasic ECG changes would correlate with histopathologic ﬁndings.
Methods: 3 groups of 10 BALB/c mice, 1 group of 10 C57BL/6 mice and 1 group of 10 
C3H mice were infected with one of three different parasite strains and evaluated weekly 
by ECG. One minute telemetry recordings were obtained for each mouse in 3 leads. 
Mean QT intervals for naïve and matched infected groups were calculated and compared. 
Prolonged QT was deﬁned as > mean QT +2SD of all mice at baseline. A subset of mice 
was periodically harvested for blinded histopathologic evaluation to determine whether 
ECG changes correlated with development of pathology. A pathology score of 0-4 was 
used to grade inﬂammation.
Results: The mean + 2SD QT among all mice at baseline was 0.035s. Signiﬁcantly 
increased proportions of infected BALB/c mice displayed prolonged QT intervals between 
3-8 weeks post-infection. In addition, signiﬁcantly prolonged mean QT intervals were 
detected in BALB/c mice infected with all strains 3-8 weeks post-infection. Prolonged 
mean QT intervals detected in infected BALB/c mice signiﬁcantly correlated with chagasic 
histopathologic changes.
Conclusions: This study demonstrated that T. cruzi infection in BALB/c mice resulted in 
signiﬁcantly prolonged QT intervals 3-8 weeks post-infection, correlating positively with 
the development of histopathologic changes. These results indicate that ECG can be used 
as a non-invasive method to screen for immune-mediated damage resulting in chagasic 
cardiomyopathy in the murine model.
9:30 a.m.
1010-07 Twenty-Four Hours Nurse Telephone Service Improves 
Clinical Outcomes in Patients With Chronic Heart 
Failure
Haiyong Zhang, Yuzhi Shen, Zhiyong Zhang, Feng Feng, Wenmin Zhao, Yue Yin, Lin 
Zhang, Heart Center, Beijing Chaoyang Hospital,Capital Medical University, Beijing, 
People’s Republic of China
Background: Growing studies interventions combining discharge education and 
postdischarge management have demonstrated beneﬁts in patients with chronic heart 
failure (CHF). The beneﬁt attributable to patients nurse 24 hours telephone service alone 
is not clearing. We hypothesized that nurse 24 hours telephone service in conjunction 
with ACE inhibitor, diuretics, beta-blocker and digoxin would improve clinical outcomes 
and costs in patients with CHF.
Methods:181 patients were randomized separated to nurse 24 hours telephone services 
group (24h-telephone, n=91) and non-24 hours telephone services (non-24h-telephone, 
n=90) group. Telephone services must tell patients how to do next step when patients 
have any questions. Clinical events and echocardiography were performed at baseline 
and after one year treatment. The primary end point of the study was the total number of 
hospital readmission and dead in the one year follow-up period.
Results:The patients receiving the nurse 24h-telephone service had a lower ratio of 
hospital readmission and death than in non-24h-telephone (p<0.01, 1.1% vs. 14.6% and 
12.2% vs. 41.6%). There is a signiﬁcant improvements on measuring of left ventricular 
ejection fraction in nurse 24h-telephone compared with non-24h-telephone (p<0.01,
51.7±0.6% vs. 42.6±0.8%); left ventricular end-diastolic dimension and left ventricular 
end-systolic dimension decrease obviously (p<0.01, 57.4±0.5mm vs.63.6±0.7mm and 
41.1±0.7mm vs. 48.9±0.8mm). Costs of care, including the costs of the intervention, 
were lower in patients receiving nurse 24h-telephone than in non-24h-telephone services 
(p<0.01, 9160.7±23.9 ¥ vs. 14441.4±77.4 ¥).
Conclusions:Our results demonstrate that the nurse 24h-telephone services in 
conjunction with ACE inhibitor, diuretics, beta-blocker and digoxin could signiﬁcantly 
improve clinical outcomes and heart function, and reduced costs of treatment in patients 
with chronic heart failure.
9:30 a.m.
1010-08 Underuse of Evidence Based Methods for Management 
of Warfarin in Atrial Fibrillation Patients in Hamilton, 
Canada
Robby Nieuwlaat, Lucy Barker, Yang-Ki Kim, John W. Eikelboom, Stuart J. Connolly, 
Population Health Research Institute, Hamilton, Canada
Background: Atrial ﬁbrillation (AF) patients at risk for stroke achieve maximum beneﬁt 
from warfarin when the international normalized ratio is kept between 2 and 3. There is 
strong evidence for 3 different methods of anticoagulation management, which improve 
time in therapeutic range: anticoagulation clinics, standardized dosing nomogram 
(especially computerized) and patient self-dosing with point-of-care device. We assessed 
the use of these evidence based methods for warfarin dosing of AF patients in a Canadian 
urban area in 2008.
Methods: For this cross-sectional survey, a questionnaire assessing methods of - and 
perceived difﬁculties with - warfarin dosing was sent to all registered general practitioners 
(GP; n=411) and specialists (internists, hematologists, and cardiologists; n=105) in the 
Hamilton (Ontario) area in 2008. All variables were categorical and differences were 
tested with chi-square test.
Results: The questionnaire was returned by 200 GPs (49%) and 48 specialists (46%). 
Evidence based methods were used for at least some patients by 49% of GPs vs 72% 
of specialists (p=0.01): anticoagulation clinic 23% vs 60% (p<0.001), manual dosing 
algorithm 30% vs 29% (p=0.89), computerized dosing programme 5% vs 0% (p=0.21), 
patient self-dosing 5% vs 7% (p=0.58). The use of an evidence based method for warfarin 
dosing was more likely when GPs were assisted by a practice nurse (79% vs 35%; 
p<0.001) and less likely when GPs had <10 AF patients on warfarin in their practice (31% 
vs 52%; p=0.02). Only 7% of GPs and 3% of specialists (p=0.567) indicated that they had 
problems with warfarin management, and 84% of GPs and 88% of specialists (p=0.877) 
indicated that they had difﬁculties in less than 1 in 4 AF patients.
Conclusion: Despite widespread availability of proven methods for improving control of 
anticoagulation, about half of GPs and a quarter of specialists in a typical Canadian 
city do not use evidence based warfarin dosing in AF patients. Addressing this failure to 
implement Best Practice could rapidly improve outcomes in AF patients.
9:30 a.m.
1010-09 Underuse of Appropriate SPECT Myocardial Perfusion 
Imaging Based on the Appropriateness Criteria for 
SPECT Myocardial Perfusion Imaging
William C. Daniel, John Spertus, Cardiovascular Consultants, Kansas City, MO, Mid 
America Heart Institute, Kansas City, MO
Background: Threats to quality of care include both overuse and underuse for those who 
could potentially be better treated. The ACCF Appropriateness Criteria for Myocardial 
Perfusion Imaging (MPI), were primarily developed to curb the growth of cardiac imaging, 
primarily among those patients who would not beneﬁt from the test. Conversely, ACs 
also provide a foundation for examining the frequency with which patients deemed by an 
expert panel to be appropriate for imaging - a cohort for whom there is potential underuse 
of the procedure.
Methods: We reviewed all patient visits from 12/07 through 5/08 at a single cardiology 
practice and classiﬁed the indications for MPI according to the ACs to describe the 
proportion of patients who did not get MPI, despite being classiﬁed as appropriate for 
such testing to describe the potential underuse of MPI. We limited the categorization to 
those with prior revascularization procedures, high Framingham risk or with diabetes.
Results: Among 23,284 visits, 10% of patients would have been considered appropriate, 
but did not receive MPI (Table). If considering the uncertain indications as potentially 
appropriate for MPI, 16% of patients may have beneﬁted from MPI.
Conclusions: Even amongst a high-volume, single-specialty cardiology practice, 
signiﬁcant underuse of MPI may be present. Future studies examining the outcomes of 
eligible patients who did and did not receive MPI are needed to examine the feasibility of 
applying ACs to improve the quality of cardiovascular care.
Results
Dec 07-May 08 N A A + U
Total Visits 23284
# with No MPI within 2 years 12427
# CABG >5 years (no MPI) 829 829 829
# PCI > 2 years (no MPI) 1255 0 1255
# Framingham High Risk 244 244 244
# DM 1319 1319 1319
Total 2392 3647
9:30 a.m.
1010-10 A National Survey of Decision-Making in Patients With 
Coronary Heart Disease: Knowledge and Perspectives 
on Coronary Revascularization
John B. Wong, Mick P. Couper, Carrie Levin, John Van Hoewyk, Brian J. Zikmund-Fisher, 
Tufts Medical Center, Boston, MA, University of Michigan, Ann Arbor, MI
Background: Patient-centered care promotes informing and involving patients in 
medical decisions. No nationally representative sample has described knowledge in 
patients with coronary heart disease (CHD), so our aim was to assess their knowledge 
and perspectives. Methods: The DECISIONS survey was a nationally representative 
computer-assisted, random digit dial telephone interview sample of 3010 English 
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speaking US adults q40 years old. Knowledge questions assessed survival, angina relief, 
and recovery time, and process questions assessed information content and delivery. 
Results: In 420 adults with CHD (mean age 67, 40% women), 15% answered q3 of 5 
knowledge questions correctly and 52% answered a1 correctly. When comparing survival 
with CABG, PCI or medications, 48% felt that they were equivalent (20% felt CABG was 
better, 6% PCI, 10% MED, 16% uncertain). For angina-relief, 37% felt that they were 
equivalent (9% CABG better, 6% PCI, 31% MED, 17% uncertain). Knowledge was 
highest for younger ages (p=0.01) but was unrelated to level of education. Increased 
discussion about reasons to avoid revascularization correlated positively with increased 
knowledge (p=0.001) and was more likely for patients having PCI than CABG (27% vs 
14%, p<0.02). Patients with physicians who explained the procedures well or who had 
asked patients for their preferences tended to have higher knowledge scores. In patients 
who felt the least informed, 6.6% answered q3 questions correctly vs 24-29% of those 
who felt more informed. Although 53% reported being asked their treatment preferences, 
82% had their preferred amount of involvement in the decision, and 58% felt extremely 
well informed (1% completely uninformed). Lastly, 81% of 72 revascularized patients were 
extremely conﬁdent in their revascularization decision, but conﬁdence was not associated 
with the amount of the discussion of pros or cons, whether patient preferences were 
discussed or whether the explanation of the reasons for revascularization was well done. 
Conclusions: Knowledge as measured in DECISIONS was generally poor. Our results 
suggest that current discussions to inform and involve patients in revascularization 
decisions could be improved.
9:30 a.m.
1010-11 Racial/Ethnic Differences in the Treatment of Acute 
Myocardial Infarction: Findings From the Get With the 
Guidelines CAD Program
Mauricio G. Cohen, Eric D. Peterson, David Dai, Gregg C. Fonarow, Adrian F. 
Hernandez, Robert O. Bonow, Sidney C. Smith, Jr., University of North Carolina at 
Chapel Hill, Chapel Hill, NC, Duke Clinical Research Institute, Durham, NC
Background: Racial/ethnic (R/E) differences in CV care have been well documented. We 
sought to determine if R/E differences in use of evidence based AMI care persist among 
hospitals participating in a national quality improvement (QI) program.
Methods: We analyzed 142,593 MI pts treated between 1/02 and 6/07 at 443 hospitals 
enrolled in GWTG-CAD, a national, prospective, observational database and QI initiative. 
R/E was categorized as Whites (n=121,528), African American (AA) (n=10,882), and 
Hispanic (n=10,183). We examined overall R/E rates of “defect-free care”, deﬁned as 
the proportion of pts receiving all eligible interventions (early ASA, D/C ASA, ACE/ARB 
-LVSD only-, beta-blockers, lipid lowering Rx, and smoking cessation); additionally, R/E 
trends were compared according to temporal trends (calendar quarters) as well as length 
of GWTG participation (program quarters).
Results: Overall rates of defect-free care were 92.2% for Whites, 91.7% for Hispanics 
and 91.1% for AA. Adj ORs (95% CI) using Whites as reference were 0.93 (0.97-0.98) for 
AA and 1.00 (0.94-1.06) for Hispanics. Defect-free care trends per calendar and program 
quarter with the respective overall and R/E differential adj ORs (95% CI) are shown in 
the ﬁgure.
Conclusions: Evidence-based MI care improved over time for all patients regardless of R/E. 
Previous differences have been minimized in contemporary practices. The remaining gaps 
should be targeted by QI programs addressing the speciﬁc needs of each racial/ethnic group.
9:30 a.m.
1010-12 Are all False Positives Alike? Tertiary Versus Referral 
Center Implications for Selection of ST-Elevation 
Myocardial Infarction Patients Undergoing Primary 
Percutaneous Coronary Interventions
Jacob M. Mathew, Joji J. Varghese, Anushree Aggarwal, Leah Turner, Lisa Page, Sheryl 
Fredrich, Jane Thompson, Frank V. Aguirre, Frank V. Aguirre, Southern Illinois University 
School of Medicine, Springﬁeld, IL
Background: The mandated emphasis on achieving expeditious mechanical reperfusion 
for ST elevation myocardial infarction (STEMI) patients heavily depends on rapid and 
appropriate emergency department (ED) physician initiated patientt selection. ECG 
misinterpretation or clinical misdiagnosis i.e. false positives, may lead to inappropriate 
patient selection for reperfusion therapy.
Methods: Between 1/2005 and 3/2008, we examined clinical characteristics, ED 
demographics and ECG ﬁndings to deﬁne factors contributing to ED false positives among 
814 presumed STEMI patients presenting directly to two tertiary primary percutaneous 
coronary intervention (PPCI) center ED’s (n=429) or nine referral ED’s (n=385) who 
underwent inter-hospital transfer for PPCI. ED physicians from both tertiary and referral 
centers directly activated the cath lab if STEMI was suspected. All patients with ischemic 
chest pain and ST elevation were triaged and underwent emergent cardiac cath. A false 
positive was deﬁned as
a) Absence of culprit vessel +/- elevated biomarkers
b) Clinically evident alternate diagnosis
Results: A total of (12%) 96 patients were classiﬁed as false positives and occurred 
more frequently within referral 17% (n=67) as compared to tertiary 7% (n=29) ED’s 
(p=<0.0001). The false positive rates were 21.5%, 16% and 6% among ED’s with annual 
patient visits of <10000/yr, 10000-30000/yr and >30000/yr respectively (p=<0.0001). 
Compared to STEMI-conﬁrmed patients (n=718), false positive patients had more history 
of bypass-surgery (p=0.007), prior PCI (0.0001) and in-hospital mortality (p=0.01).
Conclusion: Among presumed STEMI patients presenting to ED, a false positive 
diagnosis was established in 12% patients and tended to occur more commonly in lower 
volume referral EDs. Approximately 1/3rd of false positive patients had normal or no STE 
on initial ECG but had a higher prevalence of CAD . These data emphasize a continued 
need to improve patient selection for reperfusion therapy especially in lower volume EDs 
and requires cardiologists to maintain a high level awareness of alternative diagnosis in 
this high risk population.
9:30 a.m.
1010-13 Inﬂuence of Renal Function on the Use of Guideline 
Recommended Heart Failure Therapies
J. Thomas Heywood, Gregg C. Fonarow, Clyde W. Yancy, Nancy M. Albert, Anne B. 
Curtis, Wendy Gattis-Stough, Mihai Gheorghiade, Mark L. McBride, Mandeep Mehra, 
Christopher O’Connor, Dwight Reynolds, Mary N. Walsh, Scripps Clinic, La Jolla, CA, 
University of California at Los Angeles, Los Angeles, CA
Background: Guidelines exist for management of heart failure (HF) with left ventricular 
dysfunction (LVD) but renal dysfunction may limit the use of evidence-based therapy. Few 
data exist about the use of guideline-recommended therapy in outpatients with HF, LVD, 
and renal dysfunction.
Methods: IMPROVE HF is a prospective study characterizing outpatients in 167 
cardiology practices with LVD (EF a 35%). A total of 15,381 patients were evaluated 
for adherence to 7 guideline-recommended therapies for LVD. Glomerular ﬁltration rate 
(GFR) was estimated by the Modiﬁcation of Diet in Renal Disease formula and grouped 
into Stage I through Stage IV/V chronic kidney disease (CKD). For each CKD Stage, 
the number of patients treated was divided by the number eligible for therapy without 
documentation of contraindications, intolerance, or patient refusal. Chi-square analyses 
compared percent compliance by CKD Stage.
Results: Mean age and percent female increased as CKD stage increased. Compliance
differed by CKD Stage for all except CRT (Table). ACEI/ARB therapy declined sharply as 
renal function worsened; but the decrease in beta blocker use was modest. ICD use was 
more frequent in patients with Stage II or III CKD than Stage I or IV/V. CRT was used in a 
minority of eligible patients independent of CKD Stage.
Conclusions: CKD is common in HF patients with LVD and is associated with differences 
in use of guideline-recommended therapy in outpatient cardiology practice settings. 
HF Therapy* Chronic Kidney Disease (CKD) Stage Overall P-value
I
(N=1346)
II
(N=4941)
III
(N=5809)
IV/V
(N=1068)
Age (mean) 57.0 66.2 72.9 73.9 <0.001
Gender (% Male) 74.6 77.5 67.4 59.3 <0.001
ACEI/ARB,  n (%) 1134 (87.4) 3945 (83.7) 4161 (78.3) 472 (57.9) < 0.001
Beta-blockers, n (%) 1112 (90.4) 3920 (87.7) 4533 (85.4) 834 (86.2) < 0.001
Aldosterone Antagonists, n (%) 118 (48.6) 303 (37.1) 396 (37.3) 24 (37.5) 0.008
Anticoagulation for Aﬁb, n (%) 159 (68.8) 889 (69.1) 1335 (70.0) 204 (59.6) 0.002
CRT, n (%) 35 (37.6) 150 (38.9) 259 (40.4) 54 (37.8) 0.896
ICD/CRT-D, n (%) 321 (47.9) 1246 (53.5) 1492 (52.3) 256 (48.2) 0.020
HF education, n (%) 835 (62.0) 3141 (63.6) 3527 (60.7) 665 (62.2) 0.026
*Eligible patients without documented contraindications, intolerance, medical or patient 
reasons for not prescribing.
9:30 a.m.
1010-14 Potential Underdiagnosis of Sleep Apnea in Patients 
After Acute Myocardial Infarction
Tomas Konecny, Marek Orban, Fatima Sert Kuniyoshi, Christelle Van der Walt, Jose Rio 
Perez, Francisco Lopez Jimenez, Virend K. Somers, Mayo Clinic, Rochester, MN
Background: Obstructive sleep apnea (OSA) may be a common sleep disorder in patients 
with cardiovascular disease, and may contribute to cardiovascular pathophysiology. 
Recognition of the condition in patients after MI has received only limited study.
Methods: We electronically reviewed charts of 798 consecutive patients who were 
hospitalized with a diagnosis of acute myocardial infarction between January and 
September 2007. Documentation of sleep disordered breathing, and especially sleep 
apnea by the medical students, interns, residents or attending physicians were recorded.
Independently, we recruited 74 patients with acute myocardial infarction to undergo 
attended overnight polysomnography, considered to be the standard for diagnosing sleep 
disordered breathing.
Results: Of the 798 patients only 97 (12%) had had a diagnosis or evaluation for OSA 
recorded in the electronic charts. This is less than the reported prevalence of OSA in 
patients with myocardial infarction (57%).
Of the 74 patients who underwent overnight polysomnography, 51 (68%) patients were 
diagnosed with OSA based on an apnea-hypopnea index >5. OSA investigation or 
diagnosis was recorded by the primary physicians in only 10 (14%) of these patients.
Conclusion: OSA may be signiﬁcantly under-diagnosed, even though it is highly prevalent 
A370  ABSTRACTS - Quality of Care and Outcomes Assessment JACC March 10, 2009
Q
ua
lit
y 
of
 C
ar
e 
an
d 
O
ut
co
m
es
 A
ss
es
sm
en
t
in patients after acute myocardial infarction. This may be because there are possibly no 
data showing a deﬁnitive beneﬁcial effect of treating OSA on outcome after MI. Increased 
awareness of OSA among physicians and patients may lead to improved screening for 
OSA, and may possibly improve clinical course and outcome.
9:30 a.m.
1010-15 Patterns and Predictors of Discontinuation of Rhythm-
Control Therapy in Patients With Newly Diagnosed 
Atrial Fibrillation
Michael H. Kim, David Klingman, Jay Lin, David Battleman, Northwestern University, 
Chicago, IL, IMS Health, Inc., Falls Church, VA
Background: Limited information is available on the long-term use of rhythm-control 
therapy (RC) for atrial ﬁbrillation (AF). We assessed patterns and predictors of RC 
discontinuation and costs in managed care patients (pts) with newly diagnosed AF.
Methods: This retrospective cohort study included adult pts in the PharMetrics Patient-
Centric Database, newly diagnosed with AF between April 2002-March 2006, and 
with q1 RC claim within 6 months of initial diagnosis; pts with cardiac surgery in the 
previous 30 days were excluded. Pts were followed for q12 months. Outcomes included 
RC discontinuation (gap in RC coverage [days supply] q30 days) and direct medical 
costs in the ﬁrst 12 months. Predictors of discontinuation were analyzed using a logistic 
regression model.
Results: Of 3605 pts (mean age 63 years, 69% men), 35% received RC monotherapy 
and 65% combined rate-control/RC; the most common RCs were amiodarone (53%), 
sotalol (21%), and propafenone (14%). Median follow-up was 706 days. Over 12 
months, 76% discontinued initial RC (85% during all follow-up) with a median time to 
discontinuation of 89 days. Pts on amiodarone were more likely to discontinue (86%) and 
to do so sooner (median 70 days) than the overall cohort. Signiﬁcant (p < 0.05) predictors 
of RC discontinuation included cardiac arrest (odds ratio [OR] = 2.2), history of coronary 
artery bypass graft (OR = 2.0), valvular heart disease (OR = 1.7), ischemic heart disease 
(OR = 1.4), and severity of illness (Charlson score; OR = 1.1). Over 12 months, 19% had 
an AF-related hospital stay (mean duration 8 days) and 8% had an AF-related emergency 
department visit. Annual AF-related costs (mean 2007 US$ per patient) were: inpatient 
$3872, outpatient (other than laboratory/radiology) $1503, pharmacy $790, and total 
$6165. Valvular heart disease and Charlson score were signiﬁcantly (p < 0.05) associated 
with both discontinuation and AF costs.
Conclusions: Initial RC is associated with a high rate of discontinuation, especially early 
in therapy. Reasons for discontinuation and the relationship between RC discontinuation, 
AF costs, and quality of care warrant investigation.
9:30 a.m.
1010-16 Limitations of Using Cardiac Catheterization Rates 
as a Quality Measure for Non ST-Segment Elevation 
Myocardial Infarction
Shahyar M. Gharacholou, Anita Y. Chen, Karen P. Alexander, Jorge F. Saucedo, James 
de Lemos, Michael C. Kontos, Eric D. Peterson, John Rumsfeld, Matthew T. Roe, Duke 
Clinical Research Institute, Durham, NC
Background: An early invasive strategy in patients with non ST-segment elevation 
myocardial infarction (NSTEMI) is guideline recommended but variations in reported 
contraindication rates and associated patient (pt) characteristics inﬂuence utilization of 
an invasive strategy.
Methods: The ACC NCDR ACTION Registry - GWTG was used to evaluate variations in 
hospital-level reporting of contraindications to cardiac catheterization for 42,613 NSTEMI pts 
admitted to 239 hospitals with revascularization capabilities from 1/2007 - 6/2008. Hospitals 
were grouped into tertiles (low, intermediate, and high) based on rates of contraindication 
as noted on the case report form. Differences in pt clinical characteristics, use of invasive 
procedures, and acute (a 24 hrs) medication use were compared across tertiles.
Results: A total of 6,825 of 42,613 (16%) NSTEMI pts had a reported contraindication 
to cardiac catheterization. Across hospital tertiles (from low to high), co-morbidities 
increased, catheterization and PCI rates decreased, and acute medication use (aspirin, 
beta blockers, and heparin) remained similar and high. 
Patient Characteristics and Procedure Use Across Tertiles of 
Hospital-Level Cardiac Catheterization Contraindications
Hospital-level Tertile
Low 
(0-7.7%)
N=9,840
Intermediate 
(>7.7-18%)
N=17,164
High
(>18-87%)
N=15,609
P-Value
Median Age (yrs) (25th, 
75th percentiles) 65 (55,76) 66 (55,77) 69 (57,80) <0.0001
Median eGFR (ml/min) 
(25th, 75th percentiles) 79 (53,109) 76 (49,106) 66 (42,98) <0.0001
Heart failure at 
presentation 18.8% 18.3% 25.1% <0.0001
Diabetes 32.3% 33.1% 35.5% <0.0001
Peripheral Arterial 
Disease 9.9% 11.7% 13.0% <0.0001
Prior Stroke 8.1% 9.1% 10.4% <0.0001
Catheterization* 86.3% 82.6% 69.5% <0.0001
PCI* 54.6% 50.4% 40.0% <0.0001
eGFR = estimated glomerular ﬁltration rate by Cockcroft-Gault formula; PCI = 
percutaneous coronary intervention; * did not exclude patients with catheterization 
contraindication
Conclusion: Contraindications to cardiac catheterization among NSTEMI pts varies 
across hospitals, appears to relate to frequency of patient co-morbidities, but lacks 
correlation with use of recommended acute medications. These ﬁndings suggest that 
hospital proﬁling based upon use of early invasive management may have limitations as 
a quality of care measure in NSTEMI.
9:30 a.m.
1010-17 Classics and Jazz: Self-Selected or Investigator-
Selected? Anxiolytic Effects of Music in the 
Catheterization Lab
Wolfram Goertz, Klaus Dominick, Diana Ackermann, Ralf-Dieter Hilgers, Juergen vom 
Dahl, Dep. of Cardiology, Kliniken Maria Hilf, Moenchengladbach, Germany, Institute of 
Biometry, University Hospital, Aachen, Germany
Background: The anxiolytic effects of music have often been described. They are 
regulated by release of endogenous opioids and changes of the endocrinologic alarm 
reactions. Our study evaluates the effects of music therapy in patients (pts.) undergoing 
coronary angiography. The aim is to evaluate if music of different styles has different 
anxiolytic effects and if there is a difference if music is self-selected or investigator-
selected.
Methods: 200 pt. were randomized. 100 Pts. (group A) were allowed to choose between 
classical music, relaxing music, smooth jazz, or silence. In group B, pts. were randomized 
to one of these four styles. The music was chosen using several inclusion criteria: 
instrumental only, tempi 60-80 bpm, no arrhythmias, low range of dynamic changes. 
Anxiety was measured using the State-Trait Anxiety Inventary (STAI).
Results: Complete data are available for 197 pt. (65 ± 10 years, 134 male). No pt. 
requested an early stop of the music. In group A, ,,relaxation music” had the highest 
anxiolytic effect (STAI difference pre-post of 16.6 ± 13.2). In group B, the treatment effect 
was highest in the ,,classic“ arm (17.9 ± 11.2). Overall, pts. in group B had a signiﬁcantly 
higher decrease of their anxiety level (16.8 ± 10.2) as compared to group A (13.0 ± 10.8; 
ANCOVA: p = 0.0176). Pts. without music (6.2 ± 6.7) had a signiﬁcantly lower reduction of 
anxiety compared to all pt. with music (14.9 ± 10.8, ANCOVA: p < 0.0001).
Conclusions: Self-selection of music did not result in a higher reduction of anxiety as 
compared to pt. who were randomized to an investigator-selected music. Self-selection 
results only initially in a psychological advantage: pts. were uncertain which music to 
choose. Some were afraid that the operator might dislike their selection. Finally, in group 
A it was more likely that the music did not meet the expectations of pts. despite their 
selection of a certain music style. Possibly pts. in group B had lower expectations and, 
thus, a higher beneﬁt. They might saw the music as part of the therapy. Probably the 
higher effect of classical music and smooth jazz in group B are related to the higher 
attention and emotional response by musical genres which some pts. either did not know 
or even disliked.
9:30 a.m.
1010-18 False Positive Referrals for Urgent Coronary 
Angiography Among Patients With Suspected STEMI: 
Insights From a new Regional Program to Promote 
Populationwide Access to Timely Primary PCI.
Eduardo Barge-Caballero, Jose Manuel Vazquez-Rodriguez, Rodrigo Estevez-Loureiro, 
Ramon Calvino-Santos, Alejandro Rodriguez-Vilela, Guillermo Aldama-Lopez, Jorge 
Salgado-Fernandez, Pablo Pazos-Lopez, Pablo Pinon-Esteban, Xacobe Flores-Rios, 
Nicolas Vazquez-Gonzalez, Alfonso Castro-Beiras, Hospital de A Coruña, A Coruña, Spain
Background: Little is known about false positive referrals (FPR) for urgent coronary 
angiography for suspected STEMI. We aimed to assess prevalence, reasons and outcome 
of FPR in our area in the setting of a new regional program to promote populationwide 
access to timely primary PCI. Methods: Prospective registry of 1032 consecutive 
patients who underwent urgent coronary angiography for suspected STEMI at our 
hospital since the start of the program on May, 2005 to December, 2007. Main strategies 
to reduce delays were activation of the primary PCI protocol from the ﬁeld by physicians 
of Emergency Medical Services (EMS, n=215) and from Emergency Departments of 
non-PCI-hospitals by attending physicians (ED-non-PCI, n=316) and direct transfer of 
patients to the cath laboratory. Activation from the ED of the PCI hospital (ED-PCI, n=501) 
was undertaken by cardiologists. Results: 116 patients (11.2%, CI95 9.3-13.2%) did not 
undergo PCI after the coronary angiogram, including 80 (7.8%, CI95 6.1-9.4%) in whom 
no culprit coronary lesion (CCL) was identiﬁed. Among patients with no CCL, 69 (6.7%, 
CI95 5.1-8.3%) had a discharge diagnosis different to STEMI, 58 (5.6%, CI95 4.2-7.1%) 
had no signiﬁcant coronary disease and 43 (4.2%, CI95 2.9-5.5%) had normal cardiac 
biomarkers. Patients with no CCL had higher frequency of prior myocardial infarction 
(25% vs 10%, p<0.001), prior PCI (16% vs 10%, p=0.05) and left bundle branch block 
(9% vs 3%, p=0.003) than patients with CCL. Misinterpretation of prior Q-wave infarction 
(14 cases) or non-speciﬁc ST-segment abnormalities (11 cases) was the main reason 
for FPR. 30-day mortality was 5.0% with no CCL and 6.4% with a CCL (p=0.62). Deaths 
among no CCL patients were caused by aortic dissection (2 cases), aortic stenosis and 
esophageal perforation. Prevalence of no CCL was 5.8% (CI95 3.8-6.8%) in the ED-PCI 
group, 7.9% (CI95 4.1-11.8%) in the EMS group and 10.8% (CI95 7.2-14.3%) in the ED-
non-PCI group (p=0.03). Conclusions: FPR is a rather common and not benign condition 
whose main reason is misinterpretation of ECG ﬁndings. Referral by cardiologists or 
EMS physicians is associated with lower prevalence of FPR than referral by attending 
physicians at ED of non-PCI hospitals.
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1010-19 Comparison of Activated Clotting Times Obtained 
Using Hemochron and Medtronic Analyzers in Patients 
Receiving Anti-Thrombin Therapy During Cardiac 
Catheterization
Stanley Chia, Elizabeth M. Van Cott, O. Christopher Raffel, Ik-Kyung Jang, 
Massachusetts General Hospital, Boston, MA
Background: Accurate monitoring of anti-thrombin therapy with activated clotting time 
(ACT) is important to prevent thrombotic and hemorrhagic complications during cardiac 
catheterization. Signiﬁcant variability in ACT tests exists when different analyzers are used. 
Our objective was to compare ACT results obtained using Hemochron® and Medtronic 
ACT PLUS® devices and anti-Xa activity in patients undergoing cardiac catheterization.
Methods: Thirty-two patients who received unfractionated heparin or argatroban therapy 
during cardiac catheterization were enrolled. Blood sampling was performed to determine 
ACT values using Hemochron and Medtronic (with high-range cartridges) devices in all 
patients (n=130 pairs), and anti-Xa activity following heparin administration.
Results: In the heparin group, ACT tests (n=95 pairs) showed very good correlation (r=0.84, 
y=1.31x-0.81; P<0.001). However, Hemochron values were consistently higher and the 
difference more pronounced with increasing ACT (for ACT>150 sec, mean difference 
65±48 sec; P<0.001). Both Hemochron and Medtronic ACT tests correlated well with 
plasma anti-Xa levels (r=0.85, r=0.81, respectively; P<0.001); Hemochron ACT>300 sec 
corresponded to anti-Xa>1.48 IU/mL. With concomitant eptiﬁbatide therapy, the divergence 
in ACT was greater compared to heparin alone. In the argatroban group, ACT tests (n=35 
pairs) demonstrated excellent correlation (r=0.94, y=0.61x+79.9; P<0.001). In contrast to 
the heparin group, ACT values were higher with Medtronic compared to Hemochron.
Conclusion: Therefore, despite good correlation between Hemochron and Medtronic 
ACT results, and strong association with anti-Xa activity, Medtronic ACT values 
were consistently lower compared to Hemochron following heparin anticoagulation. 
Paradoxically, Medtronic ACT results were higher after argatroban therapy. Understanding 
this discrepancy is crucial when using ACT to guide invasive cardiac procedures.
9:30 a.m.
1010-20 Compliance With Dual Antiplatelet Therapy Following 
Percutaneous Coronary Intervention With Drug-Eluting 
Stents
Daniel D. Correa de Sa, Ryan J. Lennon, John F. Bresnahan, Charanjit S. Rihal, Mayo 
Clinic, Rochester, MN
Background: Compliance with dual antiplatelet therapy (DAPT) can be challenging due 
to bleeding risk and cost. This study was undertaken to examine the 6-month compliance 
with DAPT after drug-eluting stenting (DES).
Methods: In the Mayo PCI registry, all patients are contacted by trained data coordinators 
at six months, one year, and annually thereafter. We analyzed the 6-month reported 
compliance with DATP on patients who underwent successful DES from March 2003 to 
December 2006 and were free of events at 6 months.
Results: 3552 patients were classiﬁed as compliant at 6 months (48%), non-compliant 
(8%) or indeterminate (44%). 6-month compliance increased over time; p<0.001. 
Compliers were more likely to have history of CABG, type C or eccentric lesions and 
were less likely to have an Ejection fraction (EF) above 40%. There was no difference 
in mortality between compliers and non-compliers at 3 years (8.0 vs 6.0 %, p=0.38). 
Variables associated with higher mortality were age, off-label DES, diabetes mellitus, 
chronic renal failure, C type lesions and EF below 40%. Use of lipid lowering agents 
was associated with lower mortality. After adjusting for those variables, compliance with 
DAPT did not alter the 3-year rate of death, myocardial infarction, CABG or repeated 
procedures.
Conclusion: Compliance with DAPT improved signiﬁcantly over time. Our study observed 
that lower risk patients, without prior revascularization procedures and preserved EF 
were less likely to be compliant.
9:30 a.m.
1010-21 First-in-Man 18-Month Clinical Outcomes of the 
CATANIATM Coronary STent System With NanoThin 
Polyzene-F in De Novo Native Coronary Artery Lesions: 
Assessment of The LAtest Non-Thrombogenic 
ANgioplasty Stent (ATLANTA) Trial
Corrado Tamburino, Alessio La Manna, Maria E. Di Salvo, Giorgio Sacchetta, Davide 
Capodanno, Roxana Mehran, George Dangas, Thierry Corcos, Francesco Prati, 
Ferrarotto Hospital, Catania, Italy
Background: Novel approaches to modify stents have been developed to address the 
limitations of BMS and DES stents. Aim of this study was to assess safety and efﬁcacy 
of implantation of the CATANIA™ Coronary Stent System with NanoThin Polyzene®-F in 
human coronary arteries with clinical data and comprehensive intracoronary imaging.
Methods: This FIM study using the CATANIA™ stent is a prospective, single center, non-
randomized, single-arm study of 55 patients with symptomatic ischemic heart disease 
with de novo, obstructive lesions of native coronary arteries.
Results: Acute angiographic success was 100%. A core laboratory analyzed QCA and IVUS 
data immediately after stenting and at 6-month follow-up. Late lumen loss was 0.60±0.48 
mm and the percent neointimal hyperplasia volume was 27.9 ± 16.1%. In 15/55 randomly 
selected patients, 1,904 cross sections (19,028 struts) were analyzed at six months by 
optical coherence tomography. Overall, 99.5% struts were covered. Only 29/19,028 struts 
(0.15%) were malapposed. Binary angiographic restenosis was 6.8%. Full eighteen-month 
clinical follow up will be presented for the ﬁrst time next March at ACC 2009.
Conclusion: This FIM showed an excellent early and mid-term safety proﬁle and high 
level efﬁcacy of the new CATANIA™ stent in the treatment of de novo coronary lesions 
in a fairly complex population. Long term clinical 18-month data are awaited in order to 
assess if Polyzene®-F coated stents may be a durable alternative to both BMS and DES 
with reduced death, myocardial infarction, TLR and stent thrombosis without long-term 
dual antiplatelet therapy.
9:30 a.m.
1010-22 Factors Related to Delay in Transfer Time for STEMI
Chad Raymond, Deven Patel, Craig Bates, Sorin J. Brener, Inder M. Singh, Deepak 
L. Bhatt, Venu Menon, Arman Askari, Russell Raymond, Samir R. Kapadia, E. Murat 
Tuzcu, Stephen G. Ellis, Mehdi H. Shishehbor, Cleveland Clinic, Cleveland, OH
Background: For patients with STEMI being transferred for primary PCI the guidelines 
recommend a total transfer time of 40 minutes with a max 10 minute delay for the 
components of (1) patient arrival to critical care transport (CCT) activation (2) CCT 
activation to arrival (3) CCT arrival to departure from referring facility, and for (4) transfer 
time to a PCI center. We sought to determine what percentage of the patients transferred 
for primary PCI actually meet each component of the referring hospital in-door-out-door 
and transfer time intervals.
Methods: Patients with STEMI who were transferred to our institution for primary PCI 
from January 2002 to May 2007 were included. Clinical and angiographic data were 
obtained from an institutional registry. Data regarding components of local hospital in-
door-out-door and transfer time were obtained by detailed review of the medical records 
including nurse and transfer notes, and local hospital emergency room records.
Results: Data were available for 306 patients out of 566 who were transferred for primary 
PCI to our institution. The median door-to-balloon time for this cohort was 188 minutes 
(IQR = 154-256 minutes). Of these only 41% had a door-to-balloon time of less than 
120 minutes as recommended by the guidelines. Ten percent of the patients met the 10 
minutes recommended time from arrival to emergency room to CCT activation (median = 
52 minutes, IQR = 46-59 minutes); 17% met the recommended time from CCT activation 
to arrival (median = 30 minutes, IQR = 24-35 minutes); 27% met the recommended time 
from CCT arrival to departure from referring facility (median = 22 minutes, IQR = 16-26 
minutes); and 79% met the 10 minutes recommended transfer time (median = 22 minutes, 
IQR = 11-28 minutes).
Conclusions: There remains a signiﬁcant delay from patient’s arrival in local hospital to 
CCT activation, arrival, and departure. Speciﬁc protocols to activate CCT and prepare 
patients for transfer may signiﬁcantly reduce door-to-balloon time.
9:30 a.m.
1010-23 Association of Prior CABG Surgery With Early Invasive 
Therapy in Patients With Non-ST Segment Elevation 
Myocardial Infarction: A Report From the National 
Cardiovascular Data Registry (NCDR) ACTION 
Registry-GWTG
Michael S. Kim, Tracy Y. Wang, Fang-Shu Ou, Andrew J. Klein, Paul A. Hudson, John 
C. Messenger, Frederick A. Masoudi, John S. Rumsfeld, P. Michael Ho, University of 
Colorado Denver, Aurora, CO, Duke Clinical Research Institute, Durham, NC
Background: The ACC/AHA guidelines recommend an early invasive strategy for 
high-risk patients presenting with non-ST segment elevation myocardial infarction 
(NSTEMI) (Class I indication). However, little is known about adherence to this guideline 
recommendation in patients with prior coronary artery bypass graft (CABG) surgery.
Methods: This was a retrospective cohort study of 47,557 NSTEMI patients in the 
2007-2008 National Cardiovascular Data Registry (NCDR) ACTION Registry-GWTG. 
Comparing patients with and without prior CABG surgery, the primary outcomes were the 
proportion of patients undergoing early invasive evaluation (i.e., cardiac catheterization 
within 48 hours of presentation) and in-hospital mortality. Multivariable logistic regression 
with GEE analyses assessed the association between prior CABG surgery with early 
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cardiac catheterization and in-hospital mortality.
Results: A total of 8790 (18.5%) NSTEMI patients had prior CABG surgery. Patients with 
prior CABG surgery were older and male with more frequent comorbidities. Compared 
with patients without prior CABG surgery, patients with prior CABG surgery were less 
likely to undergo early cardiac catheterization (65.2% vs. 73.0%; p < 0.0001) and more 
likely to either undergo noninvasive stress testing (6.5% vs. 5.1%; p < 0.0001) or be 
managed with medical therapy alone (28.5% vs. 21.1%; p < 0.0001). In multivariable 
models, NSTEMI patients with prior CABG surgery remained less likely to undergo early 
cardiac catheterization (OR 0.84; 95% CI 0.80-0.88) compared to NSTEMI patients without 
prior CABG surgery. However, in-hospital risk-adjusted mortality did not signiﬁcantly differ 
between the two groups (OR = 0.97; 95% CI 0.86-1.09).
Conclusion: Despite their high-risk features, NSTEMI patients with prior CABG surgery 
were less likely to undergo guideline-recommended early cardiac catheterization 
compared to NSTEMI patients without prior CABG surgery. While this ﬁnding did not 
translate into higher in-hospital risk adjusted mortality, it could substantially impact 
performance measurement depending on the case mix (i.e., high proportion of prior 
CABG surgery patients) for a given hospital.
9:30 a.m.
1010-24 Case Method Learning Decreases Mortality in Patients 
With Coronary Artery Disease − Ten Years Results of a 
Randomized Controlled Study of Family Doctors
Anna Kiessling, Susanne Groot-Jensen, Peter Henriksson, Karolinska Intitutet, 
Stockholm, Sweden
Background: Despite clear evidence that lipid-lowering drugs save lives in patients with 
coronary artery disease; a gap exists between what is achieved in clinical practice and 
what is called for in guidelines. We assumed that an interactive pedagogic method such 
as Case Method Learning (CML) could facilitate the implementation of the guidelines.
The aim of this study was to evaluate the ten years mortality results in patients with 
coronary artery disease of CML assisted implementation in primary care.
Methods: A prospective randomized controlled trial performed in the Stockholm area, 
Sweden. New guidelines for secondary prevention in coronary artery disease were mailed 
to all family doctors (n=54) and presented at a common lecture for all family doctors and 
specialists in 1995. The family doctors were randomly allocated to active intervention with 
CML or to a control group. Family doctors who were randomized to the intervention group 
participated in recurrent CML dialogues at their primary health care centers during a two-
year period. A locally well-known cardiologist served as a facilitator. Consecutive patients 
(n=255) with coronary artery disease were included. The ten-year results were assessed 
as all cause mortality in the intervention and control groups.
Results: The characteristics of the two primary health care groups of patients respectively 
physicians did not differ at baseline. 44 % of the included patient in the control group had 
deceased after ten years as compared to 22 % in the intervention group (p= 0.0173; 
log rank test). Patients treated by a specialist deceased at a rate comparable to the 
intervention group (23%).
Conclusions: Case method learning for family doctors decreases the ten-year mortality 
in their coronary artery disease patients.
9:30 a.m.
1010-25 Reporting and Representation of Race in Published 
Randomized Trials
Jeffrey S. Berger, Chiara Melloni, Tracy Y. Wang, Rowena J. Dolor, Camille G. Frazier, 
Zainab Samad, Eric D. Peterson, Pamela S. Douglas, Daniel B. Mark, L Kristin Newby, 
Duke Clinical Research Institute, Durham, NC
Background: While adequate representation of speciﬁc subgroups (e.g. women and the 
elderly) in randomized controlled trials (RCTs) has been under intense scrutiny, there is a 
paucity of data on representation by race in RCTs.
Methods: We abstracted all RCTs cited by the 2007 Guidelines for CVD Prevention 
to determine whether race was reported among the baseline characteristics. Race 
categories were Caucasians, Blacks, Asians, Hispanics and ‘others’. Publication year, 
trial location and funding source were extracted.
Results: Overall, 156 trials were analyzed. Demographic data on race were reported in 
54 (35%) trials, and increased signiﬁcantly over time (Figure). Speciﬁc information on 
inclusion of Caucasians, Blacks, Asians, Hispanics, and ‘others’ was reported in 27%, 
13%, 14%, 5%, and 10%, respectively; and increased over time (P for trend <0.05 for all). 
US enrolling trials were more likely to report baseline characteristics on race (US 63% vs. 
US/non-US 62% vs. non-US 20%, P<0.01), while industry and federal/foundation funded 
RCTs reported race with similar frequency (36% vs. 38%, P=0.84).
Conclusions: Although reporting of racial composition of study populations is increasing 
over time, two thirds of all RCTs supporting a recent AHA guideline failed to provide any 
information on race. A necessary ﬁrst requirement in translating RCT evidence to patients 
of all races is information regarding racial demographics. Such information should be 
strongly encouraged in future publications.
9:30 a.m.
1010-26 High Prevalence of Persistent Lipid Abnormalities in 
High-Risk Patients Treated With Statins in Europe and 
Canada: Results of the Dyslipidemia International Study
Anslem K. Gitt, Heinz Drexel, John Feely, Jean Ferrieres, Jose-Ramon Gonzalez-
Juanatey, Kristian Korsgaard Thomsen, Lawrence Leiter, Pia Lundman, Pedro Marques 
da Silva, Terje R. Pedersen, David A. Wood, Pam S. Dellea, Francois Chazelle, John 
Kastelein, on behalf of the DYSIS Investigators, Institut fuer Herzinfarktforschung, 
Ludwigshafen, Germany
Background: The majority of patients with dyslipidemia in Europe and Canada are 
currently treated with a statin. However, many patients do not achieve recommended lipid 
targets, and persistent lipid abnormalities will continue to contribute to cardiovascular risk 
in statin-treated patients.
Methods: We performed a large cross-sectional study in 12 countries (Europe, Canada) 
in order to assess the prevalence of dyslipidemia in these patients. Since April 2008, 
13,881 consecutive statin-treated outpatients (mean age 66.0 ± 9.9 years old; 57.6% 
male) with available lipid values were recruited by primary care physicians, cardiologists, 
endocrinologists and internists. All patients had a clinical examination and their latest lipid 
values on statin (q3 month duration) were recorded.
Results: Of these patients, 15.7% were current smokers, 75.2% had hypertension, 40.6% 
diabetes, and 29.5% a family history of premature CV disease. CHD was present in 
38.2% of patients, cerebrovascular disease in 10.0% and peripheral arterial disease in 
10.1%. One third of the study population (34.6%) was obese (BMI >30 kg/m2) and 28.4%
had a metabolic syndrome (ATP III deﬁnition).
Conclusion: A majority of statin-treated patients in Europe and Canada were not at lipid 
goals and/or had abnormal levels of HDL-C and triglycerides. These results demonstrate 
the gap between guideline recommendations and clinical practice and the need for a 
more intensive and comprehensive lipid management in this high-risk population. 
Table. Percentage of statin-treated patients by lipid proﬁle and ATP III 
risk categories
Patients with 
CHD or CHD risk 
equivalent
N=9,931 (71.5%)
Patients with 2+ risk 
factors N=2,223 
(16.0%)
Patients 
with 0-1 risk 
factor
N=1,727
(12.4%)
LDL-C not at goal (1) 43.5% / 80.0% 34.6% 15.8%
Non-HDL-C not at goal (2) 71.5% 55.1% 32.6%
Low HDL-C (3) 38.5% 38.4% 2.7%
High TG (4) 41.9% 43.9% 22.4%
High TC (5) 67.9% 69.3% 69.1%
High TC / HDL-C ratio (6) 37.6% 21.2% 1.5%
LDL-C at goal with HDL-C q
40/50 mg/dL and TG < 150 
mg/dL
24.6% / 7.8% 27.7% 63.8%
CHD = coronary heart disease; LDL-C = low-density lipoprotein cholesterol; HDL-C = 
high-density lipoprotein cholesterol; TG = triglycerides; TC = total cholesterol; RF = risk 
factor
(1) q100 / 70 mg/dL (CHD/CHD equivalent), q130 mg/dL (2+ RF), q160 mg/dL (0-1 RF)
(2) q130 mg/dL (CHD/CHD equivalent), q160 mg/dL (2+ RF), q190 mg/dL (0-1 RF); % 
of patients with TG > 200 mg/dL (N=1,507) (3) < 40 mg/dL (male); < 50 mg/dL (female)
(4) q 150 mg/dL
(5) q 155 mg/dL (CHD/CHD equivalent), q 175 mg/dL (2+ RF), q 190 mg/dL (0-1 RF)
(6) q 4 (CHD/CHD equivalent), q 5 (2+ RF), q 6 (0-1 RF)
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9:30 a.m.
1010-27 Annual Case Volume Is Not a Strong Predictor 
of Bleeding Complications After Percutaneous 
Coronary Intervention: A Report From the National 
Cardiovascular Data Registry
Sunil V. Rao, Dadi Dai, Tracy Y. Wang, Matthew T. Roe, Steven P. Marso, John S. 
Rumsfeld, Ralph Brindis, Eric D. Peterson, The Duke Clinical Research Institute, 
Durham, NC
Background: Bleeding remains an important complication of percutaneous coronary 
intervention (PCI). The volume-outcome relationship as it relates to periprocedural 
bleeding has not been evaluated.
Methods: We examined data from the National Cardiovascular Data Registry 
(N=1,025,266 cases; 768 sites) between 1/2004 -12/2007 to determine the adjusted 
association between annual site PCI volume and periprocedural bleeding using a validated 
bleeding model that accounted for center clustering. Only patients who underwent PCI via 
the femoral approach were included. Bleeding was deﬁned as any clinically overt bleeding 
that was associated with a 3 g/dl decrease in hemoglobin or transfusion.
Results: The overall bleeding rate was 2.3%. 378 sites (47.9%) performed < 500 PCIs 
annually, 257 (33.4%) performed 500-999, 69 (9.0%) performed 1000-1499, 41 (5.3%) 
performed 1500-1999, and 23 (3.0%) performed > 2000. There was marked variability in 
the incidence of bleeding complications across sites (Figure). After adjusting for differences 
among patients, site PCI volume was not srongly associated with periprocedural bleeding 
(adjusted odds ratio 1.02, 95% conﬁdence interval 1.01-1.03).
Conclusions: The occurrence of bleeding after PCI is highly variable and is only weakly 
related to annual site PCI volume. Efforts to reduce bleeding complications should focus 
on aspects of a PCI program other than annual procedure volume. 
9:30 a.m.
1010-28 Direct Transfer of ST-Elevation Myocardial Infarction 
Patients for Primary Percutaneous Coronary 
Intervention From Short and Long Transfer Distances
Rodrigo Estevez-Loureiro, Eduardo Barge-Caballero, Ramon Calviño-Santos, 
Raquel Marzoa-Rivas, Jose Manuel Vazquez-Rodriguez, Jorge Salgado-Fernandez, 
Guillermo Aldama-Lopez, Nicolas Vazquez-Gonzalez, Alfonso Castro-Beiras, Complejo 
Hospitalario Universitario A Coruña, A Coruña, Spain
Background: Time to treatment and door-to-balloon delay have a strong impact in 
prognosis of patients with ST-elevation myocardial infarction (STEMI) treated with primary 
percutaneous coronary intervention (PPCI). Recent trials reported that direct transfer 
(DT) in metropolitan areas is a successful STEMI PPCI protocol by reducing these delays. 
However, the strategy of DT has not been studied in dispersed populations with a long 
distance to the hub centre. We sought to demonstrate that a program of DT reduces both 
time intervals in short and long transfer distances.
Methods: Prospective registry of 917 consecutive patients who underwent PPCI in our 
centre in the setting of a regional program of STEMI (PROGALIAM) between May 2005 
and January 2008.
Results: During this period, 193 patients (21 %) experienced DT from the ﬁeld to the 
catheterization laboratory (116 from catchment areas of non-PCI hospitals and 77 from our 
PCI-hospital area). Seven hundred and twenty-four patients (n=724) were referred from 
the Emergency Department (ED), 449 from our centre and 275 from non-PCI hospitals. 
Patients referred directly for PPCI experienced lower door-to-balloon time (median 97 
minutes; [79-126] vs. 121 minutes; [84-167], P<0.0001) and an overall shorter time to 
treatment (median 190 minutes; [143-260] vs. 264 minutes [175-397], P<0.0001) when 
compared with those referred from ED. These differences were consistent when were 
analysed in patients from our catchment area -door-to-balloon delay (median 79 minutes 
[65- 108] vs. 94 [73 - 127], P=0.001 and time to treatment interval (median 175 [124 - 
280] vs. 222[151 - 328], P=0.001)- and from long-distance transfer: door-to-balloon delay 
(median 105 [95 - 133] vs. 165 [140 - 218], P<0.0001) and time to treatment (median 196 
minutes [158 - 260] vs. 345 [254 - 461], P<0.0001). Patients in the DT group had lower 
rates of 30-day and 6-month mortality, although these differences were not signiﬁcant 
(3.2% vs. 6.4%, p=0.083 and 5.7% vs. 8.6%, p=0.192, respectively).
Conclusions:Direct transfer reduces time to treatment and door-to-balloon delay in 
patients geographically distributed around PCI-hospitals and in patients referred from 
short transfer distances.
9:30 a.m.
1010-29 A Critical Pathway for Electrical Cardioversion for Atrial 
Fibrillation as a Vehicle to Get to the Guidelines
Victor A. Umans, Esther Zwaan, Geert Kimman, MCA, Alkmaar, The Netherlands
Background: The methodology of critical pathways is known for its ability to expedite 
patient care and to better comply with the guidelines. We developed a digital critical 
pathway with full integration of nursing and physician documents.
Method: Both nurses and physicians were guided through the clinical process. Special 
attention is paid to the recommendation of the guidelines and to a variance analysis 
in case of a deviance from the pathway/guideline. The efﬁcacy endpoints were: CHAD-
score, adequate INR, patient satisfaction and walk-through time. The outcome was 
compared with the control group of 100 consecutive patients who were treated in the 
preceding 12 weeks.
Results: From 01-2008, all 550 consecutive patients who electively underwent a 
cardioversion for atrial ﬁbrillation were managed according to this pathway. The table 
summarizes the improvement in quality and variance indicators . 
quality Control Critical pathway p-value
% CHAD score 5 100 .001
% medication advice 15 100 .001
% cardioversion success 86 92 .87
% letter to fam physician 80 87 .85
variance
% inadequate INR 12 5 0.01
% no bed 0 0 0.98
Walk-through time(weeks) 96 70 .001
Part of the pathway was the introduction of a nurse out-patient clinic which reduced 
the waiting time to scheduled visits with 3 weeks and allowed us to improve patient 
knowledge on their disease management. Overall patient satisfaction increased from 
86% to 91% (p<0.01).
Conclusion: critical pathways improve standard of care and facilitate medical teams to 
comply with the guidelines. Physicians and nurses prevent duplication and spent more 
time to disease management information. Such personalized care improves patient 
satisfaction.
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3:30 p.m.
1019-01 Predictors of Guideline Adherence for Inpatient Heart 
Failure Care
Paul A. Heidenreich, Xin Zhao, Adrian F. Hernandez, Clyde W. Yancy, Gregg C. Fonarow, 
VA Palo Alto Health Care System, Palo Alto, CA
Background: The purpose of this study was to determine patient and hospital 
characteristics associated with recommended inpatient heart failure (HF) care.
Methods: We used data from the Get-With-The-Guidelines Program for patients 
hospitalized with HF to determine eligibility for assessment of left ventricular ejection 
fraction (LVEF, N=60,601), use of ACE inhibitors or angiotensin receptor blockers (ACEi/
ARBs) if LVEF<40% and no contraindications (24,130), discharge instructions (49,383), 
and smoking cessation counseling (10,152).
Results: Documentation of LVEF assessment was noted in 95%, ACEi/ARBs in 87%, 
discharge instruction in 82%, and smoking cessation counseling in 91% of eligible 
patients. Several patient and hospital characteristics were associated with performance 
measure conformity (Table). Older patients and those with renal failure were less likely 
to receive all care except for discharge instructions. Patients with higher BMI were more 
likely to receive ACEi/ARB and discharge instructions, but less likely to have LVEF 
documented or to receive smoking cessation counseling. Small hospitals (<200 beds) 
were less likely to provide all types of care compared to larger hospitals.
Conclusion: Recommended heart failure care is more likely in patients with certain 
characteristics (younger age, lower LVEF, normal renal function) and those cared for in 
larger hospitals. Programs to improve evidence-based care for HF should further address 
the reasons behind these variances in care.
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Table. Adjusted Odds Ratios For Use Of Individual HF Performance 
Measures.
LVEF 
Documentation
ACEi or ARB 
for LVEF<40%
Discharge
Instructions
Smoking
Cessation
Age (per 10yr incr.) 0.90 (0.87-0.92)
0.92 (0.88-
0.95) 1.01 (.99-1.04) 0.90 (0.84-0.97)
LVEF (per 10% 
incr.) Not applicable
0.88 (0.83-
0.92) 0.94 (0.92-0.95)
Not Signiﬁcant 
in Univariate 
Analysis
BMI (per 5 unit incr.) 0.98 (0.96-0.99)
1.04 (1.00-
1.07) 1.03 (1.01-1.04) 0.87 (0.81-0.94)
Anemia(Hg<10mg/dl) 0.90 (0.84-0.96)
0.88 (0.79-
0.98) 1.12 (1.05-1.20)
Not Signiﬁcant 
in Univariate 
Analysis
BUN (per 10 unit 
incr.)
0.98 (0.96-
0.99)
0.85 (0.83-
0.87)
Not Signiﬁcant 
in Univariate 
Analysis
0.93 (0.89-0.97)
Hospital size
(large >500 beds vs. 
small <200 beds)
2.52 (1.51-
4.21)
1.48 (1.06-
2.05) 1.46 (0.91-2.34) 1.72 (0.90-3.28)
Hospital size
(medium vs. small)
2.17 (1.55-
3.04)
1.21 (0.93-
1.58) 1.79 (1.23-2.59) 1.83 (1.25-2.68)
3:30 p.m.
1019-02 Clopidogrel Use Among Medically-Managed NSTEMI 
Patients: Insights From the NCDR ACTION Registry − GWTG
Thomas Maddox, P. Michael Ho, Tracy Y. Wang, Fang-Shu Ou, Tom Tsai, Stephen D. 
Wiviott, John S. Rumsfeld, Denver VAMC, Denver, CO, University of Colorado Denver, 
Denver, CO
Background: Clopidogrel is a Class I recommendation for medically-managed NSTEMI 
patients, yet little is known about its current clinical use. Accordingly, we studied patterns of 
clopidogrel prescription and factors associated with its non-use among eligible patients.
Methods: Using the NCDR ACTION-GWTG registry, we evaluated clopidogrel prescription 
rates at hospital discharge among medically-managed NSTEMI patients between January 
2007 - June 2008 who met CURE trial criteria (no clopidogrel contraindication, major 
bleeding during hospitalization, severe heart failure during hospitalization, or warfarin use 
at discharge). Using multi-variable regression, we identiﬁed factors associated with lack 
of clopidogrel prescription.
Results: Among 9710 eligible NSTEMI patients, 3790 (39%) were not discharged with 
clopidogrel. Patients without clopidogrel were older, more likely to be female, non-white, 
uninsured, and have fewer co-morbidities. After multivariable analysis and controlling for 
home clopidogrel use, one of the strongest associations with non-receipt of clopidogrel was 
treatment at hospitals that performed worse on other AMI performance measures (Table).
Conclusions: 39% of eligible NSTEMI patients failed to receive discharge clopidogrel 
prescription. This was more common at hospitals that performed worse on other AMI 
performance measures, suggesting that hospital-level quality improvement interventions 
may achieve higher clopidogrel prescription rates.
3:30 p.m.
1019-03 Frequent Provider Encounters Reduce Cardiovascular 
Risk Independent of Telemedicine-Based Health 
Education
Alexander Georgakis, Carol Homko, William Santamore, Mohammed A. Kashem, James 
McConnell, Andrew Freeman, Carol Duffy, Alfred Bove, Temple University Hospital, 
Philadelphia, PA
Background: Poor health knowledge has been associated with poor health outcomes. 
We used a health monitoring and educational system via the internet to improve patients’ 
health-based knowledge and reduce cardiovascular disease (CVD) risk. In this study we 
examine the effect of this telemedicine system on CVD risk knowledge among patients 
receiving frequent outpatient visits.
Methods: We randomized 388 asymptomatic patients with CVD risk >10% (Framingham 
score) to receive frequent outpatient visits (4 visits) or frequent visits plus telemedicine. 
CVD risk score and several modiﬁable risk factors including hypertension, diabetes, 
hyperlipidemia, and tobacco use were assessed four times over twelve months. Level of 
knowledge of overall health and seven CVD risk factors (diabetes, exercise, hypertension, 
lipids, nutrition, smoking, weight) was also measured. This was assessed by scoring 
a validated multiple choice questionnaire containing four questions for each health 
knowledge category. We measured differences in knowledge at baseline and at twelve 
months and compared the net change between telemedicine and control groups.
Results: At baseline, clinical characteristics of the telemedicine and control groups were 
similar. After one year, risk score (%) was reduced for all patients (baseline:17.6±9.9, 
ﬁnal:15.1±9.3, p <0.001), while hemoglobin A1c % improved only in the telemedicine 
group (telemedicine: -0.19±1.10, control: +0.02±0.99, p=0.056). Although there was a 
trend toward improved overall knowledge for all patients (p=0.06), there was no signiﬁcant 
difference between the two groups. Furthermore, there was no correlation between 
health-based knowledge and change in CVD risk.
Conclusions: Quarterly follow-up with or without telemedicine in patients with high 
CVD risk is successful in reducing cardiovascular risk. This beneﬁt does not appear to 
correlate with health-based knowledge alone. Among patients receiving frequent provider 
encounters, telemedicine provides no additional improvement in CVD risk knowledge.
3:30 p.m.
1019-04 Impact of Emergent Transfer for Percutaneous Coronary 
Intervention on ST-Elevation Myocardial Infarction 
Patients and Their Families
Jason T. Henry, Brian Lindsay, Katie M. Menssen, Ellen C. Christiansen, Barbara T. 
Unger, David M. Larson, Timothy D. Henry, Minneapolis Heart Institute Foundation at 
Abbott Northwestern Hospital, Minneapolis, MN
Background: Primary PCI is the preferred method of reperfusion in STEMI. Transfer for 
PCI is also superior to ﬁbrinolysis if it can be performed in a timely manner, although 
this requires dislocation of patients and their families from their local community. Patient 
satisfaction is increasingly viewed as an important quality indicator yet there is no data 
regarding how emergent transfer for PCI affects STEMI patient and family satisfaction.
Methods: The Minneapolis Heart Institute’s Level 1 STEMI program is a standardized 
protocol designed for PCI in STEMI patients including transfer from 31 rural and community 
hospitals currently treating 40-50 patients per month. To determine how emergent transfer 
for PCI in STEMI affects patients and families, questionnaires were given to 140 patients 
and their families, transferred from Zone 1 (up to 60 miles away) and Zone 2 (up to 210 
miles from the PCI center) prior to discharge.
Results: Responses were obtained from 100/152 (66%) patients who survived to hospital 
discharge. Mean age was 63.9 with 70.9% male. 96% of patients felt the reasons and 
process of transfer were explained and 97% felt that transfer for care was necessary. 
Despite this, 15% of patients would have preferred to stay in their local hospital. For 
families, 96% reported satisfaction with explanation of the transfer process and treatment 
plan. While 100% felt it was necessary for their family member to be transferred for 
specialized care, 9% of families would have preferred that their family member remained 
at his/her local community hospital.
Conclusions: Our results suggest that STEMI patients and families can be educated 
about the process of transfer for PCI and are eager to receive the best care possible 
despite inconvenience. Still, a signiﬁcant minority of patients and families would prefer to 
stay in their local hospital. Patients who preferred to stay in the local hospital were older, 
more likely to be female, and to be smokers. The impact on patients and their families 
needs to be considered in the development of regional systems of care in STEMI.
3:30 p.m.
1019-05 Inconsistency in the Quality of Care for Acute 
Myocardial Infarction and Heart Failure Based on 
Hospital Size
Samip Vasaiwala, John Kao, Mladen Vidovich, University of Illinois Hospital, Chicago, IL
Background: Variability in the quality of care for cardiac procedures has been well 
established, with higher volume centers performing better with fewer complications. Our 
goal was to explore a possible association between hospital size and quality of care 
measures for acute myocardial infarction (AMI) and heart failure (HF).
Methods: We analyzed 4924 hospitals from the database of the Department of Health 
and Human Services for the following quality measures: AMI and HF patients given 
angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), 
aspirin and beta-blockers (BB) on arrival and discharge, and those given smoking 
cessation counseling. Complete data were available for 1291 hospitals. Hospital size 
based on bed number per hospital was divided in tertiles: lowest (<151 beds), middle 
(152-259 beds), top (260+ beds). For statistical analysis, ANOVA with Bonferroni 
correction was performed.
Results
Lowest Tertile
(95% CI)
N=428
Middle Tertile
(95% CI)
N=417
Top Tertile
(95% CI)
N=446
p
Percent of AMI Patients Given 
ACE Inhibitor or ARB
85.5
(83.6-87.4)
86.9
(85.5-88.3)
88.5
(86.2-87.9)
.014
*#
Percent of AMI Patients Given 
Aspirin at Arrival
94.9
(94.1-95.6)
96.3
(95.7-97.0)
97.6
(97.4-97.9) .000
Percent of AMI Patients Given 
Aspirin at Discharge
90.9
(89.8-92.1)
94.5
(93.6-95.4)
97.4
(97.1-97.7) .000
Percent of AMI Patients Given BB 
on Arrival
91.3
(90.4-92.3)
93.2
(92.3-94.0)
94.7
(94.2-95.1) .000
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Percent of AMI Patients Given BB 
on Discharge
91.6
(90.5-92.7)
94.7
(93.8-95.6)
96.9
(96.6-97.3) .000
Percent of AMI Patients Given 
Smoking Cessation Advice
91.1
(89.0-93.2)
95.1
(93.9-96.4)
96.5
(95.7-97.3)
.000
#
Percent of HF Patients Given ACE 
Inhibitor or ARB
85.4
(84.3-86.5)
87.2
(86.2-88.2)
88.0
(87.2-88.7)
.001
#
Percent of HF Patients Given an 
Evaluation of LVEF
91.0
(90.1-92.0)
94.3
(93.6-94.9)
96.0
(95.6-96.3) .000
Percent of HF Patients Given 
Smoking Cessation Advice
91.1
(89.8-92.4)
93.2
(92.0-94.5)
94.4
(93.6-95.3) .000
* Group I vs. Group II = NS, # Group II vs. Group III = NS
Conclusions: Numerous studies have demonstrated an inverse relationship between 
hospital size and procedural volume on outcome of cardiac procedures. The impact of 
hospital size on guideline-based provision of medical therapy is less well established. 
Our data suggest a signiﬁcant and concerning association between hospital size and 
delivery of standard guideline-recommended medical therapy for HF and AMI. Further 
investigation in this area to identify possible system and personnel-based differences 
resulting in this discrepancy in care is warranted.
3:30 p.m.
1019-06 Two-Dimensional Intraventricular Mapping of Pressure 
and Vorticity by Digital Processing Conventional Color-
Doppler Sequences
Juan C. del Alamo, Damien Garcia, David Tanne, Cristina Cortina, Raquel Yotti, 
Francisco Fernandez-Aviles, Javier Bermejo, University of California San Diego, La 
Jolla, CA, Hospital General Universitario Gregorio Maranon, Madrid, Spain
Background. Clinical quantiﬁcation of complex ﬂow patterns and regional pressure 
differences in the LV is limited because color-Doppler methods only provide one velocity 
component. We present a new technique to obtain two-dimensional (2D) ﬂow maps from 
conventional transthoracic echocardiographic acquisitions. LV vorticity and pressure 
maps are then derived from these measurements.
Methods and Results. 2D velocity and pressure maps were calculated from color-
Doppler velocity (apical long-axis view) by solving ﬂuid mechanics equations. Clinical 
measurements in healthy volunteers showed a large anterograde vortex whose circulation 
followed the apex-base pressure difference during most of the cardiac cycle (Fig. 1). 
Validation experiments in an atrio-ventricular duplicator showed that the circulation of 
this vortex was quantiﬁed accurately (Ric = 0.7). Micromanometer measurements in pigs 
showed that apex-base pressure differences extracted from 2D maps qualitatively agreed 
with micromanometer data. Additional retrograde vortices appeared in patients with 
dilated cardiomyopathy and LV hypertrophy.
Conclusion. Mapping 2D intraventricular ﬂow by processing conventional color-Doppler 
images is feasible and accurate. This technique is fast, clinically-compliant and does not require 
any speciﬁc training. Complex ﬂow patterns and regional pressure differences within the LV can 
be readily studied in the clinical setting by processing 2D color-Doppler sequences. 
3:30 p.m.
1019-07 Detection of Errors in Facilitated Echocardiographic 
Reporting Using a Prototype Rule Generator
Sonal Chandra, Bob Arling, Joseph Rock, Kirk T. Spencer, University of Chicago, 
Chicago, IL, Philips Healthcare, Andover, MA
Facilitated reporting in which a physician selects from a drop-down menu of ﬁnding codes (FC) 
to generate an echocardiographic report has proven to be valuable. This report generation 
technique provides for consistency among readers, better report organization and quicker turn 
around of ﬁnalized reports. Although avoiding the error inherent in the dictation / transcription 
process, facilitated reporting is not error free as physicians can still select FC which are in conﬂict 
with each other. We sought to develop a tool that would automatically detect conﬂicting FC in a 
report. Methods: A prototype tool was developed which allows the user to easily generate “rules” 
consisting of FC combinations that should not appear together and then evaluate whether these 
“rules” were violated while reporting. Three sets of rules were generated: Impossible (Impos) - 
FC that cannot both be true, Incompatible (Incom) - FC combinations that, while possible, are 
physiologically unusual, Invalid (Inval) - FC which makes the use of a quantitative technique 
invalid. The rules were then applied to a database of reports to deﬁne the incidence of each error 
type. Results: A total of 2184 rules were created out of 752 total FC. 79,542 ﬁnalized reports 
were evaluated. The percentages of reports with at least one rule violation were 3.1% (Impos), 
17% (Incom) and 0.3% (Inval). The median number of rule violations per report was 1 with a 
range of 1-7. The percentages of studies with multiple errors were 9% (Impos), 25% (Incom) 
and 12 % (Inval). Conclusion: Reporting errors in facilitated reporting of echocardiograms 
are not rare. A prototype “rule” generator allows for the detection of report ﬁndings that are 
incompatible with each other and could serve as a tool to alert physician readers of important 
potential errors allowing more accurate report generation.
3:30 p.m.
1019-08 Comparison of QTinno, a Fully Automated ECG 
Analysis Program, to Semi-Automated Methods in 
Analysis of ECGs From a Drug Safety Study
Ihor Gussak, Branislav Vajdic, Ljupco Hadzijevski, Samuel George, Steven F. Francom, 
Peter Kowey, NewCardio, Inc, Santa Clara, CA
Background:Several drugs prolong cardiac repolarization and increase risk of arrhythmia. 
Early identiﬁcation of proarrhythmic effects is essential for all drugs in development. 
Current ECG analysis methods are labor-intensive and produce variable results. This 
study’s objective was to compare a novel fully automated ECG analysis method (QTinno) 
to 2 computer-assisted, manually-adjusted (semi-automated) methods in common use: 
Global Representative Beat (GRB) and Single Lead Tangent (SLT).
Methods:QTinno performs fully automated measurements on a virtual ECG lead derived 
from heart vector movement in 3D space. GRB measures QT from the earliest QRS-onset 
to the latest T-wave offset on representative beats superimposed from 12 standard leads. 
SLT measures 3 consecutive sinus rhythm beats in one lead. Annotations made by both 
semi-automated methods were manually adjusted where necessary by 3 cardiologists, 
whereas no adjustments were made in the QTinno measurements. All methods were 
applied to 1422 digital 12-lead ECGs from a Phase 1 drug study in 23 healthy subjects.
Results:Using <1 hr of computer time, QTinno returned QTcF change from time-matched 
baseline ($QTcF) that differed minimally from both GRB and SLT methods (mean pairwise 
difference, 0.1 ms between QTinno and GRB, 1.1 ms between QTinno and SLT). The 
average absolute QT and QTc intervals by QTinno were approximately 5 ms longer than 
GRB and 25 ms longer than by SLT. QTinno had lower intrinsic variability for $QTc than 
either GRB or SLT (QTinno between-subject SD 4.0 ms, GRB 5.6 ms, SLT 6.4 ms; QTinno 
within-subject SD 4.8 ms, GRB 7.4 ms, SLT 10.6 ms).
Conclusions:The methods show satisfactory agreement in detecting drug-induced QTc 
prolongation, with QTinno markedly accelerating the process and reducing the need for 
human labor. QTinno’s lower intrinsic variability for $QTcF could increase study power or 
reduce sample size in thorough QTc studies.The methods show satisfactory agreement 
in detecting drug-induced QTc prolongation, with QTinno markedly accelerating the 
process and reducing the need for human labor. QTinno’s lower intrinsic variability for 
$QTcF could increase study power or reduce sample size in thorough QTc studies.
3:30 p.m.
1019-09 An Interactive TV Platform for the Continuity of Care 
and Risk Factors Managment: “Igea-SAT”
Domenico Cianﬂone, Berzi Denise, Sergio Cornelli, Melissa DeCarolis, Alberto Monello, 
Aldo Poli, Alessandro Durante, Gabriella Borghi, Caterina Tridico, Lina Colitta, Andrea 
Mason, Antonio Carlo Bossi, and on behalf of the igeaSAT investigators, Universita’ Vita-
Salute San Raffaele, Milano, Italy, A.O.Treviglio-Caravaggio (BG), Treviglio, Italy
Telemedicine initiatives rely on three key factors: user needs, pervasive technologies and 
bidirectional communications. We developed and validated an interactive TV telemedicine 
platform for the continuity of care and risk factor control.
Hardware platform: standard TV sets, interactive set-top-boxes (STB) with Bluetooth 
and IP communications (ADSL or Satellite), webcams, scales, BP devices, glucometers, 
and telemedicine ECG recorders.Software platform: IP-TV custom application (MHP 
standards) for the patients, Oracle database, web platforms for health professionals.
The platform provides a tool for daily management and on-screen reports for weight, 
blood pressure, glucose levels, ECGs, treatment schedules. Along with the educational 
videos and videocommunication with an health professional. Physicians are given access 
via a web platform access to clinical data and can provide individual suggestions to be 
displayed on the screen of the target patient.
In the validation phase we enrolled 42 patients with diabetes and/or heart failure and/or 
hypertension for a six month trial. The system acceptance was gathered along with an 
EQ-5D quality of life questionnaire.
We observed a satisfactory compliance to the use of the system (>80%) with an improved 
control of weight, fasting glucose levels and HbA1c and blood pressure.
This interactive TV platform for telemedicine applications provides a proof of concept for 
new models of delivery of care.
/>
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3:30 p.m.
1019-10 A Novel Method for Ranking the Quality of Cardiology 
Literature
Benjamin M. Althouse, Jevin D. West, Carl T. Bergstrom, University of Washington, 
Seattle, WA
Background: Thomson Scientiﬁc’s Impact Factor is the standard measure of journal 
quality and is used routinely in making decisions ranging from choosing journal 
subscriptions to allocating research funding to deciding tenure. However it has been 
subject to much criticism over the past decade. We present a novel method for ranking 
the quality of scholarly publications, called the Eigenfactor score (http://www.eigenfactor.
org), for use as an aid to scholars and librarians for help in judging the quality of scholarly 
publications.
Methods: We employ Thomson Scientiﬁc’s Journal Citation Reports (JCR) as the source 
of our data, and use an algorithm similar to that employed by Google to rank web pages. 
The algorithm is iterative: a journal is considered inﬂuential if it is cited by other inﬂuential 
journals. The entire process can be formulated mathematically as a stochastic process.
Results: We report the methodology of calculating the Eigenfactor scores and explain the 
relevance of the measurement to decision making in academic publications. We report 
the relative rankings for the journals in Cardiology (deﬁned by the JCR categories Cardiac 
& Cardiovascular Systems and Peripheral Vascular Disease) as well as for General 
Medicine and all of science. The top 5 journals in cardiology ranked by Eigenfactor score 
are: Circulation, JACC, Circulation Research, Stroke, Arteriosclerosis Thrombosis and 
Vascular Biology, and American Journal of Cardiology. For General Medicine the top 5 
are: New England Journal of Medicine, JAMA, Lancet, PLoS Medicine, and the Annals 
of Internal Medicine.
Conclusions: We present the Eigenfactor score as a tool for academic physicians to help 
in judging the quality of a given scholarly publication. This score can be used by academic 
physicians seeking to publish in the most inﬂuential journals.
3:30 p.m.
1019-11 High-Sensitivity C-reactive Protein Versus Left Atrial 
Volume in the Prediction of First Atrial Fibrillation in 
High Risk Elderly
Grace C. Verzosa, Marion E. Barnes, Stephen S. Cha, Bernard J. Gersh, Kent R. Bailey, 
Teresa S.M. Tsang, Mayo Clinic, Rochester, MN
Background: Whether C-reactive protein (CRP) predicts ﬁrst atrial ﬁbrillation (AF) in high 
risk elderly is unclear.
Methods: SAFFIHRE is an ongoing prospective NIH-funded study of the pathophysiology 
of ﬁrst AF in persons aged q 65 years with q 2 other risk factors [hypertension 
(HTN), coronary artery disease (CAD), heart failure (HF), diabetes (DM)]. Annual 
echocardiographic left atrial (LA) volume and CRP level determination were performed.
Results:  Of 800 participants, mean age of 74 ± 6 years, 30 developed ﬁrst AF over 1.4 
± 0.9 years. A history of HTN, CAD, DM, and HF was present in 97%, 63%, 54%, and 
4%, respectively. Use of ASA, statin, and ACEi /ARB occurred in 80%, 77%, and 71% of 
cohort. CRP was low (<1 mg/L) in 37%, intermediate (1 to 2.9 mg/L) in 37%, and high (q
3 mg/L) in 26%. No relationship existed between these categories with risk of AF. CRP 
levels, analyzed continuously, were also not associated with ﬁrst AF by univariable or 
multivariable analyses. CRP was completely unrelated to LA volume (Figure). Indexed 
LA volume, was a signiﬁcant independent predictor of ﬁrst AF in univariable analyses, 
in models adjusting for age and sex (HR 1.1; 95% CI, 1.02 to 1.08; p=0.0014), and 
other clinical risk factors (p<0.001). Each 5 mL/m2 increase was associated with 1.3 fold 
increase in risk of AF event (p<0.001).
Conclusions: In this high risk elderly population that has been intensely treated with 
standard cardioprotective agents, CRP had no role while LA volume remained a robust 
predictor of ﬁrst AF. 
3:30 p.m.
1019-12 Suboptimal Oral Anticoagulant Treatment in Patients 
With Arial Fbrillation at Elevated Risk for Stroke: A 
Systematic Review
Isla M. Ogilvie, Nick Newton, Sharon A. Welner, Gregory YH Lip, BioMedCom 
Consultants inc, Montreal, QC, Canada, University Department of Medicine, City 
Hospital, Birmingham, United Kingdom
Background: Anticoagulation therapy for stroke prevention in patients with atrial 
ﬁbrillation (AF) is often suboptimal. This study evaluated the receipt of anticoagulation in 
eligible high-risk patients. Adverse event rates associated with oral anticoagulant (OAC) 
therapy from observational studies and randomized clinical trials (RCTs) were analyzed.
Methods: Literature searches identiﬁed 53 studies (2002-2008) on current treatment 
practice for stroke prevention in patients with AF, and a further 51 on adverse event rates 
(stroke, transient ischemic attack [TIA], embolism, bleeding). Percentages of patients 
eligible for OAC therapy due to prior stroke/TIA, or a ‘high-risk’ CHADS2 score (>= 2) were 
compared with those receiving prophylaxis.
Results: Of 27 studies that reported both risk level and patients treated, most showed 
underuse of OAC therapy. Treatment levels ranged from 19% to 70% for AF patients 
with prior stroke/TIA (Table). Subjects with CHADS2 score of at least 2 were also 
suboptimally treated; levels ranged from 39% to 70%, although one study reached 92.3%. 
Analysis showed higher stroke rates in hospital/general practice settings compared with 
anticoagulation clinics or RCTs; little difference was seen in major bleeding rates (Table).
Conclusions: Low levels of OAC therapy, and variation in event rates across settings, 
were observed. This indicates the need for improved management of patients with AF to 
prevent stroke in clinical practice. 
Literature review: OAC treatment levels and adverse events associated with OAC 
therapy by study setting
# of studies 
OAC therapy use
(patients with) 27 % patients treated
Prior stroke/TIA 13 19-70
CHADS2 score >=2 7 39-92.3
Other ‘high-risk’ criteria 9 23-81.9
Ischemic stroke (setting) 19 Rates (per 100 person-years)
General practice and hospital 10 1.2-3.4
Anticoagulation clinic 3 0.3-1.2
RCT 6 0-1.63
Major bleeding (setting) 24 Rates (per 100 person-years)
General practice and hospital 9 0.51-7.35
Anticoagulation clinic 6 0.8-2.1
RCT 9 0-4.1
3:30 p.m.
1019-13 The Prognostic Importance of Worsening Renal 
Function During an Acute Myocardial Infarction on 
Long-Term Prognosis
Amit P. Amin, John Spertus, Xiao Lan, Phil Jones, Donna M. Buchanan, Carole Decker, 
Frederick A. Masoudi, Mid America Heart Institute, University of Missouri - Kansas City, 
Kansas City, MO
Background:An acute decline in renal function (DRF) is an important prognostic factor in 
patients with heart failure. Although an acute DRF is also commonly seen after an acute 
myocardial infarction, its clinical signiﬁcance is unknown
Methods: 2,102 patients from the multicenter PREMIER study, surviving after myocardial 
infarction (MI), were followed for a mean of 2.6 years to assess their long-term mortality. 
Using previously established values, DRF was deﬁned as an increase in creatinine 
during hospitalization q 0.3 mg/dl above the admission value. Predictors of DRF were 
determined with multivariable logistic regression and used, along with other important 
clinical covariates, in Cox proportional hazards models to deﬁne the independent 
association of DRF with mortality.
Results:DRF was observed in 174 (8.3%) MI survivors. During follow-up (31±10 months), 
296 (14.1%) patients died, with 54 (31.0%) deaths occurring in the DRF group vs. 242 
(12.6%) in those without DRF. Age, diabetes, severe LV dysfunction, preexisting renal 
failure and systolic BP on admission were all independent predictors of DRF. After 
adjusting for these and other factors associated with long-term mortality, DRF remained 
signiﬁcantly associated with mortality (HR 1.6, 95% CI 1.02-2.5).
Conclusions:DRF occurs commonly among survivors of AMI and is signiﬁcantly 
associated with an adverse long-term prognosis. Further studies to establish whether 
prevention of DRF can improve the prognosis of these patients are needed. 
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PG may also lower risk. However, many of these reports came from low risk diabetic or 
pre-diabetic populations. How these agents affect the CV risk of high risk patients with 
documented coronary artery disease (CAD) without underlying heart failure is unknown.
Methods: Patients (N=2096) with type II diabetes, no heart failure, and CAD (stenosis >70%) 
enrolled in the Intermountain Heart registry were studied. Death and myocardial infarction 
(MI) event rates were compared between patients discharged on RG (n=209), PG (n=121), or 
other diabetic medications (n=1766). Cox Regression models adjusted for traditional CAD risk 
factors, presentation at CAD diagnosis (stable angina, unstable angina, or MI), CAD treatment 
(medical, interventional, surgical), and when available, glucose and ejection fraction (EF).
Results: Average age was 63.7±11.4 years and 65.9% were male. Average length 
of follow-up was 4.3±3.2 years. Death occurred in 30.2% (RG=17.7%, PG=16.5%, 
other=32.6%, p<0.0001) and MI in 16.3% (RG=10.5%, PG=9.9%, other=17.4%, p=0.006) 
of the patients. RG was not associated with an increased risk of death (excluding PG) 
(adjusted hazard ratio [HR]=0.78, p=0.15) or MI (HR=0.74, p=0.18) when compared to 
other diabetic medications; nor was PG when compared to other diabetic medications 
(excluding RG): death HR=0.85, p=0.48; MI HR=0.84, p=0.56. When comparing RG to 
PG (referent) no relative adverse effect on death was noted, (death HR=0.86, p=0.59; MI 
HR=0.75, p=0.43). Results were unchanged even after adjustment for glucose and EF.
Conclusion: Among a large cohort of high-risk diabetic patients without heart failure, 
neither RG nor PG was associated with an increase in the risk of CV events compared to 
other diabetic medications or compared to each other. Weak non-signiﬁcant trends toward 
lower CV risk were suggested for RG. These ﬁndings suggest that PG and RG are not 
associated with CV harm in actual practice in patients with pre-existing CAD.
3:30 p.m.
1019-17 Heart Failure Decompensation Accounts Only for a 
Minority of Readmissions in Patients Hospitalized for 
Heart Failure
Hector Bueno, Zhenqiu Lin, Maria T. Vidan, Yongfei Wang, Yun Wang, Geoffrey 
Schreiner, Jersey Chen, Joseph Ross, Sharon-Lise Normand, Elisabeth Drye, Jephta 
Curtis, John Spertus, Harlan M. Krumholz, Yale Medical School, New Haven, CT
Background: Considerable efforts have been made to predict accurately, and reduce 
the risk of readmission in patients with heart failure (HF). A number of interventions have 
proved to be effective, but the rates remain high. Most interventions are based on the 
assumption that readmissions are mainly driven by HF decompensation, but information 
about the real causes of readmissions in HF patients is lacking.
Methods: Patients ageq65 yrs hospitalized for HF during 2006 were identiﬁed from Medicare 
administrative claims. 30d all-cause readmission rates were calculated for patients who 
survived their index hospitalization. Speciﬁc causes of readmission were determined through 
the principal ICD-9 diagnosis codes and grouped into 3 mutually exclusive categories: heart 
failure, other cardiac reasons, and non-cardiac reasons. Time-to-readmission and length of 
stay (LOS) for readmission was described by medians and inter-quartile ranges (IQR).
Results: Of 501,234 hospital discharges of patients who survived a HF hospitalization, 
23.7% of patients were readmitted within 30 days, with a median time of 13 days (IQR, 
7-21 days). Heart failure accounted for 35.8% of readmissions, other cardiac causes 
for 11.5%, and non-cardiac causes for 52.7%. The most frequent non-HF cardiac 
causes of re-hospitalization were arrhythmias (33.6% of non-HF cardiac causes) and 
acute coronary syndromes (21.5%). Among non-cardiac conditions, infections were the 
most frequent (21.2%), followed by renal insufﬁciency or electrolyte disorders (17.8%), 
respiratory disorders (12.2%), non-cardiac vascular events (9.4%), and bleeding (6.5%). 
Median LOS of re-hospitalizations was 5 days (IQR, 3-8 days).
Conclusion: Non-cardiac causes of readmission are common, accounting for more than 
half of the readmissions within 30 days of discharge. Infections, renal insufﬁciency and 
electrolyte disorders account for about a ﬁfth of all the readmissions and these causes 
may be good targets for interventions to improve short-term patient outcomes.
3:30 p.m.
1019-18 Renin-Angiotensin-System and Bradykinin 
Pathway Genes Are Associated With an Increased 
Cardiovascular Risk in 10.060 Patients With Stable 
Coronary Artery Disease
Jasper J. Brugts, Moniek de Maat, Eric Boersma, Jan Danser, Roberto Ferrari, Willem 
Remme, Kim Fox, Maarten L. Simoons, Erasmus MC, Rotterdam, The Netherlands
Background: The renin-angiotensin system (RAAS) modulates blood pressure and 
water balance. Genetic defects in the RAAS may be related to cardiovascular risk.
Objective: We investigated whether genetic polymorphisms in this pathway are related 
to major cardiovascular events.
Methods: DNA was available in 10.060 patients with stable CAD. We selected 60 SNP’s 
in 10 genes of the RAAS pathways based on haplotype-tagging and functionality. Primary 
outcome measure was the incidence of cardiovasc. mortality, non-fatal MI and resuscitated 
cardiac arrest. Cox regression analysis was used to calculate hazard ratios adjusted for 
age,gender,hypertension,hypercholesterolemia, diabetes, use of beta-blockers, statins, 
ACE-inhibitors and anti-platelet-agents.
Results: In the study population, mean age was 60, 85% were male. The primary outcome 
occurred in 857 (9.0) of the patients during a mean follow-up of 4.0 years. Several genes 
indicated a strong relation with cardiovascular risk (data not shown). The strongest effect 
was seen in the angiotensinogen gene (Table 1). Four polymorphisms were identiﬁed that 
showed a clear relation with cardiovascular risk. The strongest effect was seen for rs4762 
(T174M) in the angiotensinogen gene with a 72% increased risk of events in homozygous 
174TT subjects. Haplotype analysis conﬁrmed these results.
Conclusion: This large genetic study identiﬁed several important genes related to 
cardiovascular risk, which can be used in risk prediction models.
3:30 p.m.
1019-14 Anginal Outcomes in Initial Percutaneous Coronary 
Interventions Versus Medical Therapy: A Meta-Analysis 
of Randomized Controlled Trials
John B. Wong, Cindy Wu, Thomas A. Trikalinos, Tufts Medical Center, Boston, MA
Background: Nearly all meta-analyses of initial percutaneous coronary interventions 
(PCI) versus medical therapy for non-acute coronary syndromes suggest comparable 
survival and MI-free survival. Recently, the Courage trial suggests that initial PCI improves 
angina, so our aim was to perform a systematic review and meta-analysis of randomized 
controlled trials involving PCI and medical therapy to assess long-term anginal outcomes 
for non-acute coronary syndromes. Methods: We searched Medline for randomized 
controlled trials comparing PCI and medical therapy at last reported follow-up for anginal 
outcomes. Using a random effects model, we determined odds ratio (OR, 95% CI) for 
PCI versus medical therapy for presence of angina, use of anti-anginal medications, and 
hospitalizations for angina. Heterogeneity was assessed using the I2 statistic (>50%). 
Results: Based on 14 randomized controlled trials with 8113 patients (range 44-2288) 
with mean maximum reported follow-up of 48 months (range 1.5-120), initial PCI instead 
of medical therapy signiﬁcantly reduced the likelihood of any angina at follow-up (0.70, 
0.53-0.92, 10 studies, 7044 patients, I2=75), the use of any anti-anginal medication (0.39, 
0.23-0.65, 12 studies, 5701 patients, I2=84), in particular, use of a calcium channel blocker 
(0.66, 0.50-0.86, 8 studies, 3974 patients, I2=46) and possibly use of a nitrate (0.45, 0.2-
1.01, 8 studies, 3974 patients, I2=94). PCI versus initial medical therapy did not affect 
hospitalization for angina (0.98, 0.68-1.41, 8 studies 4588 patients, I2=62) or beta-blocker 
use (0.96, 0.83-1.10, 9 studies, 4355 patients, I2=0). Our results, however, found substantial 
heterogeneity in reported results for any angina, use of any anti-anginal medication, nitrate 
use and hospitalization for angina. Conclusions: Initial PCI compared with medical therapy 
signiﬁcantly reduces the likelihood of having angina or requiring anti-anginal medication 
use. Because survival and MI-free survival appear to be comparable, patient-centered care 
should focus on patient preferences regarding the impact of angina on their daily activities.
3:30 p.m.
1019-15 A Call to Action: Rates of Noninvasive Stress Testing in 
Renal Transplant Candidates Are Dependent on Which 
Set of National Guidelines Are Applied
Scott E. Friedman, Robert T. Palac, David Zlotnick, Salvatore P. Costa, Dartmouth-
Hitchcock, Lebanon, NH
Background: The purpose of this study is to determine the variation in rates of noninvasive 
cardiac testing prior to renal transplant when different guidelines are applied: 2007 ACC/
AHA Preoperative Guidelines for Non-cardiac Surgery, 2005 National Kidney Foundation 
Guidelines (KDOQI), and an international guideline supported by the American Society 
of Transplantation (2007 Lisbon Report).
Methods: We retrospectively identiﬁed all patients who underwent a dobutamine stress 
echo as part of a preoperative evaluation prior to renal transplant over three years 
(N=159). Clinical data was collected via electronic chart review. We then applied the 
various guideline algorithms to each study subject to determine whether they would 
qualify for noninvasive testing under that guideline. We compared the projected rates of 
testing using each of the guidelines and compared the procedures generated based on 
the results of the stress tests.
Results: Projected rates of noninvasive testing for KDOQI, ACC/AHA, and Lisbon 
guidelines would have been 100%, 69%, and 22% respectively. See table. KDOQI 
approach captures the 7 PCI procedures, but tested all patients; whereas the Lisbon 
approach captures 7 PCI procedures, but with signiﬁcant less testing (110 vs. 159 
subjects). ACC/AHA approach would miss 6 of 7 PCI procedures.
Conclusions: Noninvasive testing prior to renal transplant is variable and dependent 
on which National Guideline is selected. Further efforts to resolve differences in 
recommendations are needed.
Predicted Rates of Pre-Operative Cardiac Stress Testing
National Guideline KDOQI LISBON ACC/AHA
Criteria met for non-invasive testing? Yes Yes No Yes No
N 159(100%)
110
(69.2%)
49
(30.8%)
35
(22%)
124
(78%)
Ischemia on DSE 13 (8.2%) 12(10.9%) 1 (2.0%)
3
(8.6%)
10
(8.1%)
Cardiac catheterization due to 
ischemia on DSE 12 11 1 3 9
Percutaneous intervention 7 7 0 1 6
Coronary artery bypass surgery 1 1 0 1 0
DSE with valve disease 5 5 0 1 4
Pre-operative valve surgery 2 2 0 1 1
3:30 p.m.
1019-16 Association of Rosiglitazone and Pioglitazone to Death 
and Myocardial Infarction Among Diabetic Patients With 
Coronary Artery Disease
Nazila Naderi, Heidi T. May, Benjamin D. Horne, Tami L. Bair, Jeffrey L. Anderson, 
Farangis Lavasani, Joseph B. Muhlestein, Intermountain Medical Center, Murray, UT, 
University of Utah, Salt Lake City, UT
Background: The thiazolidinediones rosiglitazone (RG) and pioglitazone (PG) are 
commonly used therapies for the treatment of type II diabetes. Recent reports have 
indicated that RG may be associated with higher cardiovascular (CV) event risk, while 
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3:30 p.m.
1019-21 Prognostic Value of Cardiac Troponin-I Elevation 
Following Percutaneous Coronary Intervention: A Meta-
Analysis
Dmitriy N. Feldman, Robert M. Minutello, Geoffrey Bergman, Issam Moussa, S. Chiu 
Wong, New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY
Background: Recent studies have suggested that troponin-T elevation after elective 
percutaneous coronary intervention (PCI) is an independent predictor of long-term 
mortality. However, the predictive value of troponin-I elevation following elective PCI is 
unclear.
Methods: Electronic and manual searches were conducted of all published studies 
reporting on the prognostic impact of troponin-I elevation after elective PCI. A meta-analysis 
was performed with all-cause mortality at follow-up (FU) as the primary endpoint.
Results: We identiﬁed 15 studies, involving 12,808 patients, published between 1998 
and 2008. Post-procedural troponin-I was elevated in 37.7% of patients, with FU 
period ranging from 3 to 45 months (mean 16.7 ± 10.2 months). The results showed 
no heterogeneity among the trials (Q-test: 11.16; I2: 0%; p=0.515). No publication bias 
was detected (Egger’s test: p=0.07). The long-term mortality in patients with troponin-I 
elevation after PCI (4.4%) was signiﬁcantly higher when compared to patients without 
troponin-I elevation (3.2%); OR 1.35 (95% CI 1.11-1.63), p=0.003 (Figure).
Conclusion: The current meta-analysis indicates that troponin-I elevation after elective 
PCI portends a 1.4-fold increase in long-term mortality. Efforts to minimize peri-procedural 
troponin-I elevation along with more intensive secondary prevention measures may help 
to improve the long-term adverse outcomes in patients undergoing elective PCI. 
3:30 p.m.
1019-22 Racial Disparities in Prescriptions for Cardioprotective 
Drugs and Coronary Bypass Surgery, and Patient 
Outcome in the Veterans Healthcare System
Jawahar L. Mehta, Zoran Bursac, Paulette Mehta, James D. Marsh, Rishi Sukhija, 
Rajesh Sachdeva, Central Arkansas Veterans Healthcare System, Little Rock, AR, 
University of Arkansas for Medical Sciences, Little Rock, AR
Background: Previous reports have suggested that Blacks receive life saving 
cardioprotective therapies less often than Whites, possibly because of lower socio-
economic status that leads to poor access to physicians. These disparities may be the 
basis of poor cardiovascular outcome among Blacks compared to that in Whites. We 
questioned if there may be racial disparity in patient treatment in the Veterans Healthcare 
System, where there is equal access to care and prescription drugs, regardless of 
economic status.
Angiotensinogen gene polymorphisms and cardiovascular risk in 
10.060 patients with stable CAD during
SNP Location Freq 1/1 1/2 2/2
HR
1/1 HR 1/2 HR 2/2
P for 
trend
rs5046 promotor 77.4 21.0 1.6 1.00 1.27(0.74-2.31)
1.46 (0.87-
2.67) 0.097
rs5051 promotor 30.9 48.8 20.3 1.00 1.06 (0.90-1.16)
1.21 (1.01-
1.46) 0.046
rs4762 exon 74.4 23.8 1.8 1.00 1.11(0.94-1.28)
1.72 (1.16-
2.56) 0.018
rs2748545 intron 56.6 37.7 5.7 1.00 1.08 (0.92-1.18)
1.38 (1.06-
1.77) 0.089
3:30 p.m.
1019-19 No Difference in the Incidence of Contrast-Induced 
Nephropathy Between Iso-osmolar (I-odixanol) and 
Low-Osmolar (Ioxalin) in Patients Given a Renal 
Protection Protocol
Timothy Malins, Stephen Minor, Jonathon Tronolone, Iwona Cygankiewicz, Christopher 
Cove, University of Rochester, Rochester, NY
Background: Contrast-induced nephropathy (CIN) is a known complication of coronary 
angiography (CA). There have been conﬂicting studies as to whether iso-osmolar contrast 
agents decrease the incidence of CIN. Our objective was to compare the incidence of 
CIN in high-risk patients, pretreated with a renal protection protocol, who received either 
iso-osmolar contrast (iodixanol) to similar patients who received low-osmolar contrast 
(ioxilan) during coronary angiography.
Methods: This is a prospectively designed non-randomized, retrospective analysis of 
395 consecutive patients with baseline renal dysfunction (q 1.5 mg/dl) having undergone 
coronary angiography using either iso-osmolar (iodixanol) or low-osmolar (ioxilan) 
contrast agents from September 1, 2006, through March 1, 2008. All patients where given 
a similar protocol of acetylcysteine, theophylline, sodium bicarbonate or combination 
thereof as part of a renal protective strategy depending on creatinine (Cr) clearance. CIN 
was deﬁned as an increase in baseline Cr q 0.5 mg/dl and/or q 25% rise in Cr 24-72hrs 
after CA. Data was analyzed for factors inﬂuencing progression to CIN using regression 
analysis and multivariable analytical methods.
Results: The incidence of CIN was similar in both groups. Factors inﬂuencing the 
development of CIN by regression analysis where baseline Cr over 3.0 mg/dl (Odds ratio 
of 3.18; p-value of 0.035) and diabetes mellitus (DM) (Odds ratio of 2.36; p-value of 0.012). 
Age, gender, LVEF, contrast type or quantity of dye were not shown to inﬂuence CIN.
Conclusions: When using a renal protection strategy the type of contrast agent did not inﬂuence 
the incidence of CIN. In our study only a baseline Cr q 3.0mg/dl and DM were independent 
factors shown to inﬂuence the progression to contrast-induced nephropathy after CA.
3:30 p.m.
1019-20 Adherence to Evidence-Based Pharmacotherapy 
Reduces the Risk of Death and Rehospitalization in 
Patients With Heart Failure
Ashley A. Fitzgerald, Pamela N. Peterson, David J. Magid, Frederick A. Masoudi, Larry 
Allen, Christina L. Clarke, Michael Ho, Susan Shetterly, David Powers, Edward P. 
Havranek, Clinical Research Unit, Colorado Kaiser Permanente, Denver, CO, University 
of Colorado at Denver and Health Sciences Center, Aurora, CO
Background: Limited literature exists on the association between medication adherence 
and outcomes in patients with heart failure (HF).
Methods: We conducted a retrospective cohort study of 3,292 patients in the Kaiser 
Permanente of Colorado HF registry. Patients were included if they had been hospitalized 
with a principal discharge diagnosis of HF, survived >=180 days following index 
hospitalization, and ﬁlled a prescription for either a beta blocker (BB) or renin angiotensin 
system inhibitor (RASi) within 90 days of discharge. Multivariable Cox proportional 
hazards models were used to access the association between adherence (high >=90%, 
low <90%) and time to ﬁrst event (cardiovascular-related hospitalization or death).
Results: During median follow-up of 1.2 years, a total of 679 patients experienced 
death or cardiovascular (CV) hospitalization. After multivariable adjustment, overall high 
adherence was associated with a lower risk of adverse CV outcomes (HR of 0.82, CI 
0.69-0.98) (Figure 1). In secondary analysis high adherence to BB appeared to have 
a greater effect on CV events, albeit of borderline signiﬁcance (HR 0.83, CI 0.68-1.03), 
while high adherence to RASi was not signiﬁcant (HR 1.01, CI 0.83-1.23).
Conclusion: High adherence to neurohormonal antagonists was associated with 
improved cardiovascular outcomes following HF hospitalization. Further research is 
needed to develop systems of care that ensure high adherence among HF patients. 
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1019-25 Impact of Anemia, Bleeding and Transfusion on 
Percutaneous Coronary Intervention Outcomes
Marcin R. Dada, Muhammed Gill, Saquib Samee, Aseem Vashist, Jeffrey Mather, 
Francis J. Kiernan, Raymond G. McKay, Hartford Hospital, Hartford, CT
Background: Although previous studies have identiﬁed baseline anemia as an 
independent predictor of poor clinical outcomes in patients (pts) treated with percutaneous 
coronary intervention (PCI), the clinical impact of concomitant bleeding and red blood cell 
(RBC) transfusion remains controversial.
Methods: We assessed in-hospital and 9-month outcomes in 6,538 consecutive PCI pts, 
of whom anemic and non-anemic pts accounted for 33% (2,159 pts) and 77% (4,379 pts), 
respectively. Pre-PCI anemia was deﬁned as hemoglobin < 13g/dL in males and < 12g/
dL in females. The study groups included 422 pts with TIMI Major or Minor bleeding, and 
291 pts treated with RBC transfusion.
Results: The groups differed statistically in respect to age, comorbidities, including 
diabetes mellitus, hypertension, hyperlipidemia, renal insufﬁciency, and prior history of 
PCI and CABG surgery, favoring the non anemia group (p<0.05). After propensity-score 
adjustment, anemia was independently associated with an increased incidence of in-
hospital mortality (OR 2.87, CI 1.58-6.23, p=0.001) and 9-month mortality (OR 1.46, CI 
1.07-1.99, p=0.018). The impact of transfusion and bleeding for anemic and non-anemic 
patients is described below: 
In-Hospital Mortality
Anemic Non-Anemic
Bleeding OR 3.31 (CI 0.46-23.95), p=NS OR 2.70 (CI 1.01-7.22), p =0.05
RBC Transfusion OR 2.74 (CI 1.10_6.82), p=0.03 OR 0.48 (CI 0.01-23.02) p=NS
9-Month Mortality
Anemic Non-Anemic
Bleeding OR 0.95 (CI 0.19-4.83), p=NS OR 2.33 (CI 1.30-4.19), p <0.01
RBC Transfusion OR 3.01 (CI 1.71_5.32), p<0.001 OR 0.06 (CI 0.003-1.35) p=NS
Conclusions: Anemia remains an independent predictor of in-hospital and 9-month 
mortality in pts treated with PCI. Likewise, transfusion predicts in-hospital and 9-month 
death in anemic patients, while bleeding remains a more powerful predictor of poor 
outcomes in non-anemics.
3:30 p.m.
1019-26 Does Systolic Blood Pressure Predict Better Prognosis 
in Heart Failure Patients Even at Very High Levels?
Maria T. Vidan, Yongfei Wang, Hector Bueno, Geoffry Schreiner, Joseph Ross, Jersey 
Chen, Zhenqiu Lin, Yun Wang, Sharon-Lise T. Normand, John Spertus, Harlan M. 
Krumholz, CORE.Yale Medical School, New Haven, CT
Background: Systolic blood pressure (SBP) has a paradoxical relationship with mortality 
risk among patients with heart failure (HF). Whether this relationship persists at higher 
blood pressure levels and is consistent in different subgroups of patients is not well 
deﬁned. Methods: Medical information of 56,942 patients included in National Heart 
Care Project, a national sample of heart failure hospitalizations, was abstracted; mortality 
was identiﬁed through Medicare Beneﬁcial Data and Master Death Index Data. The 
independent association between SBP on admission and 30-day and 1-year mortality 
was evaluated by multivariable survey logistic regression models in the overall cohort, 
and in several subgroups (age, gender, race, history of hypertension, and LVEF).
Results: Mean admission SBP was 146.9 ±31.8 mmHg and 15% presented with SBP 
>180 mmHg. Patients with higher SBP were signiﬁcantly younger, more frequently female, 
and had better LVEF and lower rates of comorbidities except hypertension. SBP showed 
a continuous inverse relationship with 30-day and 1-year mortality rates (Table). After 
adjustment for demographic and clinical factors, SBP emerged as a powerful predictor of 
lower 30-day and 1-year mortality in the whole group as well as in each subgroup.
Conclusion: Even very high levels of SBP on admission are associated with lower short- 
and long-term mortality in all type of patients hospitalized for HF. The relationship is 
strong, graded and independent of LVEF and other clinical factors. 
Methods: We explored the VISN16 database with regard to the prescription rates for 
4 classes of cardiovascular agents- aspirin, B-blockers, statins and ACE inhibitors for 
Blacks and Whites, as well as coronary outcomes and coronary bypass surgery. We 
analyzed data on 474,565 patients (25% Black; 75%.White).
Results: We observed that, after adjustment for age, income, co-morbidities, risk factors 
and other medications, Blacks as compared to Whites had signiﬁcantly lower odds of 
receiving prescriptions for 3 classes of cardioprotective agents for (B-blockers OR=0.72, 
95% CI=0.7-0.73; statins OR=0.52, 95% CI=0.51-0.53; and ACE inhibitors OR=0.94, 
95% CI=0.94-0.96) (all P<0.001). The odds for prescriptions for aspirin were higher 
among Blacks than in Whites (OR=1.29, 95% CI=1.25-1.29) (P<0.001). Further, our 
data showed that the odds for Blacks having coronary bypass surgery were markedly 
lower than in Whites (OR=0.46, 95% CI=0.42-0.51) (P<0.001). Blacks had higher odds 
of acute coronary syndromes (ACS), including acute myocardial infarction (OR=1.11, 
95% CI=1.03-1.20, P<0.001) and angina (OR=1.34, 95% CI=1.30-1.38, P<0.001). These 
associations were independent of cardioprotective drug use.
These observations suggest that Blacks receive cardioprotective drugs like B-blockers, 
statins and ACE inhibitors, as well as coronary bypass surgery at lower rates, and have 
higher rates of coronary syndromes than do Whites in the Veterans Healthcare System.
Conclusion: Racial difference in the incidence of coronary syndromes may partially be 
attributed to the difference in the prescriptions for cardioprotective drugs.
3:30 p.m.
1019-23 Self-Assessment of Health Status and Long-Term 
Prognosis in Chronic Heart Failure: A Comparative 
Evaluation of the Kansas City Cardiomyopathy and the 
Minnesota Living With Heart Failure Questionnaires
Dimitrios Farmakis, John Parissis, Maria Nikolaou, Vassiliki Bistola, Koula Venetsanou, 
Ioannis Paraskevaidis, Gerasimos Filippatos, Dimitrios Kremastinos, Attikon University 
Hospital, Athens, Greece
Background: Self-assessment of health status by questionnaires has been associated 
with severity and prognosis of chronic heart failure (CHF). We assessed comparatively 
the predictive value of Kansas City Cardiomyopathy Questionnaires (summary, KCCQ-s 
and functional, KCCQ-f) and of Minnesota Living with Heart Failure Questionnaire 
(MLHFQ) in CHF.
Methods: We studied 137 consecutive CHF patients (aged 64±12 years, mean left 
ventricular ejection fraction 27±7%). Besides KCCQ and MLHFQ, plasma B-type 
natriuretic peptide (BNP), 6-minute walked distance (6MWD), inﬂammatory markers 
(IL-6, IL-10, TNF-A) and Zung self-rated depression scale (SDS) were also assessed. 
Patients were followed for death or cardiovascular hospitalization for 250 days.
Results: During follow-up, 61% of patients experiencing an event; median event-free 
survival was 120 days. Compared to patients with uneventful course, those having 
experienced an event had signiﬁcantly worse KCCQ-s (42.4±21% vs 28.8±18%, 
p<0.001) and KCCQ-f (54.4±20% vs 37.8±20%, p<0.001) scores but similar MLHFQ 
score (59.5±22.4 vs 47.6±30.9, p=NS). Those patients also had lower EF (24±6 vs 
30±7%, p<0.001), higher NYHA class (p=0.001), lower 6MWD (256±193 vs 345±148 
meters, p<0.05), higher BNP (976±910 vs 403±311 pg/ml, p<0.001), higher levels of 
pro-inﬂammatory cytokines (IL-6, 13.4±6.9 vs 7.3±5.3 pg/ml, p<0.001; TNF-A, 42.4±43 
vs 21.2±33 pg/ml, p=0.001), lower levels of the anti-inﬂammatory cytokine IL-10 (5.8±3.2 
vs 9.3±4.8 pg/ml, p<0.05) and higher frequency of depressive symptoms (72% vs 49%, 
p=0.011). Event-free survival was signiﬁcantly shorter in patients with KCCQ-s <50% 
(130±10 vs 205±15 days, p=0.0009) and in those with KCCQ-f <50% (113±10 vs 190±12 
days, p<0.0001), but it did not differ signiﬁcantly between patients in the low and those 
in the high MLHFQ 50% percentile (118±15 vs 155±11 days, log-rank test p=0.0919). In 
multivariate analysis, only LVEF (HR=0.768, 95% CI=0.632-0.933, p=0.008) and KCCQ-f 
(<50% vs q50%, HR=0.113, 95% CI=0.016-0.803, p=0.029) remained as signiﬁcant 
predictors of survival.
Conclusion: KCCQ seems to be a better predictor of long-term event-free survival than 
MLHFQ in CHF patients.
3:30 p.m.
1019-24 Variation in Early Death and All-Cause Readmission 
After a Hospitalization for Heart Failure Among 
Medicare Beneﬁciaries
Lesley H. Curtis, Adrian F. Hernandez, Li Liang, Paul Heidenreich, Clyde Yancy, Sean M. 
O’Brien, Gregg C. Fonarow, Eric D. Peterson, Duke Clinical Research Institute, Durham, 
NC, University of California-Los Angeles, Los Angeles, CA
Background: Readmission within 30 days of a heart failure (HF) hospitalization is being 
widely touted as a metric of hospital-level quality of care for Medicare beneﬁciaries. To 
date, little is known about how 30-day HF readmission rates vary at the hospital level.
Methods: Patients 65 years and older who were hospitalized in an American Heart 
Association’s Get With the Guidelines-HF registry were matched with Medicare claims 
from 2005-06. Patients without HF as a primary diagnosis or who died prior to discharge 
were excluded. Hospitals with fewer than 30 HF patients were excluded. Within each 
hospital, risk-adjusted 30-day death or all-cause readmission rates were computed.
Results: Among 17,136 patients at 121 hospitals, 4774 (27.9%) patients died or were 
readmitted within 30-days following a HF hospitalization. The median hospital-level death/
readmission rate was 28.3%. The mean age was 80 years old with 54.6% female, 9.7% 
black and 2.9% Hispanic patients. Mean ejection fraction was 42.0%. The distribution of 
hospital-level 30-day death/readmission rates is shown in Figure.
Conclusions: Hospital-level rates of 30-day death or readmission following a HF 
hospitalization vary considerably. Further research is needed to determine the causes of 
this early failure and improve early outcomes. 
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1019-29 Biomarker Proﬁle of Younger Women After Acute 
Myocardial Infarction
Susmita Parashar, Phil G. Jones, Michael Kontos, Viola Vaccarino, Nazeera Dawood, 
Saadia Khizer, Judith Lichtman, John Spertus, Emory University, Atlanta, GA, Mid 
America Heart Institute, Kansas, MO
Background: Younger women have a higher mortality after myocardial infarction (MI) 
than men of similar age. Whether this is due to an aggressive inﬂammatory state, more 
severe myocardial injury, or other factors is unknown. We compared biomarkers of 
myocardial injury, elevated ﬁlling pressure and inﬂammation among gender-age groups 
(<60 vs.q60 yrs) after an acute MI.
Methods: In a prospective national MI registry (TRIUMPH), we measured NT-pro-brain 
natriuretic peptide (NT-proBNP), high sensitivity C-reactive protein (hsCRP), troponin-T 
(TnT) and peak CK-MB in 1602 (32% women, age 58±12 years) hospitalized MI patients. 
Unadjusted and multivariable (MV)-adjusted results were analyzed using bootstrap 
methods due to skewed distribution of biomarkers.
Results: Younger women (n=256) had the lowest TnT and hsCRP levels among all age-
gender groups (Table). In a multivariable model adjusted for various demographic, clinical 
and treatment factors listed in the table below, younger women continued to show the 
lowest levels of hsCRP, TnT, peak CK-MB and NT-proBNP, although the results for NT-
proBNP did not reach statistical signiﬁcance (Table).
Conclusions: Younger women with MI do not have a worse proﬁle of myocardial 
and inﬂammatory biomarkers compared with younger men. Other factors, besides 
inﬂammation and MI severity likely explain the higher mortality in younger women post-MI 
found in previous studies, and need to be identiﬁed to potentially improve their post-MI 
survival.
Table:
Mean
Unadjusted
Difference
(95% CI)
Multivariable-Adjusted* Difference 
(95% CI)
NT-proBNP (pg/ml)
Male <60 
(reference) 1810 - -
Female <60 2702 892 (-333, 2051) -166 (-962, 508)
Male q 60 3792 1982 (1098, 2885) 129 (-1047, 1434)
Female q 60 5399 3589 (2177, 5058) 1310 (-441, 3280)
hsCRP (mg/dl)
Male <60 
(reference) 3.53 - -
Female <60 2.69 -0.84 (-1.43, -0.27) -0.71 (-1.37, -0.08)
Male q 60 3.79 0.26 (-0.33, 0.87) -0.25 (-1.32, 0.81)
Female q 60 3.92 0.39 (-0.35, 1.08) 0.05 (-1.17, 1.27)
TnT (ng/ml)
Male <60 
(reference) 1.71 - -
Female <60 1.05 -0.66 (-0.94, -0.43) -0.44 (-0.66, -0.23)
Male q 60 1.62 -0.09 (-0.38, 0.16) -0.03 (-0.41, 0.39)
Female q 60 1.44 -0.27 (-0.61, 0.01) -0.11 (-0.57, 0.37)
Peak CK-MB (ng/
ml)
Male <60 
(reference) 118 - -
Female <60 67 -51 (-67, -39) -32 (-49, -16)
Male q 60 93 -25 (-40, -11) -28 (-50, -3)
Female q 60 70 -48 (-64, -34) -19 (-43, 7)
*Multivariable-adjusted for site, race, smoking, diabetes, hypertension, dyslipidemia, 
peripheral vascular disease, prior stroke, prior MI, PCI or CABG, heart failure, left 
ventricular systolic function, STEMI, systolic blood pressure, renal function, statin use, 
reperfusion/revascularization, GRACE risk score and time from symptom onset to lab draw.
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1028-01 Do Changes in Carotid Intima-Media Thickness Predict 
Changes in Clinical Outcomes? A Meta-Regression 
Analysis
Javier Valle, Vineet Dandekar, Zachary Goldberger, Paul S. Chan, Brahmajee K. 
Nallamothu, University of Michigan, Ann Arbor, MI
Background: Carotid intima media thickness (CIMT) has been proposed as a surrogate 
endpoint to evaluate new therapies for treating CAD. We hypothesized that reductions in 
CIMT would correlate with decreased rates of death and MI.
SBP (mmHg) <90 90-119 120-149 150-179 180-209 <=210 p
% Pop 1.6 17.7 37.3 27.4 12.2 3.8
30-day mortality 34.1% 18.6% 10.1% 5.7% 4.4% 2.9% *
Adjusted OR 2.8 1.7 1.0 0.6 0.5 0.3 *
95%CI 2.3-3.5 1.5-1.8 (Ref) 0.5-0.7 0.4-0.6 0.2-0.4
1-year mortality 69.7% 55.5% 39.5% 29.1% 25.5% 21.3% *
Adjusted OR 2.2 1.6 1.0 0.7 0.63 0.51 *
95%CI 1.8-2.7 1.5-1.7 (Ref) 0.67-0.8 0.57-0.68 0.4-0.6
3:30 p.m.
1019-27 Residual Risk of Cardiovascular Disease Among 
Patients Treated According to Guidelines for Secondary 
Prevention
Gregory A. Nichols, Kathryn L. Pedula, Fang Q. Wang, Kaiser Permanente Center for 
Health Research, Portland, OR, GlaxoSmithKline, Inc., King of Prussia, PA
Background: Despite proven pharmaceutical therapies for secondary prevention of 
cardiovascular disease (CVD), considerable CVD risk remains. We assessed the extent 
to which patients were treated according to recommended guidelines and then estimated 
the incidence of CVD events or death.
Methods: We identiﬁed 13,528 members of Kaiser Permanente Northwest (KPNW) who 
were added to the CVD registry in 2000-2005 and survived for at least 6 months. For such 
patients, KPNW deﬁnes guideline-level care (GLC) as receipt of statins, ACE Inhibitors, 
B-blockers, and aspirin or other anti-platelets. We classiﬁed patients into those who did 
and did not GLC within 6 months of addition to the CVD registry. Patients were followed 
until death, CVD hospitalization or June 30, 2008, whichever came ﬁrst. We compared 
the incidence of a composite outcome of CVD hospitalization or death while controlling 
for age, sex, body mass index, prior revascularization, prior myocardial infarction, stroke, 
smoking status, and diabetes.
Results: Mean age was 66.1 years, 60% were men, and mean follow-up was 3.5 years. 
Although the majority of patients (77%) did not receive GLC, most (80%) received at least 
2 of the 4 components. Patients receiving GLC (n=3,091) were younger, more likely to be 
male, to have had a prior revascularization or diabetes, but less likely to have had a prior 
MI. Overall, 29% of patients experienced either CVD hospitalization or death regardless 
of whether they received GLC. Fewer patients receiving GLC experienced the composite 
outcome compared with patients who did not receive GLC (25.6% vs. 30.3%, p<0.001). 
After multivariable adjustment, patients receiving GLC experienced the composite 
outcome at a rate of 80/1,000 person-years (95% CI 74-86) vs.94 (90-98)/1,000 among 
patients who did not receive GLC (p<0.001). The difference was primarily driven by 
mortality (20 [17-23] vs. 31 [28-33]/1,000 person-years).
Conclusions: In this heavily treated population, we found substantial residual risk of 
CVD or death. Even among patients receiving GLC, these events were quite common. 
Greater adherence to GLC as well as new therapies that target novel risk factors may 
prove beneﬁcial in further reducing CVD risk.
3:30 p.m.
1019-28 Readmission Rates for Heart Failure at Safety Net and 
Non-safety Net Hospitals
Joseph S. Ross, Zhenqui Lin, Héctor Bueno, Jersey Chen, Jeptha P. Curtis, Elizabeth 
E. Drye, Patricia S. Keenan, Sharon-Lise T. Normand, Geoffrey C. Schreiner, John 
A. Spertus, Maite Vidán, Yun Wang, Yongfei Wang, Harlan M. Krumholz, Mount Sinai 
School of Medicine, New York, NY, Yale University School of Medicine, New Haven, CT
Background: Safety-net hospitals are experiencing increasing ﬁnancial strains, possibly 
affecting their quality of care. Our objective was to compare readmission rates, a potential 
outcomes-based performance measure of quality, among Medicare beneﬁciaries with 
heart failure treated in urban safety net hospitals and non-safety net hospitals.
Methods: We used 2006 Medicare administrative data for all fee-for-service beneﬁciaries 
admitted to an urban hospital for heart failure, identiﬁed using ICD-9-CM codes, and 
discharged alive. Our main outcome measure was hospital-speciﬁc risk-standardized 
all-cause 30-day readmission rates (RSRR), calculated using two-level hierarchical 
linear models that accounted for age, sex, and multiple co-morbidities. The RSRR model 
has been approved by the National Quality Forum for hospital comparisons. Safety net 
hospitals were deﬁned as public hospitals or private hospitals with a Medicaid caseload 
greater than one standard deviation above the states´ mean private hospital caseload.
Results: There were 377,508 distinct hospitalizations for heart failure in 2,184 hospitals; 
60,212 in 465 safety net hospitals and 317,296 in 1,719 non-safety net hospitals. Safety 
net hospitals were more likely to be teaching hospitals but had lower average annual 
heart failure hospitalizations when compared with non-safety net hospitals (130 versus 
185; p<0.001). Unadjusted 30-day all-cause readmission rates were higher in safety 
net than non-safety net hospitals (24.6% versus 23.3%; p=0.02). Safety-net hospitals 
had statistically signiﬁcant, but clinically insigniﬁcant, higher RSRRs when compared 
with non-safety net hospitals (24.0% versus 23.7%; p=0.003). In addition, there was 
substantial heterogeneity in RSRRs among safety-net and non-safety net hospitals with 
extensive overlap in performance.
Conclusions: Urban safety net and non-safety net hospitals have similar risk-adjusted 
rates of heart failure readmission. This ﬁnding indicates that caring for vulnerable 
populations does not put safety net hospitals at a disadvantage in the RSRRs that they 
achieve.
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death 0.91 (95% CI 0.88-0.95), and mean AMR 1.26.
The relative risk reduction (RRR) by intent to treat was 15.2% in the ﬁrst period and 8.9% 
during the second (58.6% of RRR retained). The risk reduction during the second period 
could not be attributed to imbalances in receiving active therapy as the percentage of 
those who actually received it was about the same in the two groups.
Conclusions: A signiﬁcant proportion (more than half) of the beneﬁt observed during the 
open-label period among those initially randomized to active therapy is not attributable to 
imbalances in receiving therapy. Additional mechanisms such as stabilization of plaque, 
magniﬁcation of beneﬁts with time, and disease regression may be involved. These 
analyses support the importance of early initiation of therapy.
9:30 a.m.
1028-04 Risk of Bleeding Events Following Noncardiac Surgery 
or Procedure in Patients With Drug-Eluting Stents
Claudine T. Jurkovitz, Divya Tiwari, Zugui Zhang, James Bowen, Ashley Weed, Gail 
DeVecchis Wygant, William Weintraub, Christiana Care Health System, Newark, DE, 
AstraZeneca, Wilmington, DE
Background: Patients with drug eluting stents (DES) who undergo noncardiac surgery 
or procedures are at risk of bleeding. The goal of this study was to determine risk factors 
for bleeding.
Methods: We identiﬁed all patients admitted in our hospital from 2002 to 2007 who had a 
coronary DES placement. We considered noncardiac surgeries/invasive procedures up to 
2 years after DES and any bleeding within 30 days of surgery. Major bleeding was deﬁned 
as a bleed requiring a transfusion or an invasive procedure. We used a repeated logistic 
regression to estimate the bleeding risk. The independent variables were age, race, 
gender, urgent status and timing of procedure after DES placement, whether clopidogrel 
was stopped, procedure type (endoscopy, orthopedic, vascular, thoracoabdominal versus 
other), aspirin exposure, diabetes.
Results: Among 6397 patients who had a DES placement, 1268 had at least one visit for 
a noncardiac procedure for a total of 1974 visits. Clopidogrel was recorded in 1411 visits. 
Visits for which bleeding preceded the index procedure (n=178) were excluded. A total of 
17 major and 60 minor bleeding events were identiﬁed. Independent risk factors included 
age q65 (Odds ratio= 2.0, 95% CI= 1.1- 3.7), aspirin (2.1; 1.0- 4.4), urgent (3.0; 1.6- 5.6), 
orthopedic (9.9; 3.7-26.2) and vascular (3.3; 1.1- 9.9) procedures.
Conclusion: Patients with DES have a high bleeding rate (6.2%) after noncardiac 
procedures and should be carefully monitored especially if the procedures are urgent, 
othopedic, vascular 
Procedure characteristics among patients who were treated with 
clopidogrel
Overall
n=1233
Bleeding
event
n=77
(6.2%)
No bleeding 
event
n=1156
(93.8%)
P
Non Elective procedures (%) 21.4 40.3 20.2 <0.0001
Date of surgery >1 year after stent (%) 35.5 28.6 36.0 0.2191
Average number of days (median) 
between stent placement and surgery
298.8
(267.0)
273.3
(235.0)
300.5
(270.5) 0.1964
Average number of days (median) 
between surgery and bleeding
Not
applicable 2.74 (0)
Not
applicable -
Stopped clopidogrel
Yes (%)
No (%)
Unknown (%)
43.2
28.1
28.6
50.7
33.8
15.6
42.7
27.8
29.5
0.0251
Average number of days (median) 
clopidogrel was stopped prior to 
surgery
7.02 (7.31) 8.24 (7.45) 6.93 (6.57) 0.0781
% on aspirin 64.3 81.8 63.2 0.0009
Type of surgery
% endoscopy
% Orthopedic
% Vascular
% Thoracoabdominal
29.5
18.1
15.6
13.1
11.7
55.8
18.2
7.8
30.7
15.6
15.4
13.5
0.0029
Any CV event (%) 3.2 10.4 2.7 0.0020
9:30 a.m.
1028-05 Higher Heart Rate at Discharge Is Associated With 
Increased Mortality in Hospital Survivors of an Acute 
Myocardial Infarction
Esti Charlap, Paul Chan, Fengming Tang, Philip Jones, Paul Heidenreich, John Spertus, 
V.S. Srinivas, Monteﬁore Medical Center, Bronx, NY, Mid America Heart Institute at 
Saint Luke’s Hospital, Kansas City, MO
Background Although admission heart rate (HR) is a predictor of higher in-hospital 
mortality following an acute myocardial infarction (AMI), there is limited information on 
the association between discharge HR, a potentially modiﬁable therapeutic goal, and 
subsequent mortality.
Methods In a prospective 19-center registry of AMI (Prospective Registry Evaluating 
outcomes after Myocardial Infarction: Events and Recovery [PREMIER]), patients were 
categorized by discharge HR: (1) < 65 (N=689), (2) 66-75 (N=754), (3) >75 (N=896). 
Multivariable Cox regression analyses assessed the independent association of 
Methods: We performed a literature search of RCTs from 1994 to 2008 that employed high 
resolution b-mode ultrasound to measure CIMT. Eligible studies included (1) randomized 
treatment and control groups, (2) quantitative CIMT assessment using B-mode ultrasound 
to measure changes in mean CIMT and (3) reports of clinical outcomes including death, 
MI and ACS. Random-effects meta-regression assessed if changes in CIMT correlated 
with a lower odds ratio (OR) for outcomes.
Results: We found 11 studies with 6,951 patients. Mean follow-up was 27 mos. RCTs 
evaluated both statin and non-statin therapies (folic acid, torcetrapib, metoprolol 
xl, ezetimibe). Mean age was 48, 31% were women, 32% were smokers, 7.6% were 
diabetics. During meta-regression, we found no evidence that changes in CIMT by high 
resolution B-mode ultrasound correlated with lower OR of death or MI (p=0.281, Figure). 
Results were similar when we restricted analysis to RCTs that evaluated only statins.
Conclusions: We found no correlation between improvements in CIMT by b-mode 
ultrasound and a lower risk of death or MI in RCTs, suggesting that this modality may be 
limited in evaluating novel drugs.
9:30 a.m.
1028-02 Sustaining Improvements in Door-To-Balloon Times 
Over Four Years: The Mayo Clinic STEMI Protocol
David M. Nestler, Amit Noheria, Luis H. Haro, Latha G. Stead, Wyatt W. Decker, Lori 
Scanlan-Hanson, Ryan J. Lennon, Choon-Chern Lim, David R. Holmes, Jr., Charanjit S. 
Rihal, Malcolm R. Bell, Henry H. Ting, Mayo Clinic, Rochester, MN
Background: ACC/AHA guidelines recommend a door-to-balloon time (DTB) <90 
minutes for patients with ST-elevation myocardial infarction (STEMI). Obtaining DTB 75% 
of patients has rarely been reported in the literature, and sustaining this DTB performance 
over several years has not been reported.
Methods: The Mayo Clinic STEMI protocol was implemented in May 2004. Main process 
changes included enabling Emergency Medicine physicians to activate the cardiac 
catheterization lab, implementing a single call system to activate the cardiac catheterization 
lab, and utilizing real-time performance feedback. DTB were collected on consecutive, 
nontransferred patients with STEMI pre- and post-implementation of the protocol.
Results: The pre-implementation group comprised 96 patients from June 2002 to March 
2004. This group had a median DTB of 97 minutes (IQR 82, 130) and 40% had DTB < 90 
minutes. The post-implementation group comprised 368 patients from May 2004 to March 
2008. This group had a median DTB of 69 minutes (IQR 56, 87) and 77% had DTB < 90 
minutes. Median DTB over 4 years (2004-2008) post-implementation were shorter than 
pre-implementation (p<0.001). For the 4 years since implementation, there was no trend 
for increasing or decreasing DTB during this period (p=0.73).
Conclusion: The Mayo Clinic STEMI protocol implemented strategies and achieved DTB 
<90 minutes for >75% of nontransferred patients with STEMI. This DTB performance was 
sustained over four years (2004-2008) indicating that our process changes resulted in 
durable improvements in reperfusion therapy systems of care.
9:30 a.m.
1028-03 Persistence of Beneﬁcial Effects of Cardiovascular 
Preventive Pharmacotherapy After Discontinuation of 
Blinded Therapy
William J. Kostis, John B. Kostis, Jan A. Staessen, Johns Hopkins University School of 
Medicine, Baltimore, MD
Background: Controlled clinical trials have documented the beneﬁt of ACE inhibitor, 
antihypertensive, and lipid-lowering therapy in preventing mortal and morbid events 
when used in the primary and secondary prevention of cardiovascular (CV) disease. 
Investigators have reported a continuation of the beneﬁt after the end of the randomized 
phase of the studies when all participants are advised to receive the same therapy.
Methods: To evaluate this persistence effect and estimate a potential beneﬁt not attributed 
to imbalances of active therapy during the open-label follow-up, we examined 19 studies 
(85,922 patients, 9,271 deaths) where both blinded and post-trial follow-up ﬁndings were 
reported (7 ACE-I, 6 hypertension, 1 diabetes, and 5 statin studies) analyzing major CV 
events, CV mortality, and all-cause mortality.
Results: The average follow-up in the ﬁrst (blinded) period was 47.7 months, the number 
randomized to active therapy 2318 and to placebo 2205 and the overall relative risk for 
death 0.85 (95% CI 0.82-0.88). The ratio of those who actually received active therapy 
in the intervention and control groups (active medication ratio, AMR) was calculated as 
a measure of relative differences in treatment. Mean AMR in the ﬁrst period was 21.95. 
Average follow-up in the second (open-label) period was 49.6 months, the number 
randomized to active therapy 1917 and to placebo 1790, the adjusted relative risk for 
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Results: There was a clear association between pre-procedure BG and AKI risk (AKI 
rates in ﬁve BG groups (lowest-highest) were: 9.8%, 11.0%, 13.6%, 14.8%, 20.5% 
respectively, p<0.001). The relationship, however, varied markedly in pts with and without 
DM. There was a strong association between BG and AKI risk in pts without DM (AKI 
rates across ﬁve BG groups: 8.2%, 9.9%, 12.4%, 14.9%, 24.3%, p<0.001), but not in pts 
with DM (20.9%, 16.1%, 16.3%, 14.8%, 19.2%, p=0.24; P for BG*DM interaction <0.001). 
After adjusting for confounders (including baseline glomerular ﬁltration rate), relationship 
between higher BG and greater AKI risk persisted in non-DM pts (ORs [95% CIs] for BG 
groups of 110-<140, 140-<170, 170-<200, >=200 were: 1.27 [0.98-1.65], 1.50 [1.10-2.04], 
1.56 [1.02-2.39], and 2.35 [1.63-3.41] vs. BG <110 mg/dl), but was not seen in DM pts 
(corresponding ORs [95% CIs] were: 0.71 [0.44-1.14], 0.82 [0.52-1.30], 0.73 [0.45-1.12], 
0.94 [0.63-1.40] vs. BG <110, adjusted P for BG*DM interaction 0.02).
Conclusion: Elevated pre-procedure BG is associated with greater risk of contrast-
induced AKI in AMI pts without established DM who undergo cath +/- PCI. Measures used 
to prevent contrast-induced AKI should be strongly considered in this patient group.
9:30 a.m.
1028-08 Safety And Efﬁcacy Of Triple Antithrombotic Therapy 
After Percutaneous Coronary Intervention in Patients 
Requiring Long-Term Anticoagulation: A Meta-Analysis
Param Puneet Singh, Updesh Singh Bedi, Sarabjeet Singh, Rohit Bhuriya, Amol 
Bahekar, Janos Molnar, Rohit Arora, Sandeep Khosla, Rosalind Franklin Universtiy of 
Medicine and Science/Chicago Medical School, North Chicago, IL
Background: Optimal antithrombotic therapy after percutaneous coronary intervention 
(PCI) is currently undeﬁned in patients requiring long term anticoagulation. Previous 
studies comparing triple therapy (TT) of warfarin, aspirin and clopidogrel with standard 
dual therapy (DT) of aspirin and clopidogrel have yielded conﬁlicting results. Meta-analysis 
of these studies was performed to evaluate safety and efﬁcacy of TT.
Methods: A total of 1482 patients from 6 retrospective studies were analyzed using the 
Mantel-Haenszel random effect model to extract incidence of major bleeding. Secondary 
end point assessed by 3 of these studies was major adverse cardiac events (MACE) 
(cardiovascular death, myocardial infarction and thromboembolic complications). 
Incidence of MACE was determined using Mantel-Haenszel ﬁxed effect model. Combined 
relative risks (RR) across all the studies and the 95% conﬁdence intervals (CI) were 
computed. A two-sided alpha error < 0.05 was considered statistically signiﬁcant.
Results: Baseline characteristics were similar in both groups. Compared to patients 
receiving DT, the risk of major bleeding was signiﬁcantly higher in TT group (RR: 2.74, 
CI: 1.08-6.98; p=0.034). However, risk of MACE was signiﬁcantly lower in TT group (RR: 
0.72, CI: 0.56-0.98; p=0.014).
Conclusions: In patients requiring long term anticoagulation after PCI, TT may be superior 
to DT in reducing incidence of MACE; however risk of major bleeding complications is 
signiﬁcantly increased. 
9:30 a.m.
1028-09 Metabolic Syndrome Has Similar Explanatory Ability in 
Predicting Five-Year CVD Events as the Cluster of Risk 
Factors: The ATTICA Study
Demosthenes B. Panagiotakos, Christos Pitsavos, Christina Chrysohoou, Yannis 
Skoumas, Christodoulos Stefanadis, Athens Medical School, Athens, Greece
BACKGROUND: Whether the metabolic syndrome is a cluster of risk factors without any 
additive explanatory ability in predicting future cardiovascular disease (CVD) events has 
been debated by several investigators. We sought to evaluate if metabolic syndrome 
can better predict future CVD events than the cluster of the common CVD risk factors. 
METHODS: From May 2001 to December 2002, 1514 men and 1528 women (>18 y) 
without any clinical evidence of CVD, living in Attica area, Greece, were enrolled in the 
ATTICA study. In 2006, a group of experts performed the 5-year follow-up. Development 
of CVD (coronary heart disease, acute coronary syndromes, stroke, or other CVD) during 
the follow-up period was deﬁned according to WHO-ICD-10 criteria. Metabolic syndrome 
was deﬁned according to NCEP ATPIII classiﬁcation (2005). RESULTS: The 5-year 
incidence of CVD was 11.0% in men and 6.1% in women (p < 0.001); the case fatality 
rate was 1.6%. Baseline prevalence of the metabolic syndrome was 25.2% in males and 
14.6% in females. After adjusting for age, sex, physical activity, smoking, and dietary 
habits, presence of the metabolic syndrome was associated with 2.09-times higher risk 
of developing a CVD event (95% CI 1.44-3.04). We have also estimated a model that 
discharge HR with 3-year all-cause mortality, after adjusting for enrollment site, as well as 
29 demographic, clinical, psychosocial, and socioeconomic variables.
Results Unadjusted 3-year mortality rates were 10.9% among patients with a discharge HR 
<65, 12.7% with a discharge HR of 66-75, and 17.6% with a discharge HR >75 (p<0.001). 
After multivariable adjustment, compared with patients with a discharge HR <65, patients 
with a discharge HR>75 had higher 3-year all-cause mortality (HR=1.64; 95% CI 1.22-2.21; 
p=0.001) whereas patients with a discharge HR of 66-75 did not (HR=1.04; 0.76-1.43, p=0.79) 
(Figure). This relationship was unchanged even after adjustment for admission HR.
Conclusion Discharge HR is associated with 3-year mortality among AMI survivors. 
Whether discharge heart rate is a modiﬁable marker of subsequent mortality in survivors 
of an AMI warrants further investigation. 
9:30 a.m.
1028-06 Large and Small Artery Elasticity, but Not Coronary 
Calcium Score and Carotid Intima-Media Thickness, 
Predict Incident Congestive Heart Failure Events in an 
Asymptomatic Population: Results of the Multiethnic 
Study of Atherosclerosis (MESA)
Daniel A. Duprez, David R. Jacobs, Jr., Pamela L. Lutsey, David A. Bluemke, Lyndia C. 
Brumback, Joseph Polak, Richard A. Kronmal, University of Minnesota, Minneapolis, MN
Background: Coronary calcium score (CAC score) and carotid intima-media thickness 
(cIMT) are considered as predictors for ischemic heart disease. Arterial elasticity can 
predict coronary heart disease events beyond blood pressure (BP). The predictive value 
of these biomarkers for congestive heart failure (CHF) is unknown. We examined the 
prognostic value of large (LAE) and small (SAE) artery elasticity on clinical CHF events 
in the MESA cohort study.
Methods: 6177 women and men of white, African American, Hispanic, and Chinese 
ethnicity, aged 45-84 years and free of overt cardiovascular disease (CVD), were 
enrolled. Radial artery pulse wave registration was performed at baseline in all subjects 
using radial tonometry. LAE and SAE were derived from diastolic pulse contour analysis. 
Carotid ultrasound and coronary computed tomography were performed at baseline. 
Median follow-up of 4 years resulted in 71 adjudicated CHF events.
Results: Table 1 presents proportional hazards regression models (HR) for CHF events, 
adjusted as indicated.
Model 1: adjusted for age, race, gender, site, height, cIMT and CAC score
Model 2: adjusted for variables in model 1 plus heart rate, systolic and diastolic BP, use of 
antihypertensive medication, BMI, ever and current smoking, total and HDL-cholesterol, 
triglycerides, use of cholesterol lowering medication, and diabetes
Conclusion: In asymptomatic subjects free of overt CVD, arterial elasticity predicted 
incident CHF events, but cIMT and CAC score did not.
Table 1
Model 1
Predictor variable HR 95% CI P trend HR 95% CI P trend
LAE 0.54 (0.37, 0.80) 0.002 0.63 (0.42, 0.97) 0.04
SAE 0.68 (0.45, 1.02) 0.06 0.64 (0.41, 1.00) 0.05
cIMT 1.18 (0.97, 1.43) 0.09 1.13 (0.93, 1.37) 0.23
CAC score 1.30 (0.99, 1.70) 0.06 1.16 (0.88, 1.52) 0.30
9:30 a.m.
1028-07 Hyperglycemia and Risk of Acute Kidney Injury After 
Coronary Angiography in Patients Hospitalized With 
Acute Myocardial Infarction
Mikhail Kosiborod, Peter A. McCullough, Seshu Rao, Silvio E. Inzucchi, Thomas M. 
Maddox, Frederick A. Masoudi, Lan Xiao, Suzanne Fiske, John A. Spertus, Mid America 
Heart Institute of Saint-Luke’s Hospital, Kansas City, MO
Background: Contrast-induced acute kidney injury (AKI) is a serious complication with 
adverse prognostic implications. While diabetes (DM) is a known risk factor for AKI after 
coronary angiography +/- intervention (cath +/- PCI), whether elevated pre-procedure 
blood glucose (BG) levels (regardless of DM diagnosis) are associated with higher risk 
of AKI is not known.
Methods: We studied 6358 patients (pts) hospitalized with acute myocardial infarction 
(AMI) in 40 US hospitals between 01/00-12/05 who underwent cath +/- PCI. Standard AKI 
deﬁnition was used (>=0.3 mg/dL absolute or >=50% relative serum creatinine increase 
during 48 hrs post-procedure). Pts were stratiﬁed into ﬁve pre-procedure BG groups: 
<110, 110-<140, 140-<170, 170-<200, and >=200 mg/dL. Logistic regression models 
evaluated the relationship between BG and risk of post-procedure AKI, ﬁrst in the entire 
cohort and then within subgroups of pts with and without established DM.
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contrast exposures (mean=1.10.4), most commonly from computed tomography to rule 
out pulmonary embolism (n=10) or aortic dissection (n=6). Patients with multiple contrast 
exposures received similar contrast volume during catheterization (162 vs 141 ml; p=0.19), 
but twice the total contrast volume (287 vs 142 ml; p<0.001). 171 (21%) ACS patients 
developed CIN, with a signiﬁcantly higher rate after multiple contrast exposures (29.2% vs 
13.5%; p=0.043). Results were consistent after multivariable adjustment (Table).
Conclusions: Over 10% of ACS patients undergoing angiography had multiple contrast 
exposures, which were subsequently associated with a higher total contrast volume and 
increased risk of CIN. 
Risk Factor Adjusted Odds Ratio [95% Conf. Interval] P
Multiple Contrast Exposures 2.92 1.02 8.33 0.045
Age (per 10 yrs) 1.03 0.73 1.46 0.848
Gender (male) 0.90 0.38 2.13 0.811
History of CRI 1.16 0.38 3.57 0.793
History of Diabetes 5.10 2.30 11.28 0.001
History of CHF 0.78 0.24 2.50 0.673
9:30 a.m.
1028-12 Association Between Baseline Levels of Plasma Renin 
Activity and Risk of Cardiovascular Events
Tami L. Bair, Heidi T. May, Margaret F. Prescott, Jeffrey L. Anderson, Benjamin D. 
Horne, John Penman, Joseph B. Muhlestein, Intermountain Medical Center, Murray, UT, 
Novartis Pharmaceuticals, East Hanover, NJ
Background: Plasma renin activity (PRA), an upstream marker of the activation of the 
renin-angiotensin aldosterone system, has been proposed to be associated with an 
increased primary risk of myocardial infarction (MI) among hypertensive patients and a 
worse outcome in heart failure, though conﬂicting reports exist. The predictive value of 
PRA on future cardiovascular events among patients with pre-existing coronary artery 
disease is not known.
Methods: Patients (n=1,172) with pre-existing CAD (>70% stenosis) enrolled in the 
Intermountain Heart Collaborative Study cardiac catheterization registry who met 
appropriate criteria (EF > 45%, no history of MI, and no beta-blocker therapy [because 
of their PRA lowering activity]) were evaluated. PRA levels were evaluated as tertiles 
(<0.4, 0.41-2.09, >2.1 ng/ml/h) as well as by categories (<0.5, 0.51-2.3, >2.3 ng/ml/h) 
determined by recursive partitioning. Patients were followed for 3 years for the endpoints 
of all cause death, myocardial infarction, and hospitalization for congestive heart failure 
(CHF). Results were adjusted for baseline characteristics.
Results: Age averaged 64.4 ± 11.6, 73.1% were male, 63% were hypertensive and 25% 
had diabetes. At 3-years, at total of 112 (9.6%) died, 40 (3.4%) experienced MI and 19 
(1.6%) were hospitalized with CHF. Elevation in PRA (Tertile 3 vs. 1) was associated with 
an increased risk of death (adjusted hazard ratio [HR]=1.40, p=0.02) and CHF events 
(HR=2.06, p=0.006), but not myocardial infarction. When analyzed by category (Category 
3 vs. 1), the increased risk of death (HR=1.56, p=0.002) and CHF events (HR=2.12, 
p=0.004) persisted.
Conclusion: Among patients with pre-existing CAD but normal left ventricular function, 
PRA predicts the future risk of death and hospitalization for CHF, but not MI. This indicates 
that PRA may be more related to the physiology of myocardial function than plaque 
rupture. Future studies are indicated to evaluate this interesting ﬁnding.
9:30 a.m.
1028-13 Glycemic Status and Incident Heart Failure in Elderly 
Wthout Established Diabetes Mellitus: The Health, 
Aging, and Body Composition (Health ABC) Study
Andreas P. Kalogeropoulos, Vasiliki V. Georgiopoulou, Tamara B. Harris, Stephen B. 
Kritchevsky, Douglas C. Bauer, Andrew L. Smith, Elsa Strotmeyer, Anne B. Newman, 
Peter WF Wilson, Bruce M. Psaty, Javed Butler, Emory University, Atlanta, GA
Background: It is unclear whether measures of glycemic status beyond fasting glucose 
(FG) improve risk stratiﬁcation for incident heart failure (HF) in patients without established 
diabetes mellitus (DM).
Methods: We studied 2386 elderly participants without established DM enrolled in the 
Health ABC Study (median age 73 years, 47.6% men, 62.5% white, 37.5% black). The 
association of incident HF (deﬁned as hospitalization for new onset HF) with measures 
of glycemic status at baseline including FG, oral glucose tolerance testing (OGTT), 
fasting insulin, hemoglobin A1c (HbA1c), and homeostasis model assessment (HOMA) 
of insulin
resistance and insulin secretion was evaluated using Cox models.
Results: Incident HF rate was 10.7 /1000 person-years in participants with FG <100mg/
dL, 13.1/1000 with FG 100-125mg/dL, and 26.6/1000 with FG q126mg/dL (P=0.002, 
P=0.003 for trend). Addition of OGTT (pre-DM: q140-200 mg/dL, DM: q200mg/dL)
to classify glycemic status did not improve risk classiﬁcation (net reclassiﬁcation 
improvement -1.0%, P=0.77). When used as a continuous variable, FG was the strongest 
predictor of
incident HF in adjusted models (Table 1); the addition of OGTT, HbA1c, fasting insulin, 
and HOMA measures did not improve HF prediction. Results were similar across race 
and gender.
Conclusions: In elderly without DM, FG is a strong determinant of HF risk. Other 
glycemic measures provide limited additional prognostic information.
contained age, sex, physical activity, smoking, dietary habits, and all the features of the 
syndrome. Based on the calculated Negelkerke R-squared statistics we observed that the 
two models had similar explanatory ability (i.e., Negelkerke R-square of the model that is 
based on the metabolic syndrome = 23.8% and Negelkerke R-square of the model that is 
based on the individual components of the syndrome = 24.7%). Moreover the C-statistic 
(a measure of the predictive accuracy of a model, ranged between 0-1) was equal to 0.83 
for the ﬁrst model that included the metabolic syndrome and 0.828 for the model that 
included the cluster of the determinants of the syndrome (p=0.9). Conclusion: Our data 
suggest that the accuracy of the metabolic syndrome in predicting 5-year CVD events 
was similar to the accuracy of the cluster of the common CVD risk factors.
9:30 a.m.
1028-10 Blood Pressure Parameters, Arterial Stiffness, and 
Incident Heart Failure in the Elderly - The Health ABC 
Study
Syed A. Agha, Andreas Kalogeropoulos, Grigorios Giamouzis, Vasiliki Georgiopoulou, 
Samer Najjar, Kristen Bibbins-Domingo, Kim Sutton-Tyrrell, Stephen Kritchevsky, 
Andrew Smith, Tamara Harris, Anne Newman, Javed Butler, Emory University Hospital, 
Atlanta, GA
Background: Arterial stiffness, quantiﬁed by pulse wave velocity (PWV), or blood 
pressure (BP) parameters beyond systolic BP (SBP), such as diastolic BP, mean arterial 
pressure (MAP), or pulse pressure (PP), may have additive value for incident heart failure 
(HF) prediction compared to systolic BP alone.
Methods: We studied 2550 participants in the Health ABC Study (73.6 ± 2.9 yr, 47.2% 
men, 59.5% white) without HF at baseline. Cox proportional hazard models were used to 
assess the association of BP parameters (systolic BP, diastolic BP, MAP, PP) and PWV 
with incident HF (deﬁned as hospitalization for new onset HF).
Results: Median follow-up was 6.5 years. Incident HF developed in 229 (8.7%) 
participants. All BP parameters and PWV were individually predictive of incident HF. After 
adjustment for other predictors for incident HF (Table 1) SBP, MAP and PP remained 
associated with incident HF, with SBP being the strongest predictor among these.(16% 
increase in risk, 95% conﬁdence interval 9%-23% per 10mmHg increase in SBP) There 
were no racial or gender differences among the various BP parameters for HF prediction 
(all interaction terms p>0.1). If adjustment included systolic BP among predictors of 
incident HF, none of the other BP parameters retained their signiﬁcance.
Conclusion: Among BP parameters, systolic BP is the strongest predictor of incident HF 
in the elderly. Additional BP parameters or PWV do not appear to reﬁne HF prediction in 
this population group.
Table 1. Hazard Ratios of Blood Pressure Parameters for Incident 
Heart Failure
Unadjusted Adjusted 
-1* Adjusted-2†
Variable X 2 HR (95% CI) p X 2
HR (95% 
CI) p X 2
HR (95% 
CI) p
Systolic BP, 
per 10 mm 
Hg
41.59 1.20 (1.14-1.27) <0.001 23.79
1.16 (1.09-
1.23) <0.001 - - -
Diastolic 
BP, per 10 
mm Hg
4.83 1.14 (1.01-1.27) 0.028 3.29
1.11 (0.99-
1.25) 0.070 0.46
0.96 (0.84-
1.09) 0.497
Mean 
Arterial 
Pressure, 
per 10 mm 
Hg
23.55 1.28 (1.16-1.41) <0.001 14.24
1.22 (1.10-
1.35) <0.001 0.46
0.94 (0.77-
1.13) 0.497
Pulse 
Presure, per 
10 mm Hg
36.22 1.21 (1.14-1.29) <0.001 20.24
1.17 (1.09-
1.25) <0.001 0.46
1.05 (0.92-
1.19) 0.497
Pulse Wave 
Velocity, per 
100 cm/s
9.52 1.05 (1.02-1.08) 0.002 3.02
1.03 (1.00-
1.07) 0.082 0.46
1.02 (0.98-
1.06) 0.319
* Adjusted for age, gender, race, history of hypertension, fasting glucose, creatinine, albumin, 
heart rate, left ventricular hypertrophy,, history of coronary heart disease and smoking status.
† Adjusted for variables in model 1 plus systolic blood pressure.
9:30 a.m.
1028-11 Multiple Contrast Exposures in Patients With Acute 
Coronary Syndromes and the Risk of Contrast-Induced 
Nephropathy
Rhonda Lahiri, Christos Kasapis, Spencer Walsh, Bruce Rogers, Umesh Tamhane, 
James Froehlich, Brahmajee K. Nallamothu, University of Michigan, Ann Arbor, MI
Background: Contrast volume used during coronary angiography is a risk factor for 
contrast induced nephropathy (CIN). Acute coronary syndrome (ACS) patients often 
undergo multiple contrast studies during hospitalization; the effect of this on CIN has not 
been described.
Methods: We analyzed clinical data from 224 consecutive ACS patients admitted to the 
University of Michigan in 2006. Patients who underwent angiography and had an additional 
contrast study during index hospitalization were identiﬁed, and total contrast volume was 
calculated. Univariate and multivariate analyses described the effect of multiple contrast 
exposures on total contrast volume and CIN (q25% rise in baseline creatinine).
Results: Of 224 ACS patients who underwent angiography, 24 (10.7%) had multiple 
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Conclusions: Our data suggests not all eligible patients with AF are treated with warfarin. 
Reasons for not treating are unclear. Furthermore, those that are treated only spend 
approximately half their time in the therapeutic INR range regardless of whether in a 
community or clinic setting.
9:30 a.m.
1028-16 Risk of GUSTO Moderate or Severe Bleeding identiﬁed 
by the CRUSADE Bleeding Model
Sumeet Subherwal, Anita Y. Chen, Richard G. Bach, Matthew T. Roe, Eric D. Peterson, 
Karen P. Alexander, Duke Clinical Research Institute, Durham, NC
Background: The incidence of major bleeding in NSTEMI varies based on its deﬁnition. 
The ability of a prediction model developed for one bleeding deﬁnition (CRUSADE) to 
accurately estimate risk of bleeding deﬁned by another (GUSTO) and its relation to 
outcome is unknown.
Methods: CRUSADE bleeding includes HCT drop >12%, ICH, retroperitoneal bleeding, 
transfusion if baseline HCT >28% or transfusion if baseline HCT <28% and witnessed 
bleeding. GUSTO bleeding includes fatal bleeding, ICH, bleeding with hemodynamic 
compromise requiring intervention, or witnessed bleeding preceding transfusion. The 
covariates in the CRUSADE Bleeding Model and Score were entered in a model to 
determine outcome of GUSTO bleeding among 71,277 NSTEMI CRUSADE patients. The 
relationship between GUSTO bleeding and in-hospital mortality was assessed across 
CRUSADE Bleeding Score quintiles.
Results: GUSTO bleeding (1.6%) occurred less often than CRUSADE bleeding (9.4%) 
overall, and within each quintile: Very Low Risk (0.5 v. 3.1%), Low (0.9 v. 5.5%), Moderate 
(1.6 v. 8.6%), High (2.1 v. 11.9%), Very High (3.3 v. 19.5%). Discrimination by the GUSTO 
and CRUSADE models was similar (c index in CRUSADE 0.717 vs. GUSTO 0.713). In-
hospital mortality associated with GUSTO bleeding is shown across CRUSADE Bleeding 
Score quintiles. (Figure)
Conclusions: The covariates in the CRUSADE model also predict risk of GUSTO 
bleeding. GUSTO bleeding is associated with a stepwise increase in mortality across 
quintiles of CRUSADE Bleeding Score. 
9:30 a.m.
1028-17 Associations Between Clinical Encounters and Statin 
Adherence
Thomas Maddox, Elizabeth Williams, P. Michael Ho, John Steiner, John S. Rumsfeld, 
Denver VAMC, Denver, CO, University of Colorado Denver, Denver, CO
Background: Our previous research demonstrated that half of veterans are non-adherent 
to statin medications in the year following ACS hospitalization. This study assesses 
whether clinical encounters are associated with statin re-initiation among these veterans 
following ACS discharge.
Methods: In a national VA cohort, we evaluated statin adherence among 6533 patients 
hospitalized with acute coronary syndrome (ACS) between October 2003 and September 
2004. Data was available through 2007. Adherence was deﬁned as >80% of days covered 
with a statin prescription. From this cohort, we identiﬁed patients who had a period of 
non-adherence for 4-8 months after ACS hospitalization, and then re-initiated statin use 
(‘re-initiators’). Using a case-crossover analysis, we evaluated the two-week period prior 
to their re-initiation for any clinical encounter temporally associated with the resumption 
of statin use.
Results: 71% (4613 of 6533) of patients were non-adherent within the ﬁrst 6 months 
after ACS hospitalization. Of these patients, 42% (2764 of 4613) re-initiated statin therapy 
(mean time between statin use periods = 133 ± 95 days). Re-initiators were more likely 
to be younger, but had similar socio-economic status, co-morbidities, and prior statin use 
rates. In case-crossover analysis (where patients serve as their own control), a clinical 
encounter with a primary care provider was more likely to be associated with subsequent 
statin re-initiation (OR 2.9; 95% CI [2.4, 3.7]). Clinical encounters with cardiology (OR 1.3; 
95% CI [0.9, 2.0]), pharmacists (OR 1.4; 95% CI [1.0, 1.9]), or other clinicians (OR 1.1; 
95% CI [0.9, 1.3]) were not signiﬁcantly associated with statin re-adherence.
Conclusions: Among veterans non-adherent to statins following ACS discharge, a clinical 
encounter with a primary care physician was signiﬁcantly associated with resumption 
of statin use. Similar associations were not present with other provider types, including 
cardiologists. Identifying those elements of a primary care provider visit that increase the 
likelihood of statin re-initiation and applying them to non-adherent patients may improve 
use and outcomes.
Table 1. Measures of Glycemic Status at Baseline and Incident Heart 
Failure Risk (N=2386)
Model 1* Model 2†
Variable Mean±SD HR (95% CI) Wald P HR (95% CI) Wald P
Fasting Glucose, 
mg/dL 96±18
1.20 (1.07-
1.35) 10.34 0.001 - - -
Hemoglobin A1c, % 6.1±0.7 1.21 (1.05-1.39) 6.85 0.009
1.08 (0.91-
1.28) 0.71 0.40
2-Hour Glucose, 
mg/dL 133±53
1.17 (1.01-
1.36) 4.17 0.041
1.02 (0.85-
1.23) 0.04 0.85
Fasting Insulin, 
μIU/dL 8.2±5.5
1.01 (0.83-
1.22) 0.00 0.96
0.96 (0.82-
1.12) 0.32 0.57
Insulin resistance, 
HOMA units 2.0±1.6
1.06 (0.92-
1.21) 0.65 0.42
0.95 (0.82-
1.12) 0.34 0.56
B-cell function, 
HOMA units 1.0±0.6
0.91 (0.77-
1.08) 1.05 0.30
0.98 (0.83-
1.15) 0.09 0.77
* Adjusted for age, history of coronary artery disease and smoking, systolic blood 
pressure and heart rate, left ventricular hypertrophy on
electrocardiogram, and creatinine and albumin levels. Hazard ratio (HR) is calculated 
per standard deviation (SD) of increase.
† Adjusted for variables included in model 1 plus fasting glucose levels. Hazard ratio 
(HR) is calculated per standard deviation (SD) of increase.
9:30 a.m.
1028-14 Age and Gender-Speciﬁc Incidence of Atrial Arrhythmia 
Following Elective Total Hip Arthroplasty
Daniel K. Chan, Rachel C. Steckelberg, Dirk Larson, Matthew R. Jensen, Paul 
Huddleston, L. Joseph Melton, III, Veronique Roger, Jeanne Huddleston, Mayo Clinic, 
Rochester, MN
Background: Limited data exist on the incidence and mortality of postoperative atrial 
arrhythmia following elective total hip arthroplasty (THA). The authors identify the 
incidence and mortality of atrial arrhythmia in all patients undergoing elective THA from 
1988-2002 in Olmsted County, Minnesota.
Methods: All residents of Olmsted County, Minnesota who underwent an elective THA 
during 1988-2002 were included in a retrospective cohort study utilizing the computerized 
all-county medical record linkage system of the Rochester Epidemiology Project. 
Incidence rates were calculated using incident cases of postoperative atrial arrhythmia as 
the numerator and number of elective THAs as the denominator.
Results: The one-year incidence of postoperative atrial arrhythmia in all individuals 
(n=689) following elective THA per 1,000 person-years was 33.1 (95% CI 20.8, 50.2). 
Of these within the ﬁrst 7 postoperative days the incidence per 1,000 person-years was 
844.9 (95% CI 421.7, 1511.7), at 28 days 77.4 (95% CI 2.0, 431.2), and at 6 months 7.1 
(95% CI 0.9, 25.6). Although gender was not signiﬁcantly related to atrial arrhythmia (2.9, 
and 5.3 for females and males, respectively), there was a small but signiﬁcant association 
between increasing age and atrial arrhythmia (HR = 1.08, p=0.013). One-year mortality 
was associated with postoperative atrial arrhythmia: Among patients who experienced 
atrial arrhythmia within 30 days post THA, the one-year mortality rate was 10% (95% CI 
0.0, 26.8), compared to 1.6% (95% CI 0.6, 2.5) among patients who did not experience 
atrial arrhythmia within 30 days (p=0.02).
Conclusions: Most atrial arrhythmias following elective total hip arthroplasty occur 
within the ﬁrst 7 days accompanied with a signiﬁcant reduction in one-year survival. 
Further investigation is necessary to determine risk factors contributing to postoperative 
atrial arrhythmias and in turn to determine optimal perioperative protection in patients 
undergoing elective total hip arthroplasty.
9:30 a.m.
1028-15 WhatI is the Quality of Real World Warfarin Control in 
Atrial Fibrillation Patients Treated in the United States? 
A Meta-Analysis
William L. Baker, Jr., Deborah A. Cios, Stephen D. Sander, Craig I. Coleman, Hartford 
Hospital, Hartford, CT
Background: Although for patients diagnosed with atrial ﬁbrillation (AF) the optimal use 
of warfarin [including consistent maintenance within the goal international normalized 
ratio (INR) range] is strongly associated with decreased risks of thromboembolic and 
bleeding events, only a handful of studies have evaluated the quality of anticoagulation 
management in the United States (US). Therefore, we conducted a meta-analysis of US-
based population-based studies to estimate the proportion of eligible AF patients treated 
with warfarin and their time spent within the therapeutic INR range.
Methods: A systematic literature search from January 2005-February 2008 and a review 
of previous warfarin meta-analyses were conducted. Studies were included if they: 1) 
contained at least one warfarin dosing arm enrolling >25 patients; 2) monitored INR 
control for at least 3 weeks; 3) only included patients treated for AF in the US; and 4) 
reported the proportion of time spent in the therapeutic INR range (using a patient-time 
approach). Meta-regression was used to assess impact of study setting.
Results: Our random-effects meta-analysis found that 48% [95% conﬁdence interval 
(CI), 43% to 54%; n=5 studies] of eligible AF patients were treated with warfarin and that 
those treated spent on average 55% [95%CI, 51 to 58%, n=7 studies] of their time in the 
therapeutic INR range. Meta-regression suggests that AF patients treated in a community 
practice setting compared to an anticoagulation clinic spent 11% [95%CI 2% to 20%, n=7 
studies] less time in range.
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1028-20 Why the Delay? Identiﬁcation of Factors Which Delay 
Diagnosis of Acute Aortic Dissection
Craig E. Strauss, Tesfaye D. Kebede, Gina M. Adolphson, Alan T. Hirsch, Sue Duval, 
Frazier Eales, Timothy J. Kroshus, Subbarao Inampudi, Jonathan D. Cohen, Barbara T. 
Unger, Quirino G. Orlandi, Christopher Kapsner, Thomas F. Flavin, Vibhu R. Kshettry, 
Timothy D. Henry, Kevin J. Graham, Kevin M. Harris, Minneapolis Heart Institute 
Foundation at Abbott Northwestern Hospital, Minneapolis, MN
Background: Patients with acute aortic dissection (AAD) suffer a high early mortality. 
This mortality increases with time yet limited data delineate the factors which contribute 
to delays in establishing the AAD diagnosis.
Methods: We reviewed 86 consecutive patients with AAD presenting to a large tertiary 
hospital system over a 4 year period. Factors that contributed to early (<300 minutes) vs. 
late (q 300 minutes) diagnosis were assessed.
Results: We evaluated 54 early patients (median age 62, 61% male, 65% type A, median 
time to diagnosis 124 minutes) and 32 late patients (median age 73, 47% male, 72% type 
A, median time to diagnosis 941 minutes). Among the late diagnosis patients, the initial 
diagnosis was acute coronary syndrome, pulmonary or other etiology in 47%, 19%, and 
34%, respectively. For the 32 patients in the late group, the deﬁnitive imaging modality 
for AAD diagnosis was CT scan in 81%, echocardiogram in 16%, and MRI in 3%. Five 
late patients had initial imaging that was inconclusive for aortic pathology. Late diagnosis 
patients were less likely to have chest pain (53% vs. 85% p<0.001) or back pain (37% 
vs. 57% p=0.07) and were more likely to present with no pain (25% vs. 0%, p<0.0001). 
Mortality was similar for late vs. early diagnosis (31% vs. 24%, p=ns). Patients presenting 
to a community hospital had a median time to diagnosis of 250 minutes compared to 86 
minutes in patients presenting to the tertiary center.
Conclusions: Delayed AAD diagnosis was associated with atypical presenting symptoms, 
initial suspicion of ACS or a pulmonary etiology, and presentation to a community hospital. 
Mortality remains high for patients diagnosed late and a heightened suspicion of AAD 
may improve the time to diagnosis and to deﬁnitive treatment.
9:30 a.m.
1028-21 The Pediatric Cardiac Quality of Life Inventory: A New 
Generalizable Disease-Speciﬁc Quality of Life Measure 
for Children and Adolescents With Congenital and 
Acquired Heart Disease
Bradley S. Marino, Judy A. Shea, Amy Cassedy, Ryan Tomlinson, Kim Hart, Kathleen 
Mussatto, Lynn Mahony, Jane Newburger, Elizabeth Tong, Mitchell I. Cohen, Mark A. 
Helfaer, Anne E. Kazak, Elaine Buchakjian, Gil Wernovsky, Dennis Drotar, Richard 
Ittenbach, The Children’s Hospital of Philadelphia, Philadelphia, PA, Cincinnati 
Children’s Hospital Medical Center, Cincinnati, OH
Background: Survival rates for pediatric cardiac patients have improved, making quality 
of life (QOL) assessment increasingly important. No disease speciﬁc, pediatric cardiac 
QOL tool has been shown to be generalizable to other geographic regions in the US. The 
Pediatric Cardiac Quality of Life Inventory (PCQLI) is a self-administered, reliable, valid, 
disease speciﬁc QOL measure for children with heart disease with parent proxy reporting. 
The purpose of this study was to demonstrate the generalizability of the PCQLI scores.
Methods: The PCQLI development (beta) site and 6 geographically diverse US 
pediatric cardiac centers (national sample) recruited patients 8-18 yrs, with acquired and 
congenital heart disease (CHD). Patient-parent pairs completed appropriate PCQLI forms 
(Child, 8-12 yrs, 23 items; Adolescent, 13-18 yrs, 29 items). The PCQLI generates a 
Total score (TS), and Disease Impact (DI) and Psychosocial Impact (PI) subscale scores. 
We compared item response distributions (frequency counts), patterns of correlation 
(item-total, item-scale, scale-scale, and scale-total), and internal consistency (Cronbach 
A) between the beta site and national sample. Correlation patterns were assessed by 
Pearson-r coefﬁcients. Cronbach A q0.7 was acceptable.
Results: We compared the responses of 1470 patient-parent pairs (578 beta site; 892 
national sample); 72% CHD. No items in the beta and national cohorts had a distribution 
of >90% on a single response option. Patterns of correlation among the beta site and the 
national sample were comparable. Median item-total correlations (beta: 0.57; national: 
0.59) and item-scale correlations (beta: DI 0.58, PI 0.59; national: DI 0.58, PI 0.56) 
were moderate for both samples. Median scale-scale correlations (0.79 for both sites) 
and scale-total correlations (beta: DI 0.95, PI 0.95; national: DI 0.95, PI 0.94) were high. 
Median internal consistency estimates were very high at the beta site (TS 0.93, DI 0.90, 
PI 0.84) and not distinguishable from the national sample (TS 0.93, DI 0.89, PI 0.85).
Conclusion: The PCQLI scores are generalizable across the US pediatric cardiac 
population and may be used for multi-center research studies assessing QOL.
9:30 a.m.
1028-22 Electronic Clinical Decision Support to Improve 
Recognition and Treatment of Patients at Risk for 
Sudden Cardiac Arrest
William C. Daniel, John Spertus, Brian Ramza, Cardiovascular Consultants, Kansas 
City, MO, Mid America Heart Institute, Kansas City, MO
Background: While Sudden Cardiac Arrest (SCA) is both a leading cause of death in 
the US and readily prevented with intracardiac deﬁbrillators (ICDs), the recognition of 
patients at risk for SCA is reportedly only 15-30%. We developed a novel recognition 
algorithm consisting of electronic decision support with prospective data abstraction from 
an electronic medical record, comparison to guidelines-based ICD recommendations and 
electronic ‘ﬂags’ at the time of an outpatient visit to improve recognition.
9:30 a.m.
1028-18 The Impact of Medical Non-Compliance on Long-Term 
Outcomes, Following an Acute Coronary Syndrome in a 
Minority and Uninsured Population
Amit P. Amin, Ekanka Mukhopadhyay, Sandeep Nathan, Sirikaran Napan, Russell F. 
Kelly, John H. Stroger Hospital of Cook County, Chicago, IL
Background:The long-term impact of non-compliance with evidence-based medical 
therapies after acute coronary syndromes (ACS) on long-term outcomes is not well 
recognized, particularly in minority and uninsured populations.
Methods:Consecutive ACS patients admitted at a large urban hospital, were followed 
long-term for compliance with evidence-based medical therapies (aspirin, clopidogrel, 
statins, beta blockers and ACEI/ARBs). Non-compliance was deﬁned as proportion of 
days covered (PDC) a 80% and a non-compliance score was calculated as a sum of non-
compliant medications. The primary combined outcome was mortality and myocardial 
infarction (MI). Kaplan-Meier and Cox regression analyses were used to explore the 
impact of medical non-compliance. Propensity score analysis was used to adjust for the 
effect of loss-to-follow-up bias.
Results:Of the 878 patients (84% minorities, 73% uninsured, 54% diabetics), 134 (15.3 
%) presented with STEMI, 390 (44.4 %) with a NSTEMI and 354 (40.3 %) with unstable 
angina. Revascularization was performed in 566 (64.5%); with PCI 406 (46.3%) and CABG 
160 (18.2%). The remainder 312 (35.6 %) patients underwent medical management. A 
total of 100 (11.4%) patients died, and 25 (2.9%) patients had an MI at median follow-up of 
2.2 years. Medical non-compliance with greater than 4 medical therapies was associated 
with a prohibitive adverse event-free survival rate as compared with compliant patients 
(37.7% vs. 85.2% respectively). A multivariate Cox model adjusting for risk factors, 
presentation acuity, revascularization, LV function, CAD severity and loss-to-follow-up 
bias, showed that medical non-compliance with 4-5 evidence-based medication classes 
was the strongest factor associated with death or MI (HR 6.24; 95% CI 4.16 to 9.35).
Conclusions:Non-compliance with evidence-based medical therapies post-ACS is 
strongly and independently associated with adverse events in minority and uninsured 
patients and is the single most important factor contributing towards adverse events on 
long-term follow-up.
9:30 a.m.
1028-19 Blood Pressure Response During Exercise and 
Cardiovascular Outcome in Coronary Artery Disease: 
Heart and Soul Study
Mohammad R. Habibzadeh, Ramin Farzaneh-Far, Beeya Na, Mary A. Whooley, Nelson 
B. Schiller, University of California, San Francisco, San Francisco, CA, Veterans Affairs 
Medical Center, San Francisco, CA
Background: The prognostic implications of a higher blood pressure response to exercise 
are controversial. We sought to evaluate the association of blood pressure response to 
exercise with cardiovascular events in ambulatory adults with coronary artery disease.
Methods: A study population of 937 patients with stable coronary artery disease 
underwent treadmill exercise stress and were followed for 5 years. Participants were 
divided into quartiles based on peak systolic blood pressure (SBP) change during 
exercise. We used Cox proportional hazards models to evaluate the association of change 
in SBP with subsequent hospitalization for heart failure (HF), myocardial infarction (MI), 
stroke or transient ischemic attack (TIA), and all cause mortality
Results: (Figure). Compared with the 244 participants who had SBP changes in the lowest 
quartile, the 204 participants with SBP changes in the highest quartile had a decreased 
rate of hospitalization for HF [Hazard Ratio (HR) 0.4, 95% CI, 0.2-0.7; p=0.001], MI (HR 
0.3, 95% CI 0.3-0.7; p=0.002), stroke or TIA (HR 0.3, 95% CI 0.1-0.8; p=0.02), and all 
cause mortality (HR 0.5, 95% CI 0.3 - 0.8; p=0.001). After adjusting for age and exercise 
capacity, participants with SBP change in the highest quartile remained at decreased risk 
of MI (HR 0.5, 95% CI 0.2-1.0, P=0.04) and death (HR 0.3, 95% CI 0.1-1.0, P=0.05).
Conclusion: In ambulatory patients with coronary artery disease, a higher blood pressure 
response to exercise is associated with a reduction in future adverse events 
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1028-25 Long-Term Outcomes of Drug-Eluting Versus Bare-
Metal Stents in Underrepresented Populations: Results 
From the Linked NCDR and CMS Database
J Matthew Brennan, Kevin J. Anstrom, Eric L. Eisenstein, David Dai, Ghazala Haque, 
David F. Kong, Ralph G. Brindis, Art Sedrakyan, David Matcher, Eric D. Peterson, 
Pamela S. Douglas, Duke University Medical Center, Durham, NC
Background: Previous comparisons of drug eluting stents (DES) with bare metal stents 
(BMS) have not been sufﬁciently powered to evaluate outcomes in women, minorities 
and the elderly.
Methods: We studied 262,700 Medicare patients undergoing PCI in the National 
Cardiovascular Data Registry (NCDR) from 2004 to 2006. Follow-up events were obtained 
by linking to Medicare claims data. Outcomes were adjusted using propensity modeling with 
inverse probability weighted estimators as well as with Cox proportional hazards models.
Results: Underrepresented populations made up a substantial portion of the NCDR 
population including 112,450 women, 125,890 patients q75 years old and 15,456 minority 
patients. DES were used in 83% of patients; mean follow-up was 15 months. Unadjusted 
30-month mortality rates were higher in blacks and in older individuals and slightly lower in 
women than in their counterparts. DES were associated with signiﬁcantly lower adjusted 
death or death/recurrent MI risk in all but the Hispanic population. Revascularization was 
also slightly less common in DES patients from all but black and Hispanic populations. 
(Table; Bold HR values = signiﬁcant differences)
Conclusions: Among Medicare patients, DES use was associated with a lower risk of 
death, MI, and revascularization independent of age or gender. However, this beneﬁt was 
not consistent across racial and ethnic lines despite universal access to insurance.
Subgroup Analysis of Outcomes Following PCI
Patient 
Characteristics n
Death Death/MI Revascularization
30-Month
Crude 
Event 
Rate (%)
Adjusted HR
30-Month
Crude 
Event 
Rate (%)
Adjusted
HR
30-Month
Crude Event 
Rate (%)
Adjusted
HR
Sex
Male
---
---
Female
---
---
150,233
---
---
112,450
---
---
8.13
---
---
8.04
---
---
0.74
(0.71,0.78)
---
0.76
(0.72,0.80)
---
11.07
---
---
11.17
---
---
0.75
(0.72,0.78)
---
0.75
(0.72,0.78)
---
13.73
---
---
12.56
---
---
0.92
(0.89,0.95)
---
0.91
(0.87,0.95)
Age
65-75
---
---
q75
---
---
136,810
---
---
125,890
---
---
5.71
---
---
10.68
---
---
0.73
(0.69,0.77)
---
0.76
(0.73,0.79)
---
8.68
---
---
13.76
---
---
0.75
(0.72,0.79)
---
0.75
(0.72,0.78)
---
14.36
---
---
12.00
---
---
0.88
(0.85,0.91)
---
0.96
(0.92,1.00)
Race
White
---
---
Black
---
---
Hispanic
---
---
237,289
---
---
11,035
---
---
4,421
---
---
8.03
---
---
10.13
---
---
9.18
---
---
0.75
(0.72,0.77)
---
0.69
(0.60,0.79)
---
0.94
(0.72,1.22)
---
11.01
---
---
13.94
---
---
12.78
---
---
0.75
(0.73,0.77)
---
0.69
(0.61,0.79)
---
0.91
(0.73,1.14)
---
13.35
---
---
11.69
---
---
12.62
---
---
0.91
(0.89,0.94)
---
0.90
(0.78,1.04)
---
1.20
(0.94,1.53)
Methods: 553 ICD-eligible patients with clinic visits between 8/07 and 12/07 were 
included for analysis. Since all patients met eligibility criteria for possible implantation 
of ICDs, the optimal rate of recognition and treatment (ICD implantation or documented 
medical or patient reason for refusing an ICD) is 100%.
Results: The baseline recognition of patients in 2005 prior to implementation of the 
electronic decision support was 25% with ICD implantation rate of 18%. The Table 
describes the recognition and treatments of 553 patients with LVEF<36% evaluated 
between 8/07-12/07 after protocol implementation.
Conclusions: A comprehensive practice wide electronic decision support process for 
recognition of pts at risk for SCA, markedly improved the rates of both recognition and 
treatment. Such decision support tools hold great promise in accelerating the translation 
of guidelines into clinical practice and should be prospectively tested for their impact on 
clinical outcomes.
Results of 553 pts with LVEF <36% evaluated between 8/07-12/07
ICD Implanted Number % of Total
ICD Implanted 312 56%
Not a Candidate for ICD 55 10%
Pt refusal of ICD 50 9%
Lost to Follow Up 19 3%
LVEF Improved to > 35% 58 10%
Temporary Exclusion 40 7%
Unrecognized at Risk for SCA 19 3%
Caucasion ICD Implantation 214/452 47%
Non-Caucasion ICD Implantation 39/79 49%
9:30 a.m.
1028-23 A Systematic Review of the Validity of Administrative 
Claims in Cardiovascular Research
Leonardo Tamariz, Nicole Stevens, Shirin Shafazand, Hermes Florez, Hua Li, Quanli 
Ma, Vinit Nair, Ana Palacio, University of Miami, Miami
Background: Administrative claims are commonly used in cardiovascular research. 
Lack of validity of medical claims can result in bias. Our aim was to review the available 
evidence regarding the accuracy of billing codes when compared to medical records.
Methods: We searched MEDLINE® using “International classiﬁcation of diseases (ICD) 
” and “medical records” as medical subject headings. Articles were retrieved if they were 
reported in English, reported original data, and compared administrative claims with 
medical records. We calculated sensitivity, speciﬁcity, positive and negative predictive 
values.We evaluated the quality of the studies using a validated tool.
Results: The literature search yielded 150 articles that were potentially relevant, we 
identiﬁed 18 cardiovascular studies. The most commonly validated databases were local 
hospital or outpatient databases (39%) and regional databases. The median quality of 
cardiovascular studies was 69% (39-100%).Eight studies evaluated codes for myocardial 
infarction. Five studies evaluated the sensitivity of the 410.x code alone and the median 
sensitivity was 85% (67-94%), speciﬁcity ranged from 93-100% and a PPV of 90% (84-
100%). Five studies evaluated codes for heart failure. Two studies evaluated the 428.x code 
had a sensitivity that ranged from 63-82%, speciﬁcity 95-96% and a PPV that ranges from 
84-90%. One study evaluated codes for hypertension (401.x). The sensitivity of this code 
was 71% with a speciﬁcity of 75% and a PPV of 77%.One study evaluated the validity of 
ventricular arrhytmias with a sensitivity of 91%. Two studies evaluated codes for venous 
thromboembolism. The codes for deep vein thrombosis (451.x, 453.x) had a sensitivity 
ranging from 67 to 86% and a PPV ranging from 31 to 75%. Codes for pulmonary embolism 
(415.x) had a sensitivity of 74-82% and a PPV that ranges from 24-86%.
Conclusion: There are a limited number of studies exploring the validity of ICD claims 
in cardiovascular research. The validity is highest for acute myocardial infarction and 
ventricular arrhythmias and lowest for hypertension and heart failure.
9:30 a.m.
1028-24 Identifying Risk of New-Onset Heart Failure in the 
Elderly: NT-proBNP, Echocardiography or Both
Christopher R. DeFilippi, Stephen Seliger, John Gottdiener, Robert Christenson, Willem 
Kop, University of Maryland School of Medicine, Baltimore, MD
Introduction. The elderly account for the majority of heart failure (HF) admissions. A 
strategy to identify those at highest risk could lead to targeted interventions in this large 
population. We hypothesized that N-terminal pro B-type natriuretic peptide (NT-proBNP) 
levels and echocardiograpic (echo) evaluation of left ventricular ejection fraction (LVEF) 
in combination could stratify risk of HF.
Methods. Baseline echo’s and NT-proBNP were measured in 3,765 Cardiovascular 
Health Study (CHS) participants without a HF history. LVEF was qualiﬁed as normal ([NL], 
>55%, n=3,468), borderline ([BORD], 45-55%, n=194), abnormal ([ABN], <45%, n=100). 
A high NT-proBNP is >190 pg/mL (n=1,156) for HF risk, based on prior analysis in CHS. 
Participants were followed for up to 15 years for new-onset HF.
Results. Subjects age was 72.7±5.4 with 41.4% being male, with an incidence of HF 
of 2.6/100 person-years. A low NT-proBNP level identiﬁed subjects at low-risk for HF 
irrespective of LVEF. For those with a high NT-proBNP level, LVEF further differentiated 
risk (ﬁgure). These ﬁnding remained signiﬁcant after adjustment for demographics, 
traditional risk factors and renal function.
Conclusions. New onset HF is common in the elderly. An NT-proBNP level can serve as 
an initial “gatekeeper” with assessment of LVEF further stratifying risk in those with an 
elevated level. Such a strategy may direct targeted interventions to those at highest risk.
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Conclusions: Among Medicare Beneﬁciaries, important clinical characteristics, vital 
signs, and laboratory values should be considered for risk-adjustment for 30-day 
mortality.
9:30 a.m.
1028-28 Recent National Trends in Heart Failure Readmission 
Rates
Joseph S. Ross, Jersey Chen, Zhenqui Lin, Héctor Bueno, Jepth P. Curtis, Elizabeth 
E. Drye, Patricia S. Keenan, Sharon-Lise T. Normand, Geoffrey C. Schreiner, John 
A. Spertus, Maite Vidán, Yun Wang, Yongfei Wang, Harlan M. Krumholz, Mount Sinai 
School of Medicine, New York, NY, Yale University School of Medicine, New Haven, CT
Background: In July 2009, as a performance measure of quality, Medicare will begin 
publicly-reporting for all U.S. hospitals risk-standardized all-cause 30-day readmission 
rates (RSRRs) among beneﬁciaries discharged after heart failure hospitalization. 
However, recent national trends in RSRRs have not been reported and it is not known if 
hospital-level performance is improving or variation is decreasing.
Methods: We used 2004-2006 Medicare administrative data for all fee-for-service 
pts admitted to a U.S. hospital for heart failure, identiﬁed using ICD-9-CM codes, and 
discharged alive. We examined annual RSRRs, calculated using two-level hierarchical 
linear models that accounted for age, sex, and multiple co-morbidities. The RSRR model 
has been approved by the National Quality Forum for hospital comparisons.
Results: There were 570,996 distinct hospitalizations for heart failure in 4728 hospitals 
in 2004; 544,550 in 4694 in 2005; and 501,234 in 4674 in 2006. Unadjusted 30-day all-
cause readmission rates were grossly similar over this period: 23.0% in 2004, 23.3% 
in 2005, and 22.9% in 2006. The mean and distribution of RSRRs were also similar: 
mean 23.7% in 2004, 23.9% in 2005, and 23.8% in 2006, and there was substantial 
heterogeneity in RSRRs among hospitals in all years (Figure).
Conclusions: National mean and RSRR distributions among Medicare beneﬁciaries 
discharged after heart failure hospitalization have not changed in recent years, indicating 
no recent improvement in readmission care.
9:30 a.m.
1028-29 Trends in Volume and Major Complications Among 
Medicare Beneﬁciaries Undergoing Revascularization 
Procedures: Fiscal Year 2003 Through Fiscal Year 2006
Phillip P. Brown, Aaron D. Kugelmass, David J. Cohen, Matthew R. Reynolds, Steven D. 
Culler, April W. Simon, Cardiac Data Solutions, Atlanta, GA, Emory University, Atlanta, GA
Background: This analysis identiﬁes trends in revascularization procedures, both CABG 
surgery and PCI among Medicare beneﬁciaries (MB) and the frequency of selected 
complications associated with these procedures.
9:30 a.m.
1028-26 Baseline Clinical Characteristics Associated With 
All-Cause Mortality in CRT-D Patients: A Ten-Year 
Retrospective Analysis From the CONTAK CD Study
Teresa De Marco, John Boehmer, Brian Jaski, Colleen Curran, Patrick Yong, University 
of San Francisco Medical Center, San Francisco, CA, Boston Scientiﬁc, Saint Paul, MN
Background: Cardiac resynchronization therapy with deﬁbrillation (CRT-D) has been 
studied for over ten years. While all-cause mortality (ACM) has been reported with CRT-D, 
the inﬂuence of baseline clinical variables as a function of follow-up duration has not been 
previously examined.
Methods: ACM data from the CONTAK CD study, which began in 1998, were analyzed 
retrospectively. Baseline clinical covariates including patient history, functional capacity, 
medications, electrocardiographic, and echocardiographic variables were initially 
analyzed for a univariate association with mortality using a Cox proportional hazards 
model with continuous variables split at the median value. Covariates signiﬁcant at p<0.05 
were entered into a multivariate model and analyzed at two years, ﬁve years, and ten 
years to determine associations over time.
Results: Of 501 patients (pts) enrolled, 338 (67%) have died. The Kaplan-Meier curve 
for ACM is displayed below along with a table reporting clinical variables signiﬁcantly 
associated with ACM from the multivariate analysis over time.
Conclusions: In this retrospective analysis of the CONTAK CD study, diminished 
exercise capacity, measures of poor renal function, absence of heart failure medications, 
and small body mass index consistently demonstrated signiﬁcant associated with ACM in 
CRT-D recipients over time. With increased follow-up duration, ischemic etiology, age, and 
Class IV heart failure also emerged as independent predictors of ACM.
9:30 a.m.
1028-27 The Importance of Clinical Predictors of 30-Day 
Mortality Among Medicare Beneﬁciaries
Adrian F. Hernandez, Li Liang, Sean M. O’Brien, Paul Heidenreich, Clyde Yancy, 
Lesley H. Curtis, Eric D. Peterson, Gregg C. Fonarow, Duke Clinical Research Institute, 
Durham, NC, University of California-Los Angeles, Los Angeles, CA
Background: Public reporting of 30-day mortality for patients hospitalized for heart failure 
by administrative data only has recently initiated. Merging of clinical data with Medicare 
claims may allow clinical characteristics to be used for improved risk-adjustment of 
outcomes.
Methods: Patients 65 years and older who were hospitalized in an American Heart 
Association’s Get With the Guidelines-HF registry were matched with Medicare claims 
from 2005-06. Stepwise models with multivariable logistic regression analysis using the 
generalized estimating equations (GEE) method, adjusting for within-hospital clustering, 
was performed to determine the importance of clinical factors associated mortality within 
30 days after admission.
Results: Among 9560 patients from 83 hospitals, the 30-day mortality after admission 
was 9.4%. The mean age was 80 years old with 55.6% female, 7.7% black. Mean ejection 
fraction was 42.5%. Mean laboratory data included BNP of 1175 pg/mL, creatinine of 
1.6 mg/dL, BUN of 31.4 mg/dL, and 23.0% with abnormal troponin. Stepwise modeling 
showed improvement in performance: Demographics only (C-index 0.596), plus past 
medical history (C-index 0.641), plus HF characterization/other conditions (C-index 
0.657), plus vital signs (C-index 0.711), plus labs (C-index 0.741) (Final model Table).
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Orange County Convention Center, West Hall D
3:30 p.m.
1037-01 Long-Term Survival of Infective Endocarditis: A 
Population-Based Study in Olmsted County, Minnesota
Daniel D. Correa de Sa, Jason C. Schultz, Justin M. Thomas, Alok Bachuwar, Michal 
Pazdernik, Nandan S. Anavekar, Imad M. Tleyjeh, James M. Steckelberg, Wilson R. 
Walter, Larry M. Baddour, Mayo Clinic, Rochester, MN
Background: The long-term prognosis of infective endocarditis (IE) in the US has not been 
examined in a population-based study. Therefore, we conducted this retrospective investigation 
to characterize the long-term survival of patients with IE in Olmsted County, MN.
Methods: Utilizing resources of the Rochester Epidemiology Project, we identiﬁed all 
deﬁnite or probable IE cases by Duke Criteria in Olmsted County adults from 1985 to 
2006. Cumulative probability of death was calculated using Kaplan-Myer.
Results: A total of 94 cases were identiﬁed. Median age was 66 years with a male 
predominance (66%). The most commonly affected valves were mitral (57%) and aortic 
(23%). Prosthetic valves (PV) were involved in 31%. Pathogens included Staphylococcus 
aureus (29%) and viridans group streptococci (22%). Overall, 3-month cumulative 
probability of death was 24%. S. aureus etiology was signiﬁcantly associated with 3-month 
mortality (HR: 4.7, 95%CI: 1.7-12.7, p=0.02). Among patients who survived the initial 3 
months, 5-year cumulative probability of death was 28%. After adjusting for age, chronic 
renal failure (CRF) (OR: 2.0, 95%CI: 1.1-3.5, p= 0.02) and PV infection (OR: 2.0, 95%CI: 
1.1-3.5, p= 0.02) were associated with long-term mortality.
Conclusion: Long-term survival of IE among patients in Olmsted County, MN was low, 
particularly for patients with S. aureus IE due to high short-term mortality. In patients who 
survived six months, CRF and PV endocarditis were associated with high mortality.
3:30 p.m.
1037-02 Heart Failure and Mortality in Diabetes: Pooled Analysis 
of 30,197 Subjects
Masoor Kamalesh, Ton Cleophas, Indiana University, Indianapolis, IN, European College 
of Pharmaceutical Medicine, Lyon, France
Background: Despite recent successes in improving mortality from CHF with drugs and 
devices, several reports suggest increased mortality among CHF subjects with diabetes. 
Our objective was to conduct a meta-analysis to determine aggregate risk of mortality and 
hospitalization in CHF and diabetes.
Methods: Observational and randomized trials reporting on CHF and mortality in diabetes 
since 2001 were identiﬁed through MEDLINE and Cochrane database searches and 
hand searching of cross references. Minimum follow up of the study cohort should have 
been at least 6 months. Studies with very small sample size (n<200) were excluded. Major 
outcome measure of mortality and secondary outcome measure of CHF hospitalization 
were extracted from published results. Analysis was done for composite mortality and 
hospitalization risk, heterogeneity, robustness and publication bias.
Results: A total of 15 trials (n=30,197 subjects) were eligible. There were a total of 8260 
deaths with 2351 among diabetics, from available data. The relative risk (RR) was signiﬁcantly 
higher for diabetics by 28% (95% conﬁdence interval CI 1.22-1.34 -p<0.0001). Similarly 
pooled RR for hospitalization was signiﬁcantly higher for diabetics by 36% (95% CI 1.26-1.48- 
p<0.0001). Heterogeneity was present (p<0.01) and accounted for by observational studies. 
There was no signiﬁcant publication bias and lack of robustness was not obvious. 
Conclusions: Aggregrate mortality and recurrent hospitalization risk for diabetic subjects 
with CHF is 28% and 36% higher than for non-diabetic subjects.
3:30 p.m.
1037-03 Do Clinical Trials Represent the Population at Risk?
Robert J. Bryg, Tae Yang, Sahar Sohrabian, David J. Bryg, Olive View-UCLA Medical 
Center, Sylmar, CA
Background: Randomized clinical trials (RCT) are considered the gold standard for 
determining evidence for the practice of clinical medicine. There is increasing controversy 
about the results of drug company sponsored trials and how they should be applied to 
Methods:This retrospective study examined MedPar Files from ﬁscal year 2003 (FY03) 
to ﬁscal year 2006 (FY06) and selected all MB undergoing a revascularization procedure. 
The study population consists of 519,014 CABG and 1,524,490 PCI admissions. ICD-9-
CM codes were used to identify the complications.
Results: The table indicates CABG surgery admissions have declined (7.4% annually, 
p<0.001) during the study period, while PCI volume peaked in FY04 at 396,960 and has 
also declined (p<0.001) since. The table indicates that in-hospital mortality has declined 
(p<0.001) for both. Both PCI complication rates declined (p<0.001) during the study 
period. The perioperative stroke rate among CABG surgery has also declined (p<0.001). 
However, the rates of infection and ARDS following CABG increased (p<0.001) from 
FY03-FY06.
Conclusions: There has been a signiﬁcant decline in CABG volume amongst MB from 
FY03-FY06 and PCI peaked amongst MB in FY04. Despite the well documented increase 
in risk factors of patients undergoing revascularization, we ﬁnd improved outcomes for all 
complications except for post-op infection and ARDS in MB undergoing CABG.
Trends among Medicare Beneﬁciaries Undergoing Revascularization 
Procedures: FY 2003 - FY 2006
FY-2003 FY-2004 FY-2005 FY-2006
PCI Admissions (no CABG)
Number of Admission 364,555 396,960 384,317 378,658
In Hospital Mortality, % 1.80 1.74 1.46 1.42
New Onset Hemodialysis, % 0.89 0.90 0.80 0.44
Any Vascular Complication, % 5.32 5.28 4.75 3.94
CABG (no Valve Surgery)
Number of Admission 143,042 134,707 127,679 113,586
In Hospital Mortality, % 3.63 3.60 3.29 3.12
New Onset Hemodialysis, % 0.91 0.96 0.96 0.92
Post Operative Stroke 1.67 1.55 1.44 1.33
Post Operative Infection 2.50 2.69 2.76 2.83
Post Operative ARDS 5.63 6.07 6.58 7.55
9:30 a.m.
1028-30 Patient Attitudes for Discussing Health-Related Quality 
of Life in Clinical Practice
Prashant Vaishnava, Eldrin Lewis, Brigham and Women’s Hospital, Boston, MA
Background: Improvement in health-related quality of life (HRQL) is increasingly 
recognized as a priority in the management of heart failure (HF). Despite increasing 
use of HRQL assessment in clinical studies, HRQL is rarely used in clinical practice. 
We assessed patient attitudes for the incorporation of HRQL discussions into clinical 
practice.
Methods: A total of 98 patients (mean age 57, LVEF 39, 26.5% women, 33% with NYHA 
class III/IV) completed a modiﬁed patient attitudes questionnaire for the incorporation of 
assessment and discussion of HRQL into ambulatory practice. Patients reported their 
HRQL through a) the Minnesota Living with Heart Failure Questionnaire (MLHF), a 21 
item validated instrument of HRQL with scores ranging from 0 to 105 and higher scores 
representing worse HRQL and b) the Visual analog scale (VAS) for overall health with 
scores ranging from 0 to 100 (higher score representing better health state). In a written 
patient attitudes’ questionnaire, subjects were asked about their preferences, including 
whether improvement in their HRQL was their most important goal and if they would be 
interested in knowing how their HRQL compared to that of other patients.
Results: Mean MLHF score was 40.4±27; and VAS, 62.2±20. Most (94%) would be 
willing to complete a brief survey on HRQL 5 minutes before their doctor’s visit. 96% of 
participants agreed or strongly agreed that improving their HRQL was their most important 
goal, with 74% agreeing or strongly agreeing that they would want to know how their 
HRQL compared to that of others with heart failure. 98% agreed or strongly agreed that 
it was important to discuss ways to feel better with their doctor. Only 46% of participants 
agreed or strongly agreed that they would be willing to sacriﬁce some of their remaining 
time alive to live better. There was no difference in attitudes based upon HRQL.
Conclusions: The majority of patients acknowledge the importance of discussing HRQL 
directly and would be willing to complete HRQL assessment prior to clinic irrespective of 
HRQL. Routine use of HRQL instruments in clinical practice will not be limited by patient 
preference.
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inappropriate indications. A higher percentage of SE were for inappropriate indications 
and appropriateness score was lower in the academic practice. The major inappropriate 
indication (37%) was use of SE when exercise electrocardiography would have sufﬁced. 
Conclusions: SE were commonly requested for inappropriate indications in both 
institutions, but especially in the academic practice. Educational initiatives including 
dissemination of the AC may achieve substantial health care savings. 
Table Appropriateness score and rating for stress echocardiograms for the entire study 
group and by site
Total (n = 287) Academic practice (n = 208) VAMC (n = 79)
Score mean ± SD 5.7 ± 2.3 5.5 ± 2.3 6.1 ± 2.2*
Rating n (%)
Appropriate 160 (55.7) 110 (52.9) 50 (63.3)
Inappropriate 75 (25.8) 60 (28.9) 14 (17.7) **
Uncertain 25 (8.7) 18 (8.6) 7 (8.9)
Unclassiﬁed 28 (9.8) 20 (9.6) 8 (10.1)
* p < 0.05 VAMC vs academic practice, ** p < 0.05 VAMC vs academic practice for 
inappropriate studies
3:30 p.m.
1037-06 Patterns of Cardiac Stress Testing After 
Revascularization in Community Practice
Bimal R. Shah, Patricia A. Cowper, Manesh R. Patel, Pamela S. Douglas, Eric D. 
Peterson, Duke Clinical Research Institute, Durham, NC
Background: Recent ACC appropriateness criteria have deﬁned recommendations for 
cardiac stress testing following coronary revascularization, but current testing patterns 
are not well characterized in community practice.
Methods: Utilization and timing of stress testing >30 days after revascularization with 
CABG or PCI were determined from UnitedHealthcare’s national claims database from 
July 1, 2004 to June 30, 2007. Subsequent rates of angiography and need for repeat 
revascularization were examined.
Results: Of 45,382 members undergoing revascularization (34,298 PCI and 11,084 
CABG), 49% had at least one cardiac stress test during a mean follow-up period of 
435±270 days. One-third had multiple stress tests, and nuclear imaging accounted for 
75% of tests. Table 1 shows the frequency of stress testing and time to ﬁrst stress test. 
Of those tested, 2149 (10%) subsequently had a cardiac catheterization and 975 (4%) 
required repeat revascularization within 30 days of repeat stress testing.
Conclusions: Half of all members in community practice had at one or more stress test 
within 18 months of coronary revascularization. Of those tested, less than 5% required 
repeat revascularization. Our ﬁndings demonstrate the potential need to better deﬁne the 
role for stress testing after recent revascularization.
Table 1. 
All
(n=45,382)
PCI
(n=34,298)
CABG
(n=11,084)
Mean (STD) Age (years) 59(10)
58
(10)
60
(9)
Female 22% 23% 19%
Any stress test 49% 52% 41%
Stress Echo 6% 7% 5%
Nuclear 40% 43% 29%
Exercise ECG 8% 7% 12%
Multiple Stress Tests 30%
Median time to 1st test (days) 351 325 528
Mean (STD) follow-up
(days)
435
(270)
437
(270)
427
(270)
3:30 p.m.
1037-07 Follow-Up Studies After Normal Stress SPECT 
Sestamibi Studies: How Often Are They Done 
Routinely?
Damita J. Carryer, John W. Askew, David O. Hodge, Todd D. Miller, Raymond J. Gibbons, 
Mayo Clinic, Rochester, MN
Purpose/Objectives: We sought to determine the prevalence and timing of follow-up 
SPECT after a normal stress SPECT scan in patients without prior CAD and to compare 
the timing of routine follow-up SPECT scans with the patient’s Cedars-Sinai “warranty 
period” (time to 1% risk of death/MI).
Background: Clinicians may perform follow-up imaging after normal SPECT studies on a 
“routine” basis (no change in symptoms, no intervening MI or revascularization) to provide 
continuing reassurance, but there are few data regarding this practice.
Methods: Using the Mayo Rochester Nuclear Cardiology Lab database, we identiﬁed 
all patients with normal stress SPECT scans in 2002 and no prior CAD (deﬁned as prior 
MI, PCI, or CABG). The Mayo electronic medical record and, when necessary, a mailed 
patient questionnaire were used to identify the initial follow-up SPECT study (if any) 
performed at Mayo or another institution over the next 5 years. “Routine” follow-up studies 
were those performed without a change in symptoms or intervening MI, PCI, or CABG. 
The “warranty” period for each patient was calculated from tables published by Cedars-
Sinai Medical Center (JACC 41: 1329-1340, 2003).
Results: There were 2,354 patients without prior CAD who had normal stress SPECT 
studies in 2002. During 5-year follow-up, 449 patients (19%) had follow-up scans. 309 
patients (69% of the follow-up scans; 13% of the total study group) had routine follow-
up scans. Routine scans were more common in women (p<0.0001) and after exercise 
SPECT (p=0.02). The time to routine follow-up scan was a median of 2.1 years (25th
clinical practice. There is little data on how well the populations selected for clinical trials 
represent the populations at risk for death and disability from cardiovascular disease. We 
sought to determine cardiac and noncardiac mortality normalized for age and gender in 
the control arms of blood pressure and cholesterol lowering studies published over the 
past 20 years.
Methods: We analyzed the control arms in 37 RCT’s, 18 for cholesterol lowering and 19 
for blood pressure lowering and calculated cardiac and noncardiac mortality compared to 
what would be expected in similarly age and gender matched populations.
Results: Noncardiac mortality was extremely low in all studies. In primary prevention 
cholesterol studies, it averaged 57% of expected, in secondary prevention trials 68% and 
in hypertension studies, 52%. Cardiac mortality was highest in the secondary prevention 
trials at 225% of expected. The hypertension studies and primary prevention studies 
were similar with cardiac mortality 25% higher than an unselected population. There was 
marked heterogeneity in the trials evaluated with signiﬁcant inter-trial variation of both 
cardiac and noncardiac mortality, though only 3 trials had noncardiac mortality above that 
expected from an unselected population. None of the hypertension trials had noncardiac 
mortality higher than expected.
Conclusions: RCTs for both hypercholesterolemia and hypertension have highly 
selected populations; with noncardiac mortality 33-50% lower than expected. Cardiac 
mortality was not as high as would be expected for a “high risk” population. Extreme care 
must be utilized in extrapolating results of these studies in determining net clinical beneﬁt. 
In addition, we need a better understanding of how clinical trial populations relate to the 
“real world”.
3:30 p.m.
1037-04 Distribution of Coronary Artery Disease by Cardiac 
CT Angiography in Patients With Appropriate, 
Inappropriate and Uncertain Indications Based Upon 
the Published Appropriateness Criteria
M. Rizwan Khalid, Fatima R. Khalid, Gorgi Kozeski, Leonidas Vlantis, William Tenet, 
Frank C. Messineo, Olakunle Akinboboye, Emory University, Atlanta, GA, New York 
Hospital Medical Center Queens, Flushing, NY
Background:Cardiac CT Angiography (CTA) has evolved into a robust non-invasive 
modality to evaluate CAD. The ACCF has published appropriateness criteria for CTA in 
2006. We intend to assess the distribution of CAD amongst patients (pts) with appropriate 
(A), uncertain(U) and inappropriate(I) criteria for CTA. The study also examines the 
current utilization pattern of CTA in a large cardiology practice.
Methods:We performed a cross-sectional review of 191 pts referred for CTA. Pts were 
divided into three categories A, U or I based on the guidelines. CTA results were further 
divided into three groups: Obstructive CAD (deﬁned as at least one lesion with stenosis 
>50%), non-obstructive CAD and normal.
Results:A total of 191 CTA studies were examined. The mean age was 63 years and 
58% were males. Chest pain and asymptomatic CAD was the indication in 36% and 29% 
of pts respectively. According to the guidelines, 48 (25%) pts had A, 49 (26%) had U and 
93 (47%) had I indications. Fifty-eight pts (30%) had signiﬁcant CAD, 71(37%) had non-
obstructive CAD and 47(25%) had no CAD. Distribution of CAD in pts without known CAD 
(n=128) in the three groups is shown in table 1.
Conclusions:Chest pain evaluation is the most common indication for CTA in our study 
while 47% of the tests performed would be considered inappropriate according to the 
guidelines. Frequency and severity of CAD was not different among the three pre-deﬁned 
categories.
Table 1: Distribution of CAD in pts without known CAD (n=128) in the 
three pre-deﬁned categories 
Indication Obstructive CAD
n(% of row total)
Non-obstructive CAD
n(% of row total)
Normal
n(% of row 
total)
Total
n(% of column 
total)
Appropriate 12(31) 17(44) 10(26) 39(30)
Uncertain 9(32) 11(39) 8(29) 28(22)
Inappropriate 14(23) 27(44) 20(33) 61(48)
Total 35(18) 55(29) 38(30) 128(100)
3:30 p.m.
1037-05 Comparison of Compliance With Appropriateness 
Criteria for Stress Echocardiography in an Academic 
Practice and Veterans Administration Medical Center
Howard J. Willens, Orlando Gomez-Marin, Alan Heldman, Maureen H. Lowery, Simon 
Chakko, Roberto Miki, Sharon Andrade-Bucknor, Cheryl Postel, Tahira Hasan, Fareed 
Mohammed, University of Miami Miller School of Medicine, Miami, FL, Miami VAMC, 
Miami, FL
Background: Although there are differences in the rate of utilization of invasive cardiac 
procedures between the Veterans Administration and other health care systems, whether 
there are also variations in the use of noninvasive cardiac imaging is unknown. This 
survey compares adherence to appropriateness criteria for stress echocardiography (AC) 
in an academic private practice and Veterans Administration Medical Center (VAMC). 
Methods: We reviewed 208 consecutive stress echocardiograms (SE) performed in an 
academic practice and 79 in a VAMC. SE requested for indications not addressed in 
the AC were considered unclassiﬁed. Those for indications addressed were scored on a 
scale of 1-9 according to the AC. Those with scores of 7-9 were rated appropriate, 4-6 
uncertain and 1-3 inappropriate. Results: Scores and ratings are shown in the table. 
Over 90% of SE were for indications addressed in the AC and could be scored and rated. 
For the entire group slightly more than half of the SE were for appropriate and 1 of 4 for 
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1037-10 Comparing the Cost of Treatment for Peripheral Artery 
Disease and Coronary Artery Disease in US Managed 
Care Enrollees
Michael R. Jaff, Richard H. Chapman, Cheryl P. Ferruﬁno, Stacey L. Kowal, Daniel 
Smith, Prafulla Girase, Edward Rosen, Luella Engelhart, Cordis Corporation, Warren, 
NJ, IMS Health, Falls Church, VA
Background: Peripheral artery disease (PAD) is an under-diagnosed and under-treated 
condition, perhaps in part because this illness is not considered as serious as other 
atherosclerotic disorders. To better understand the costs of care for patients with PAD, we 
compared these to costs for patients treated for coronary artery disease (CAD).
Methods: In a retrospective cohort analysis among adult enrollees in ~90 US health 
plans, we identiﬁed patients with revascularization (revasc) treatment for PAD or 
CAD from Jan 2003 - Jan 2008 (inclusive). Revasc was deﬁned as surgical bypass, 
percutaneous transluminal angioplasty (PTA) or stent (St) of the coronary arteries or of 
the lower extremity arteries. Patients with prior PAD or CAD diagnoses or procedures 
were excluded. Total health care costs for PAD or CAD revasc and for 1 year of follow-up 
were compared.
Results: Prevalence of PAD grew 45%, from 0.42% (2003) to 0.61% (2007), while 
prevalence of CAD grew 20%, from 1.42% to 1.71%. Mean (SD) age was similar for PAD 
and CAD patients (57.2 [9.4] and 55.1 [7.4] years, respectively), while more PAD patients 
were female (39.6% vs. 23.1%). 
PAD Patients CAD Patients P value
N 3,301 20,705
Total Costs
Mean
Median
$56,583
$32,145
$51,269
$38,927 P < .0001
Non-Diabetic Patients
Mean
Median
$47,764
$28,439
$47,359
$37,138 P <.0001
Type 1 Diabetes
Mean
Median
$107,766
$72,193
$80,143
$53,506 P=NS
Type 2 Diabetes
Mean
Median
$65,734
$36,618
$56,782
$41,537 P <.0001
Conclusions: Mean health care costs are higher for PAD than CAD, especially in diabetic 
patients, due to more high-cost cases in PAD. Earlier diagnosis and treatment may 
decrease variability in cost for PAD patients.
3:30 p.m.
1037-11 What is an Economic Tipping Point for Creating a New 
PCI Facility for STEMI?
Jeffrey A. Bakal, Padma Kaul, Robert C. Welsh, David Johnstone, Paul W. Armstrong, 
University of Alberta, Edmonton, AB, Canada
Background: AHA/ACC guidelines recommend PCI for ST-segment elevation myocardial 
infarction (STEMI) < 90 min from 1st medical contact. In this context, we evaluated 
the economic implications of alternative scenarios including costs, community size, 
geography and new PCI center deployment in dispersed regions. 
Methods: We modeled cost/PCI by (A) moving all pts to PCI centers via air (B) creating 
new centres (currently 2 exist) in Alberta, Canada [pop. 3.5 M/ area 662 km2]. Since a 
signiﬁcant % of the population resides outside a 60 min transportation window & primary 
PCI is unrealistic, the model assumes cath lab construction in a community hospital & 
costs amortized over 10 yrs & discounted 5%/yr. Costs from a payer perspective are 
provided.
Results: Based on estimates from Alberta health administration, in-hospital PCI costs 
approximately $7000. Air transport from 450km increases this ~ 2-fold & given the 
anticipated delay, is clinically inadvisable. Consistent with ACC/AHA recommendations 
for operator volumes, a minimum of 75 PCIs with 1/3 being primary PCI for STEMI to 
maintain skills of 3 interventionalists (providing 24/7 PCI call), the regional population 
needs to approximate 200,000. At this level the addition of a PCI facility increases the 
cost of each procedure by $3500 over an existing facility but is less expensive than 
transporting pts to an existing facility (Figure). 
Conclusions: We provide a novel approach to inform assessment of the economic 
feasibility of new PCI facilities for STEMI. 
percentile, 1.2 years; 75th percentile, 3.6 years). This interval was a median of 45% of the 
warranty period (25th percentile, 24%; 75th percentile, 79 %). Only 64 patients (21 % of the 
routine scans) had routine follow-up scans after the end of their warranty period.
Conclusions: 1. Routine follow-up scans are performed infrequently (13% over 5 years) 
in patients with normal SPECT scans and no prior CAD.
2. Those routine scans that are performed are generally performed well before expiration 
of the patient’s “warranty period”, suggesting that they may have limited clinical value.
3:30 p.m.
1037-08 Adherence to Appropriateness Criteria for 
Transthoracic Echocardiography: Comparisons 
Between a Regional Department of Veterans Affairs 
Health Care System and Academic Practice and 
Between Physicians and Mid-Level Providers
Howard J. Willens, Orlando Gomez-Marin, Alan Heldman, Simon Chakko, Cheryl Postel, 
Tahira Hasan, Fareed Mohammed, University of Miami Miller School of Medicine, Miami, 
FL, Miami VAMC, Miami, FL
Background: Whether differences in ﬁnancial incentives and other non clinical factors 
between health care systems and level of training between providers affect utilization 
of echocardiography is unknown but of interest given the rapid growth of this service. 
We compared adherence to recently published appropriateness criteria for transthoracic 
echocardiography in a Veterans Administration Medical Center (VAMC) and academic 
practice and, within the VAMC, between physicians and mid-level providers. Methods: 
We reviewed 201 echocardiograms performed in an outpatient laboratory of an academic 
practice and 424 in-patient and outpatient studies performed at a VAMC. Studies 
requested for indications addressed in the criteria were considered classiﬁed and those 
for indications not addressed unclassiﬁed. Classiﬁed studies were further rated as 
appropriate or inappropriate. Results: Of 625 echocardiograms reviewed, 99 (16%) were 
unclassiﬁed. Of the remaining 526 classiﬁed studies, 45 (8.6%) were for inappropriate 
indications. Of the echocardiograms ordered by physicians at the VAMC, outpatient 
studies were signiﬁcantly more likely to be unclassiﬁed than inpatient studies (18.1% 
vs 2.0%, p < 0.001) and when classiﬁed more likely to be for inappropriate indications 
although this difference was not signiﬁcant (7.0% vs 3.0%, p = 0.161). Of classiﬁed 
VAMC outpatient echocardiograms, mid-level providers were signiﬁcantly more likely to 
request studies for inappropriate indications than physicians (16.0% vs 7%, p = 0.024). 
There was no signiﬁcant difference in the frequency of outpatient studies requested for 
inappropriate indications by VAMC and academic practice physicians (7.0% vs 9.5%, p = 
0.558). Approximately 80% of unclassiﬁed studies could be assigned 4 clinical categories. 
Conclusion: The appropriateness criteria perform very well for hospitalized patients 
and reasonably well for outpatients at evaluating utilization of echocardiography among 
different health care systems and providers. The large majority of studies are requested 
for appropriate indications although there is room for improvement with potential savings 
especially among mid-level providers.
3:30 p.m.
1037-09 Appropriateness and Utilization of Cardiac Computed 
Tomography: Implications for Development and 
Implementation of Future Guidelines
Meagan K. Murphy, Ron Blankstein, Khuram Nasir, G. Scott Gazell, Fred Mamuya, 
Suhny Abbara, Thomas H. Lee, Thomas J. Brady, Massachusetts General Hospital, 
Boston, MA, Partners Community Healthcare, Inc., Boston, MA
Background: Cardiac CT (CCT) is a relatively new imaging modality with rapidly 
increasing use. The CCT Appropriateness Criteria (AC) were jointly published by multiple 
societies to guide physicians in CCT use. We sought to determine how these criteria apply 
to a tertiary care hospital.
Methods: Prospective data was collected from medical records, patient interviews and 
surveys on 267 patients referred for CCT. Two physicians designated exam indication 
as appropriate (A), inappropriate (I), or uncertain (U) by AC, or not known (NK) if not 
listed in AC. CCT results were classiﬁed as having no, mild/moderate (<70% stenosis), or 
signiﬁcant (>70%) coronary artery disease (CAD).
Results: Among 267 patients (age 56.2±14.8, 36% female), 66% of exams were for 
evaluation of CAD, 33% for non-CAD indications. Exam indication was A in 43%, I in 15%, 
U in 12%, NK in 30%. The most common A indication (34%) was for symptomatic patients 
with equivocal stress test. The most common I indication (46%) was for symptomatic 
patients with high pretest probability of CAD. Appropriate exams were more frequent 
among patients referred for non-CAD than CAD indications (83% vs 25%). Inappropriate 
exams were most frequent among asymptomatic patients for evaluation of CAD (60%). 
Undetermined (U/NK) exams were most frequent among patients referred for preoperative 
evaluation (93%) or after percutaneous revascularization/coronary artery bypass grafting 
(69%). There was no difference in exam appropriateness whether ordered by cardiologists 
or internists, but providers who completed training >25 years ago ordered proportionally 
fewer A (22% vs 53%) and more I exams (28% vs 9%) than younger providers. Exams 
that identiﬁed severe CAD were proportionally less likely to be A (17%), and exams with 
no CAD less likely to be I (10%).
Conclusion: Using the published AC, though a large proportion of exams were 
appropriate, many indications remained undetermined in appropriateness. Providers who 
had been in practice longer, regardless of specialty, were less likely to order appropriate 
scans. Given the rapid adoption of CCT, these results emphasize the need to continue to 
develop and implement future guidelines for appropriate utilization.
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Cost and Resource of Usual Care (UC) vs. Projected CT Strategy (CTS) Stratiﬁed by 
Results of CTA
Usual
Care
(N=368)
Cardiac CT (N=368)
CCT Results: ---
No Plaque / 
No Stenosis 
(N=183)
(+) Plaque: 
Mild / Moderate 
Stenosis
(N=117)
Signiﬁcant
Stenosis (N=34)
Acute Coronary 
Syndrome:
STEMI
NSTEMI
Unstable Angina
-
-
1
7
23
-
-
0
0
0
-
-
0
3
4
-
-
1
4
14
Cardiac Testing UCS UC CTS UC CTS UC CTS
Cardiac CT
Invasive Angiography
0
33
0
6
183
0
0
10
117
10
0
13
34
13
SPECT
Exercise Treadmil Testing
151
117
68
72
0
0
50
34
50
34
17
4
17
4
Echocardiography (rest)
Stress Echo
44
1
20
0
0
0
9
0
9
0
9
0
9
0
No Cardiac Imaging 
Testing 74 36 0 25 0 7 0
Length of stay (hours) 38.7 30.9 6.8 36.5 36.5 73.9 73.9
Average cost (Note: All 
costs indexed as they 
can not be disclosed per 
hospital policy
100% 79.0% 76.7% 90.5% 94.0% 213.8% 217.4%
3:30 p.m.
1037-14 Would Loss of STEMI Patients to High-Volume PCI 
Centers Put Low-Volume/Non-PCI Hospitals Out of 
Business? Empirical Evidence From Florida
Elizabeth B. Pathak, Margaret M. Comins, Joel A. Strom, University of South Florida, 
Tampa, FL
Background: The negative ﬁnancial impact on low volume/non-PCI capable hospitals, 
resulting from losing patients to high volume PCI centers, is frequently cited as an 
important barrier to implementing regional STEMI (ST-elevation myocardial infarction) 
bypass/transfer protocols. However little empirical data is available that directly quantiﬁes 
this potential impact. In this study, we statistically modeled the potential negative ﬁnancial 
impact on low volume/non-PCI capable hospitals of losing all STEMI patient revenue. 
We hypothesized that for >90% of these hospitals, STEMI charges represented <1% of 
total charges.
Methods: Hospital discharge data (including detailed patient ﬁnancial charges) for 
Florida in 2006 were analyzed. Per ACC/AHA guidelines, “low volume” hospitals 
performed <200 PCIs/year. For patients 18+ years old, we calculated projected revenue 
losses (PRLs) using STEMI patient charges as a % of total patient charges. We assumed 
that the ratio of charges to revenue received did not vary signiﬁcantly across hospitals. 
Stratiﬁed analyses examined hospital rurality, speciﬁc revenue centers (e.g. emergency 
department, cardiology), and payers (e.g. Medicare).
Results: There were 2103 STEMI patients at 115 low volume/non-PCI hospitals. There 
were no PCIs at 65% of these hospitals. For the whole state, PRL were 0.35% (i.e. 
35 cents for every $100). For individual hospitals, total PRLs ranged from 0.008% to 
3.8%. The 90th percentile of PRL for these 115 hospitals was 0.78%, and was <1% in all 
geographic areas. Emergency department PRL were low (90th percentile = 1.0%), while 
cardiology PRL were highest (median = 0.75%, 90th percentile = 3.22%). 90th percentile 
PRLs varied by payer: 0.78% for Medicare, 1.27% for Medicaid, 0.93% for commercial 
payers, 2.04% for self-pay, and 2.62% for charity patients. Together, self-pay and charity 
patients were 9.5% of all STEMI patients at these hospitals.
Conclusion: Loss of self-pay and charity STEMI patients would likely result in some 
cost savings for low volume/non-PCI hospitals. Overall, loss of all STEMI patients would 
not threaten the ﬁnancial viability of these hospitals, including those located in non-
metropolitan areas.
3:30 p.m.
1037-15 What Is the Price for Maintaining Normal Sinus 
Rhythm? Economics of Prerequisite Admission for 
Antiarrhythmic Drug Initiation in Atrial Fibrillation
Michael H. Kim, David Klingman, Jay Lin, David Battleman, Northwestern University, 
Chicago, IL, IMS Health, Inc., Falls Church, VA
Background: Initiation of some rhythm-control therapies for atrial ﬁbrillation (AF) 
requires an inpatient hospital stay and telemetry monitoring, adding to the cost burden 
of AF. However, speciﬁc cost data for inpatient initiation of AF therapies are lacking. We 
therefore examined costs associated with initiating sotalol or dofetilide in the inpatient 
setting in the United States.
Methods: This retrospective cohort study used data from inpatient hospital billing/
discharge records in the Premier Perspective™ Database for adults with a primary AF 
diagnosis, hospitalized between January 2002-September 2007, and receiving q4 sotalol 
doses or q5 dofetilide doses starting within 2 days of admission (with q1 dose within 3 
days of discharge). Patients (pts) admitted solely for AF drug initiation were identiﬁed 
by excluding pts admitted on an emergency basis, who received care in the emergency 
department, or underwent major surgical procedures during the stay. The primary 
3:30 p.m.
1037-12 Relationship Between Anemia Status and Health Care 
Costs in Patients With Symptomatic Heart Failure
Larry A. Allen, Kevin J. Anstrom, John Horton, Linda K. Shaw, Eric L. Eisenstein, G. 
Michael Felker, University of Colorado at Denver, Aurora, CO, Duke Clinical Research 
Institute, Durham, NC
Background: Anemia is associated with higher morbidity and mortality in heart failure 
(HF) patients, but its implications for heath care costs are not well described.
Methods: We analyzed data on 1056 patients with symptomatic HF seen at Duke 
University between 2002 and 2006 to explore the association between the presence of 
anemia (using WHO deﬁnition) and health care costs. Health care costs were obtained 
from the hospital cost accounting data system. Adjustments for censoring and covariate 
imbalance were performed using inverse proportional weighted estimators and propensity 
weighting.
Results: The prevalence of anemia was 32%. Anemic HF patients were older and had 
a greater burden of co-morbidity. Unadjusted mortality at 3 years was 50% in anemic 
versus 26% in non-anemic patients. Adjusted cumulative costs are shown in the Figure. 
The adjusted costs per year alive were $27,504 for patients with anemia and $20,890 
for those without (p=0.01). The impact of anemia on costs was greatest in patients with 
impaired systolic function (adjusted cost per year alive $34,552 for anemic vs. $23,361 for 
non-anemic patients, p=0.04).
Conclusions: Anemia in HF patients was associated with a greater total costs after 
accounting for differences in survival (using costs per year alive). The impact of anemia 
on costs appeared to be particularly marked in patients with heart failure and depressed 
ejection fraction. 
3:30 p.m.
1037-13 Cost and Resource Utilization Associated with Use 
of Cardiac CT for the Evaluation of Chest Pain in the 
Emergency Department
Ron Blankstein, Fabian Bamberg, John H. Nichols, Ian S. Rogers, Quynh A. Truong, 
John T. Nagurney, Thomas J. Brady, G. Scott Gazelle, Udo Hoffmann, Massachusetts 
General Hospital, Boston, MA, Brigham and Women’s Hospital, Boston, MA
Background: Cardiac CT (CCT) may allow rapid discharge of patients (pts) who present 
to the ED with chest pain who may otherwise require admission. We compared length of 
stay (LOS), cost and use of cardiac testing procedures observed under usual care (UC)
with those projected by a theoretical CT based strategy (CTS).
Methods: 368 consecutive pts w/ inconclusive ED evaluation underwent CCT with 
physicians blinded to results. Data on downstream procedures & outcomes were 
obtained. Hospital costs were determined by cost accounting decision support software. 
Assumptions for CTS based on observed long term outcomes: (1) pts without CAD on 
CCT (no plaque & no stenosis) were discharged 1 hour post results without further testing 
(2) pts with CAD had an identical strategy to UC (i.e. cross over to UC) given that ACS 
could not be reliably excluded & further testing needed.
Results: Table shows cardiac testing, LOS and cost under UC & CTS. In pts without CAD 
(50%) CTS resulted in lower LOS (30.9 vs. 6.8 hours), improved resource utilization, 
and lower cost. However, for pts with plaque (32%) or stenosis (9%), higher costs, more 
testing and longer LOS were observed for both UC & CTS.
Conclusions: For certain sub-groups of pts admitted with chest pain, CCT has the potential 
to result in reduced costs, LOS, and resource utilization. Identiﬁcation of low-risk pts who 
are appropriate candidates for further testing and avoidance of CCT in high risk pts (i.e. 
more likely to have inconclusive CCT) are key points to ensure cost-effective use.
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1037-18 Midterm Clinical Outcome of CATANIA™ Coronary 
Stent System With NanoThin Polyzene® in a Real World 
Unselected Population
Corrado Tamburino, Alessio La Manna, Davide Capodanno, Maria E. Di Salvo, 
Alessandra Sanﬁlippo, Anna M. Caggegi, Giombattista Barrano, Sergio Monaco, Irene 
Cascone, Giorgio Sacchetta, Thierry Corcos, Ferrarotto, Catania, Italy
Background: Bare metal stents are associated with high levels of binary restenosis and 
target lesion revascularization (TLR). Drug eluting stents have been shown to decrease 
restenosis rates but are associated with an increased risk of late stent thrombosis and 
a requirement for long term dual antiplatelet therapy. Therefore, novel approaches to 
modify stents (e.g., bioactive agents, coatings, surface treatment), have been developed 
to address the limitations of bare metal stent and drug eluting stent. Thus, we sought to 
evaluate the safety and performance of the new CATANIA Coronary Stent System with 
NanoThin Polyzene®-F in an unselected population of patients, without application of 
restrictive clinical or angiographic criteria.
Methods: From May 2007 to October 2008, in our Institution, 159 consecutive patients 
with coronary artery disease underwent percutaneous coronary angioplasty with 266 
CATANIATM stent on 213 lesions. Primary end point was the incidence of major adverse 
cardiac and cerebral events (MACCE), deﬁned as cardiac death, myocardial infarction, 
stroke and target lesion revascularization (TLR).
Results: Main clinical and angiographic characteristics of the 159 enrolled patients were 
as it follows: age 63.5 ± 11 years; male 59.7%; diabetes 28.9%; mean ejection fraction 
52.1±9.7%; UA/NSTEMI 53.5%; STEMI 13.4%; type B2-C lesions 34.2%, bifurcation 
7.1%, mean lesion length 16.9±9.5 mm. During hospitalization no event occurred. At 
8.4±5.7 clinical follow up MACCE were 7.0%; cardiac death 0%; stroke 0.6%; myocardial 
infarction 1.2%; TLR 5.0%.
One patient (0.6%) experienced deﬁnite subacute stent thrombosis due to inadequate 
stent expansion. No cases of late stent thrombosis were recorded.
Conclusion: This real world experience showed a favourable early and mid-term safety 
proﬁle and high level efﬁcacy of the new CATANIA stent. The use of Polyzene-F coated 
stents may be an alternative to both bare metal stents and drug eluting stents, with 
reduced TLR without the requirement for long-term dual antiplatelet therapy.
3:30 p.m.
1037-19 Long-Term Outcomes of Sirolimus-Eluting Stent 
Fracture
Takeshi Serikawa, Tomohiro Kawasaki, Shin-Koga Hospital, Kurume, Japan
Background: Stent fracture is one of the important factors of in-stent restenosis (ISR) 
after sirolimus-eluting stent (SES) implantation. However, a long-term outcome of SES 
fracture has been still unclear. We disclosed long-term outcomes of SES fracture. We 
examined the relationship between the lesion background and fractured SES with in-stent 
restenosis (ISR).
Methods: Consecutive 1228 SESs underwent follow-up coronary angiography (CAG) 
or coronary computed tomographic angiography (CTA) at 8 months after stenting were 
enrolled. Stent fracture was deﬁned as complete or incomplete discontinuation of stent 
strut and the ISR deﬁned as %diameter stenosis > 75%, and those assessed by two 
independent observers. Fractured SESs without signiﬁcant in-stent restenosis at 8 
months were observed continuously more than 9 months since fracture was detected.
Results: Of all 1228 SES, 104 (7.7%) were identiﬁed SES fracture (22 SES fracture with 
ISR, 82 without ISR). Those 82 fractured SESs without ISR were observed and underwent 
follow-up CAG or CTA more than 9months after initial follow-up (mean follow-up interval 
was 18.3 months). As a result, 7 of 82 (8.5%) revealed late ISR, while 75 of 82 (91.5%) 
revealed no late ISR. Overall ISR in the fractured SES was 25.9% (29/104) and 22of all 29 
ISR (74%) had been occurred within early 8 months. The lesion backgrounds of fractured 
SES with ISR were compared with that without ISR as follows; bending site (37% vs. 
42%, p=0.59), hinge-motion (33% vs. 22%, p=0.37), mixed (25% vs. 34%, p=0.60) and 
corresponding to the original lesion site (70% vs. 20%, p<0.01).
Conclusion: Late ISR of fractured SES is relatively rare, it however can be occurred in 
the fractured SES if the SES fracture is corresponding to the original stenotic lesion. The 
fractured SES, therefore, required long-term observation carefully.
3:30 p.m.
1037-20 The Unrestricted Use of Sirolimus-Eluting Stents: Five-
Year Results of the RESEARCH Registry
Neville Kukreja, Yoshinobu Onuma, Jannet Eindhoven, Hector M. Garcia-Garcia, Ron T. 
van Domburg, Patrick W. Serruys, Erasmus MC, Rotterdam, The Netherlands
Background: Although the safety of drug-eluting stents (DES) has been under scrutiny, 
limited follow-up data up to 5 years are available, particularly among real-world patients. 
Therefore, we evaluated the 5-year clinical event rates in patients from the The Rapamycin-
Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry to 
establish the safety and efﬁcacy of sirolimus-eluting stent (SES) in an unselected all-
comer population.
Methods: On April 16, 2002, our institution commenced the use of SES (Cypher; Cordis 
Corporation, Miami Lakes, Florida) as the default strategy for all percutaneous coronary 
interventions at our institution. In the ﬁrst 6 months of enrolment, 508 patients with de 
novo lesions were treated exclusively with SES (the SES group) and compared with a 
group of 450 consecutive patients treated with BMS for de novo lesions in the preceding 
6 months (the pre-SES group), matched for stent diameter. Survival data was acquired 
from municipal civil registries. Questionnaires have been sent to all living patients 
to obtain data on adverse clinical events. Medical records will be reviewed and family 
outcome was direct medical costs for in-hospital services during the stay.
Results: Of 7290 pts (59% men, mean age 66 years), 4847 received sotalol and 2443 
dofetilide. The majority (92%) were admitted to urban hospitals, and 53% to teaching 
hospitals; median stay was 3 days. For most pts (89%) the attending physician was 
a cardiologist. The most common comorbidities were hypertension (53% of pts), 
hyperlipidemia (30%), and coronary atherosclerosis (18%). Most (85%) received 
anticoagulant therapy with warfarin. Overall, 34% underwent cardioversion and 12% 
transesophageal echo. Mean total inpatient costs per pt were $3278 (2007 US$) in 
the sotalol group and $3610 in the dofetilide group. The greatest costs were for room/
board ($1875 sotalol, $1985 dofetilide) and cardiology/electrocardiograms ($406 sotalol, 
$452 dofetilide). Pharmacy costs were $230 and $201 per pt in the sotalol and dofetilide 
groups, respectively.
Conclusions: The prerequisite admission of patients for in-hospital initiation of AF 
rhythm-control therapy represents a high cost burden. Alternative rhythm-control drugs 
that can be initiated safely and effectively in an outpatient setting may reduce resource 
utilization and thus be more cost-effective.
3:30 p.m.
1037-16 Socioeconomic Differences Between Hospitals Are 
Not Associated With Differences in Heart Failure Core 
Performance Measures in California Hospitals
Terence Lin, Raymond Yau, Linda Houston-Feenstra, Marvin C. Sy, Daniel M. Blanco, 
Francis R. Su, Jun R. Chiong, Loma Linda University Medical Center, Loma Linda, CA
Background:Medicare’s Pay for Performance program (PFP) provides ﬁnancial 
incentives to hospitals with the highest compliance with four heart failure (HF) core 
measures. While PFP initiatives are intended to improve quality of care, it is unclear 
whether hospitals are disproportionately penalized for caring for a larger percentage of 
underserved populations. The purpose of this study was to determine whether adherence 
with four PFP core measures for heart failure were different for hospitals serving different 
socioeconomic demographics.
Methods:Centers for Medicare and Medicaid Services (CMS) data for heart failure 
admissions in 2006 were analyzed for 288 hospitals in California. Hospitals were 
stratiﬁed into two groups based on ﬁnancial proﬁt or loss. These groups were compared 
for adherence to heart failure core measures, size of hospital staff, average Medicare 
reimbursement per patient, and length of hospital stay. IRS data was used to evaluate the 
proportion of the population in the geographic locale of each hospital earning >$50,000 
as a measure of the afﬂuence of the community served.
Results:Community socioeconomic status and the hospitals’ ﬁnancial health did not 
correlate with performance on any of the core measures (HF-1: ACE-I or ARB for LV 
dysfunction 89% vs. 84%; HF-2: Evaluation of LV Function 95% vs. 92%, HF-3: Discharge 
Counseling 72% vs. 67%, HF-4: Smoking Cessation Advice 98% vs. 93%, all p = ns) or 
length of hospital stay (4.6 vs. 4.75 days, p=ns). Hospitals that demonstrated net proﬁt had 
more beds (213 vs. 170, p=<0.01), full time employees (977 vs. 492, p=<0.01), academic 
afﬁliation (8% vs. 1%) while receiving less reimbursement from Medicare ($7,279 vs. 
$8,127 per patient, p<0.022).
Conclusions:While both community and hospital factors may affect the ﬁnancial health 
of a hospital, they do not appear to signiﬁcantly affect compliance with HF core measures. 
Further studies are required to determine how a P4P program will affect hospital 
compliance with core measures, and whether higher compliance translates into improved 
patient outcomes.
3:30 p.m.
1037-17 Inﬂammatory Polymorphisms and the Risk of Late-
Acquired Stent Malapposition
Sandrin C. Bergheanu, Douwe Pons, Bas van der Hoeven, Su-San Liem, Martin Schalij, 
Johanna van der Bom, J. Wouter Jukema, Leiden University Medical Center, Leiden, 
The Netherlands
Background: Late-acquired stent malapposition (LASM) is a common ﬁnding after 
sirolimus-eluting stent (SES) implantation and may be the main cause for late stent 
thrombosis. Inﬂammation may play a pivotal role in LASM just as it plays in stent 
restenosis. We have therefore investigated 7 inﬂammatory polymorphisms, previously 
related to restenosis, on the risk of LASM in SES patients.
Methods: Patients with ST-elevation myocardial infarction who underwent SES 
implantation and had intravascular ultrasonography (IVUS) data available for both post-
intervention and 9-month follow-up were included in the present study. In total, 104 
patients from the MISSION intervention study were genotyped for caspase-1 5352 A/G, 
eotaxin 1382 A/G, CD14 260 A/G , colony stimulating factor 2 1943 C/T, IL10 -1117 C/T , 
IL10 4251 C/T and the tumor necrosis factor alpha 1211 C/T polymorphisms.
Results: LASM occurred in 26/104 (25%) of patients. We found a
signiﬁcantly higher risk for LASM in patients carrying the caspase 1
(CASP1) 5352 A allele (OR= 3.3, 95%CI: 1.3-8.3, p=0.013). Mean
neointimal growth was signiﬁcantly lower in patients carrying this risk allele
(1.6 vs 4.1%, p=0.014). The other 6 inﬂammatory polymorphisms were not
signiﬁcantly related to the risk of LASM.
Conclusions: Carriers of the 5352 A allele in the caspase-1 gene are at
increased risk of developing LASM after SES implantation. Screening for
this polymorphism in patients undergoing percutaneous coronary
interventions may help cardiologists to better select between drug-eluting and
bare-metal stents.
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those with a CV event. Bleeding was also more frequent. Nonelective procedure was the 
only independent risk factor for CV events (odds ratio= 5.1, 95% CI= 2.5, 10.2).
Conclusion Patients with DES who undergo noncardiac procedures have a high event 
rate at 3.4%. Clinical trial data are lacking to guide appropriate medical decision making.
Procedures characteristics among patients who were treated with clopidogrel
Overall
n=1411
CV event
n=48
(3.4%)
No CV 
event
n=1363
(96.6%)
P
Non Elective procedures (%) 30.1 64.6 28.9 <0.0001
Date of surgery >1 year after stent (%) 34.3 31.3 34.4 0.7576
Average number of days (median) 
between stent placement and surgery
291.3
(258.0)
281.8
(283.0)
291.6
(258.0) 0.7753
Average number of days (median) 
between surgery and CV event
Not
applicable 4.48 (0)
Not
applicable
Stopped clopidogrel
Yes (%)
No (%)
Unknown (%)
44.5
28.6
26.9
37.5
39.6
22.9
44.8
28.3
27.0
0.2461
Average number of days (median) 
clopidogrel was stopped prior to 
surgery
7.17 (7.31) 15.35(8.98) 7.02 (6.59) 0.0062
% on aspirin 66.2 70.8 66.0 0.5380
Type of surgery
% endoscopy
% Orthopedic
% Vascular
% Thoracoabdominal
35.8
15.8
14.1
11.8
31.3
8.3
12.5
27.1
36.0
16.1
14.2
11.3
0.0408
Any bleeding post surgery (%) 5.5 16.7 5.1 0.0035
3:30 p.m.
1037-23 Contemporary Trends in the Elderly Undergoing 
Percutaneous Coronary Intervention for Acute 
Coronary Syndromes: Results From the Euro Heart 
Survey PCI Registry
Timm Bauer, Christian Hamm, Uwe Zeymer, Matthias Hochadel, Franz Eberli, Ricardo 
Seabra-Gomes, Franz Weidinger, Jean Marco, Anselm Gitt, Kerckhoff-Klinik, Bad 
Nauheim, Germany, Herzzentrum Ludwigshafen, Ludwigshafen, Germany
Background: As the population of the western world ages, the number of high-risk 
percutaneous coronary interventions (PCI) in the elderly will continue to increase. We 
evaluated age-related differences in clinical characteristics, adjunctive medical treatment, 
procedural details and in-hospital outcomes of patients undergoing PCI for acute coronary 
syndromes (ACS).
Methods: From 2005 to 2008, 40612 consecutive patients undergoing PCI were 
prospectively enrolled into the PCI-Registry of the Euro Heart Survey Programme (99 
centres in 30 ESC-countries). For the present analysis we examined 20900 patients with 
ACS who were divided into two groups: >75 years (n=4179, 20.0%, 80.0 ± 3.8 years) and 
a75 years (n=16721, 80.0%, 59.0 ± 9.7 years).
Results: Elderly were more frequently female and had more comorbities, including 
diabetes, hypertension, renal insufﬁciency and a history of stroke and congestive heart 
failure. The proportion of elderly patients was higher among those with Non-ST-elevation 
ACS compared to those with ST-elevation myocardial infarction. Younger patients 
presented less often with cardiogenic shock and coronary pathology was less severe. In 
the entire study population a high use of guideline adherent adjunctive therapy could be 
observed. However, elderly patients were less likely to receive clopidogrel and GP IIb/IIIa 
antagonists before or during PCI. Among elderly the number of segments treated was 
higher; PCI of the left main stem and the LAD was more often performed, while stenting 
rate was lower. The incidence of in-hospital death (5.7 versus 1.9%, p<0.0001), non-
fatal stroke (0.8 versus 0.3%, p<0.0001), renal failure requiring dialysis (1.5 versus 0.6%, 
p<0.0001) and major bleedings (2.0 versus 1.0%, p<0.0001) was signiﬁcantly higher 
among elderly, whereas there was no difference in the rate of non-fatal reinfarction (2.5% 
respectively). Age >75 years was strongly predictive of hospital mortality (OR:2.79, 95%-
CI:2.28-3.41) by multivariate analysis.
Conclusions: In clinical practice elderly with ACS undergoing PCI face a two- to threefold 
higher risk for hospital complications, strongly inﬂuenced by comorbidities and coronary status.
3:30 p.m.
1037-24 Drug-Eluting Stent Versus Bare Metal Stent Use in 
Patients With Chronic Kidney Disease
Renato M. Santos, Matthew J. Sacrinty, Michael A. Kutcher, Sanjay K. Gandhi, William C. 
Little, Robert J. Applegate, Wake Forest University School of Medicine, Winston-Salem, NC
Background: Drug-eluting stents (DES) reduce restenosis compared to bare metal 
stents (BMS) in low and high risk groups. Chronic kidney disease (CKD) is associated 
with adverse cardiac events after PCI, however, data on long term outcomes of DES in 
this patient population is limited.
Methods: 1,101 patients with stage 3-5 CKD (glomerular ﬁltration rate <60 mL/min/1.73 
m2) underwent PCI at Wake Forest Baptist Medical Center between 4/02 and 4/05, 
doctors or referring cardiologists contacted as necessary. The primary end-point was 
composite major adverse events (MACE: all-cause death, myocardial infarction or target 
vessel revascularization [TVR]). Secondary endpoints included all-cause death, TVR and 
stent thrombosis. A propensity score-adjustment will be performed to compensate for 
differences in baseline characteristics between the groups.
Results: At 5 years follow-up survival status was available for 94% of the patients. 
The 5-year all-cause mortality rates were 14.0% for SES and 13.4% for BMS (p=0.9). 
Cumulative MACE was found to be signiﬁcantly lower in the SES group (23.0% vs. 
28.7%; adjusted HR 0.66, 95%CI 0.51-0.86), as were the rates of TVR (12.2% vs. 17.8%, 
adjusted HR 0.57, 95%CI 0.39-0.83). There was no difference in overall stent thrombosis 
(2.3% vs. 2.2%), p=1.0).
Conclusions: There is no difference in the 5-year survival rates in the real-world 
unselected patients treated with SES, compared with BMS.
3:30 p.m.
1037-21 Polymer Free Biolimus A9-Eluting Stent Demonstrates 
More Sustained Intimal Inhibition, Improved Healing 
and Reduced Inﬂammation in Comparison to a Polymer 
Coated Sirolimus-Eluting Cypher Stent in a Porcine 
Model
Norio Tada, Gordon Grant, Alexander Black, Renu Virmani, Saibal Kar, Cedars-Sinai 
Medical Center, Los Angeles, CA
Background: Drug eluting stents reduce restenosis but may increase late thrombosis 
and delayed restenosis. Persistent polymer and/or drug may be causal. Local delivery 
of Biolimus A9 (BA9), a rapamycin derivative, from a porous non-polymer-coated Bio-
Freedom stent (Biosensors Intl, Singapore) may prevent these complications.
Methods: We compared high (225μg BA9) and low (112μg BA9) dose Bio-Freedom 
(HD,LD) to a polymer-coated sirolimus eluting Cypher stent (SES) and a bare metal stent 
(BMS) at 28 and 180 days in an overstretch coronary mini-swine model. Endpoints were 
histomorphometry and histology.
Results: At 28 days, there was a reduction in neointimal area by HD, LD and SES 
compared to BMS (neointimal area: HD 1.25±0.31, LD 1.19±0.31, SES 1.26±0.30, BMS 
2.07±0.73 mm², BMS > HD, LD & SES, p<0.05). At 180 days, SES exhibited increased 
neointima (neointimal area: HD 1.61±0.24, LD 1.43±0.25, SES 2.50±1.00, BMS 2.01±0.67 
mm², SES > HD & LD, p<0.05). At 180 days, SES showed increased ﬁbrin and giant cells 
as well as a trend to more granulomas than the other groups (Figure).
Conclusions: The polymer-free BA9 eluting stent demonstrates equivalent early 
reduction of intimal proliferation with late efﬁcacy compared to SES in a porcine model. 
There appears to be delayed healing and persistent inﬂammation in SES compared to 
Bio-Freedom at 180 days. The use of non-polymeric versus traditional polymeric coating 
may be beneﬁcial and should be examined in a randomized clinical trial. 
3:30 p.m.
1037-22 Risk of Cardiovascular Events Following Noncardiac 
Surgery or Procedure in Patients With Drug-Eluting 
Stents
Divya Tiwari, Claudine Jurkovitz, James Bowen, Zugui Zhang, Ashley Weed, Gail 
DeVecchis Wygant, William Weintraub, Christiana Care Health System, Newark, DE, 
AstraZeneca, Wilmington, DE
Background Patients with drug eluting stents (DES) who undergo noncardiac surgery 
or procedures are at risk of cardiovascular (CV) events. The goal of this study was to 
determine risk factors for CV events.
Methods We identiﬁed all patients admitted in our institution from 2002 to 2007 who had 
a coronary DES placement. We considered all noncardiac surgeries/invasive procedures 
up to 2 years after DES placement. CV events were deﬁned as death, stroke and 
myocardial infarction within 30 days of surgery. We used a repeated logistic regression 
to estimate the risk of ﬁrst CV event. The independent variables were age, race, gender, 
elective status, type and timing of procedure after DES placement, whether clopidogrel 
was stopped, aspirin exposure and diabetes status.
Results: From 2002 to 2007, 6397 patients had a DES placement. Among those, 1268 
had at least one visit involving a noncardiac procedure for a total of 1974 visits. Clopidogrel 
was recorded in 1411 visits (71.5%). Mean age was 68, 86% of the patients were white, 
60% male, 45% had diabetes. The crude rate of CV events was 3.4% of surgical visits 
(table). The number of days clopidogrel was stopped prior to procedure was larger among 
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and greater %CIn (22.9 vs. -15.1%, p=0.01) after a 900mg LD (Fig 1). 4/5 (PRU) and 4/9 
(%CIn) poor responders responded after a 900mg LD.
Conclusions: Whilst ineffective on a population basis 900mg LD increase the antiplatelet 
effect of clopidogrel in initial poor responders. Platelet function testing is necessary in 
a clinical setting to target higher LDs to this high risk group. This may correlate with 
improved clinical outcome. 
Fig 1
3:30 p.m.
1037-27 Effect of Indapamide on In-Stent Restenosis Following 
Percutaneous Coronary Intervention
Spyridon Deftereos, Georgios Giannopoulos, Charalampos Kossyvakis, Konstantinos 
Raisakis, Metaxia Driva, Vasiliki Panagopoulou, Olga Ntzouvara, Chrysoula 
Papapolychroniou, Nikolaos Kouvousis, Evangelos Matsakas, Cardiology Department 
and Cardiac Catheterization Laboratory, Athens General Hospital “G. Gennimatas, 
Athens, Greece
Background: Indapamide, a nonthiazide diuretic, has been shown to possess, apart from 
antihypertensive properties, free-radical scavenging activity and to be involved in lipid 
peroxidation. It has also been suggested to exert a protective action during postischemic 
reperfusion.
Methods: 102 patients (67 males, age 61±8) with stable angina, were submitted to 
percutaneous coronary intervention (PCI) with bare stent implantation in at least one 
obstructive (>70%) coronary lesion. All patients received standard treatment with a beta-
blocker, a statin, dual antiplatelet therapy, plus either indapamide 2.5 mg qd (N=51) or 
chlorthalidone 12.5 mg (N=51) (randomized assignment). Six months later - or earlier in 
case of recurrent angina, all patients were submitted to coronary angiography to evaluate 
in-stent restenosis (>50%).
Results: Arterial pressure did not differ between the two groups (systolic arterial pressure 
115±6 mmHg vs. 118±5 mmHg, p=NS). Cardiac death and nonfatal myocardial infarction 
rates did not differ; however, there was signiﬁcant difference in angiographic restenosis 
rate, in favor of indapamide (9.8% vs. 25.5%, p=0.038). In the Kaplan-Meier analysis, the 
log-rank statistic for restenosis-free survival was marginal (p=0.044) (see Fig.).
Conclusion: In this hypothesis-generating study, a marginally signiﬁcant difference was 
observed in in-stent restenosis between patients receiving indapamide, which could 
favour the use of indapamide in patients submitted to PCI. 
3:30 p.m.
1037-28 Safety of Short-Term Discontinuation of Anti-Platelet 
Therapy in Patients With Drug-Eluting Stents
Kristian B. Filion, Pierre R. Richard, Danielle Libersan, Mark J. Eisenberg, Jewish 
General Hospital/McGill University, Montreal, QC, Canada
Background: Anti-platelet therapy is often discontinued in patients with drug-eluting 
stents (DES) who are undergoing surgical procedures. However, the safety of short-term 
discontinuation of these agents remains unknown.
Methods: We systematically searched Medline for reported cases of late stent 
thrombosis (LST) published between January 2001 and February 2008. LST was 
deﬁned as angiographically-conﬁrmed cardiac events occurring q 30 days following index 
percutaneous coronary intervention (PCI) with a DES. We restricted our study to reports 
that speciﬁed the time from discontinuation of antiplatelet therapy to LST.
589 with DES and 512 with BMS. Clinical outcomes at two years were retrospectively 
reviewed.
Results: Baseline characteristics were similar, including similar rates of any MI (38% 
BMS, 35% DES, p=0.45). Procedural characteristics were similar. Clopidogrel use at 
two years was 48% for BMS and 53% for DES patients, p=0.16. Kaplan-Meier plots of 
target vessel revascularization (TVR), non-fatal MI or death and stent thrombosis (ST) 
are shown (ﬁgure). After adjusting for baseline clinical and procedural characteristics, the 
hazard ratio for DES vs. BMS for TVR was 0.56 (0.38-0.82), for non-fatal MI or death was 
0.81 (0.63-1.06) and for ST was 1.65 (0.63-4.33).
Conclusions: In this clinical study of patients with stage 3-5 CKD, use of DES vs. BMS 
was associated with signiﬁcant reduction in TVR and a trend toward reduction of non-fatal 
MI or death. Incidence of ST at two years was similar. Thus DES appears to have superior 
efﬁcacy and similar safety to BMS in patients with stage 3-5 CKD.
3:30 p.m.
1037-25 The Unrestricted Use of Everolimus-Eluting Stents 
for De-novo Coronary Lesions: The Xience V 
Stent Evaluated at Rotterdam Cardiology Hospital 
(X-SEARCH) Registry
Neville Kukreja, Yoshinobu Onuma, Jannet Eindhoven, Anne-Louise Gaster, Nicolo 
Piazza, Nieves Gonzalo-Lopez, Christoforou Girasis, Hector M. Garcia-Garcia, Ron T. 
van Domburg, Patrick W. Serruys, Erasmus MC, Rotterdam, The Netherlands
Background: Everolimus-eluting stents (EES) are effective in the context of randomized 
trials with selected patients. However, the effect of EES implantation in more complex, 
unselected patients cannot be directly extrapolated from these ﬁndings. We sought 
to evaluate the impact of this second generation DES in comparison to bare metal, 
sirolimus-eluting and paclitaxel-eluting stents (BMS, SES and PES respectively) on 
clinical outcomes in a real-life all-comer population.
Methods: Since March 1st 2007, our institution commenced the use of EES (Xience V; 
Abbott Vascular) as the default strategy for every percutaneous coronary intervention. 
Between 1st March and 31st October 2007, 649 consecutive patients presenting with 
de novo lesions were treated exclusively with EES. These patients were compared to 
3 historical cohorts of consecutive patients; 450 patients treated with bare metal stents 
(BMS), 508 with sirolimus-eluting stents (SES) and 576 paclitaxel-eluting stents (PES) 
from the RESEARCH and T-SEARCH registries. 1-year follow-up on the occurrence of 
all-cause death (data obtained from municipal civil registries), MI, TVR and deﬁnite stent 
thrombosis are currently being collected and will be presented at the time of the meeting. 
Logistic regression analysis will be used to correct for differences in the 4 groups.
Results: 6-month results are shown in the table.
Conclusions: EES were more effective than BMS and PES. There no signiﬁcant 
differences between EES and SES
6-month Adjusted Hazard ratios vs. EES
BMS SES PES
Mortality 2.10 (0.99-4.47) 1.05 (0.45-2.44) 0.95 (0.47-1.95)
TVR 2.51 (1.29-4.89) 0.74 (0.32-1.72) 1.82 (0.96-3.47)
MACE 2.11 (1.36-3.50) 1.14 (0.68-1.93) 1.63 (1.03-2.58)
3:30 p.m.
1037-26 Platelet Function Testing can Be Used to Optimise the 
Use of 900mg Clopidogrel Loading Doses in the Setting 
of Percutaneous Coronary Intervention
Alex Hobson, Zeshan Qureshi, Phil Banks, Nick Curzen, Southampton General Hospital, 
Southampton, United Kingdom, Southampton University, Southampton, United Kingdom
Background: Hyporesponse to clopidogrel is associated with poor outcomes post PCI. 
It is unclear whether 900mg clopidogrel loading doses (LD) provide greater platelet 
inhibition than 600mg. We have used platelet function tests to compare 600mg and 
900mg LD responses in (i) PCI patients (ii) clopidogrel poor responders identiﬁed by 
platelet function tests.
Methods: Blood tests were taken before and 6 hours post clopidogrel and analysed 
using VerifyNow P2Y12 Assay and short TEG: a modiﬁcation of Thrombelastograph 
PlateletMapping.
(i) 60 patients were randomized 1:1 to 600mg or 900mg clopidogrel LDs pre PCI.
(ii) 30 healthy volunteers received 600mg clopidogrel. After a 2 week washout period 
900mg clopidogrel LD was administered to initial poor responders. Poor response was 
deﬁned as TEG %CIn<30%, or VerifyNow PRU reduction<30%.
Results: (i) There was no difference in %CIn or %PRU reduction for the 900mg LD group 
(%PRU reduction 55.3 ± 9.1 vs 37.2 ± 15.8, p=0.06, %CIn 35.7 ± 8.7 vs 25.8 ± 8.6, 
p=0.13).
(ii) Poor responders to 600mg had greater %PRU reduction (45.0 vs. 20.1%, p=0.03) 
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1037-30 Predictors of Postprocedural Myonecrosis Following 
Successful Percutaneous Coronary Intervention - A 
BRIEF-PCI Substudy
Margot K. Davis, Graham C. Wong, Andrew Starovoytov, Jacqueline Saw, Christopher 
E. Buller, Tasleem Rajan, Anthony Y. Fung, Division of Cardiology, Vancouver General 
Hospital, University of British Columbia, Vancouver, BC, Canada
Background: Periprocedural myonecrosis (PPM) is a frequent complication of 
percutaneous coronary intervention (PCI) and may be associated with adverse short- and 
long-term outcomes. Factors associated with PPM following successful, uncomplicated 
PCI have not been previously well deﬁned.
Methods: This was a prespeciﬁed substudy of the BRIEF PCI trial. Blood samples 
were analyzed for CD40 ligand (CD40L), interleukin (IL)-6, C-reactive protein (CRP) 
and troponin I at baseline and at 16 hours postprocedure from 169 patients undergoing 
elective PCI. Detailed clinical, procedural and angiographic data were recorded for each 
patient. All patients received aspirin, clopidogrel, unfractionated heparin or enoxaparin, 
and intravenous eptiﬁbatide.
Results: 49/169 patients (30.6%) who underwent successful and uncomplicated PCI had 
PPM according to study criteria. Compared to baseline, mean levels of CD40L and CRP 
increased signiﬁcantly post-PCI (3.41 ng/mL vs 4.02 ng/mL, p=0.003, and 9.86 mmol/L 
vs. 12.79 mmol/L, p<0.001). Elevations in both CD40L (<5ng/mL) and CRP (>5mmol/L) 
were seen in signiﬁcantly more patients with an ACS at baseline compared to patients 
without ACS (32.6% vs 14.3%, p=0.007 and 50% vs 15.2%, p<0.0001). Patients with 
elevated troponin at baseline were also more likely to have an elevated baseline CD40L 
(44.2% vs 17.5%, p=0.001) and CRP (67.4% vs 22.7%, p<0.0001). In contrast, PPM was 
not associated with elevation of either baseline or postprocedural inﬂammatory markers. 
However, the presence of PPM was associated with several procedural characteristics 
including number of treated lesions, number of stents used, and length of stents on 
univariate analysis. Use of >1 stent retained the strongest independent association with 
PPM after multivariate analysis (OR 3.8, 95% C.I 1.8-7.9).
Conclusions: PPM is a common ﬁnding in patients undergoing contemporary PCI. PPM 
was associated with several procedural characteristics on a univariate level. Although 
there was a signiﬁcant association with baseline troponin elevation and inﬂammation, this 
association was not seen with PPM, suggesting a different pathophysiology underlying 
myonecrosis following successful PCI.
ACC.ORAL CONTRIBUTIONS
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8:00 a.m.
0915-3 Impact of Nurse Practitioners on Implementation of 
Evidence-Based Therapy: Results of the St. Paul Heart 
Clinic Heart Failure Database
Ann Hayden, Denise Carlson, Marjorie Webb, Kristal Jones, Thomas H. Johnson, Alan 
J. Bank, Spencer H. Kubo, St. Paul Heart Clinic, St. Paul, MN
Background: Implementation of evidence based therapies has been challenging outside 
of controlled clinical trials. We utilized nurse practitioners, in combination with physician 
visits, to maximize medication initiation/titration, instruction for standard heart failure 
(HF) education (e.g. dietary sodium restriction and daily weights) and referral for device 
therapy in the outpatient setting.
Methods: SPHC is an independent cardiology practice with 36 physicians and 3 nurse 
practitioners with specialty interest in HF. All patients (pts) who had at least one outpatient visit 
coded for either HF or cardiomyopathy over a 24 month period were entered into a database 
that tracks clinical outcomes and utilization of medications, devices and HF education.
Results: Among 2,302 pts, there were 1,482 with a LVEF < 45%. Pts seen by a HF-NP 
(n=677) were similar to those not seen by a HF-NP (n=805) in terms of age (70 vs. 71), 
male predominance (69 vs. 68%) and etiology. However, pts seen by a HF-NP had a lower 
EF (27 vs. 30%) and a higher frequency of co-morbidities, such as AF (39 vs. 36%), renal 
insufﬁciency (26 vs. 17%), COPD (19 vs. 13%) and non-compliance (10 vs. 5%)
Utilization of ACE (85.0 vs. 85.0%) and BB (91.2 vs. 85.1%) was high with or without HF-
NP. However, pts seen by a HF-NP were much more likely to receive instruction on sodium 
restriction (86.1 vs. 19.9%), daily weights (77.7 vs. 15.3%), smoking cessation (92 vs. 
50.4%) and an exercise/rehab program (57.6 vs. 19.8%) than pts without a NP visit. Device 
therapy (CRT and ICD) was used in 63.7% of pts with a HF-NP visit compared to only 46% 
of pts without a HF-NP. Further, pts seen by a NP had a higher survival rate (86.1 vs. 82.4%) 
and a lower lost to follow up rate (1.5 vs. 4.1%) over 1300 days of follow up.
Conclusions: These data demonstrate that compliance with evidence based therapy is 
enhanced by a team approach that utilizes concomitant visits with nurse practitioners. 
Pts seen by HF-NP have higher rates of education and device therapy which may be due 
to greater accessibility and to a focus on education. The use of nurse practitioners is a 
simple method to enhance the achievement of HF quality goals for a cardiology practice.
Results: We identiﬁed 148 cases of LST from 76 articles. Patients had a mean age of 59 
± 13 years, and 89% were male. The median time from PCI to LST was 365 days (95% 
CI=278, 435). If patients stopped both agents simultaneously, the median time to event 
was 7 days (Figure). If patients had previously stopped their thienopyridine with no ill 
effect and subsequently stopped ASA, the median time to event was 7 days from ASA 
cessation. If the thienopyridine was stopped but ASA was maintained, the median time to 
event was 112 days. Among the 47 patients who stopped both agents, 35 cases of LST 
(74%) occurred within 10 days. Among the 84 patients who discontinued a thienopyridine 
but continued ASA, only 6 cases of LST (7%) occurred within 10 days (p<0.0001).
Conclusion: If ASA therapy is maintained, short-term discontinuation of thienopyridine 
for < 10 days is relatively safe in patients with DES. 
3:30 p.m.
1037-29 Gaps in Clopidogrel Use Explain Stent Related 
Myocardial Infarction
Leonardo Tamariz, Ana Palacio, Pablo Echeverria, Eduardo de Marchena, Hermes 
Florez, William O’Neill, University of Miami, Miami
Background: Clopidogrel use decreases the risk of myocardial infarction (MI) after stent 
placement. Premature discontinuation of clopidogrel has been associated with MI. We 
compared MI and all cause mortality in patients with stents by gaps in their clopidogrel use.
Methods: We performed a retrospective analysis in a large managed care plan between 
January 1, 2003 to June 20, 2005. We identiﬁed subjects who received coronary stents, 
using (Current Procedural Terminology (CPT) codes: drug eluting stents (CPT 36.07) and 
bare metal stents (CPT 36.06). We identiﬁed clopidogrel treatment using the Generic 
Product Identiﬁer (GPI) code 85158020. We calculated the number of gap days deﬁned 
as the sum of days without clopidogrel supply in between the ﬁrst and last prescription. 
We divided the gap days by quartiles, the lowest quartile was the lowest number of gap 
days and the highest quartile was the highest number of gap days. MI was deﬁned by the 
ICD-9 code for acute myocardial infarction (410.xx) with an associated hospitalization and 
all cause mortality was ascertained using the social security death index.
Results: We identiﬁed 5,838 subjects who used clopidogrel after a stent. Subjects in the 
lowest quartile of clopidogrel gap days were of similar age (63.7±11.3 vs. 63.0±11.9, 
years), had similar use of drug eluting stents (87 vs. 85,%), and were less likely to have 
Medicare insurance (53 vs. 60,%). After 72 months of follow-up 3% of the subjects in the 
lowest clopidgrel gap days had a MI compared to 7% of those in the highest clopidogrel 
gap days (p<0.01). The RH of MI for the highest quartile of clopidogrel gap days was 
1.74 (95% C.I.: 1.21-2.56) when compared to those in the lowest quartile of clopidogrel 
gaps days after adjustment for type of stent, demographics, MI at presentation, heart 
failure, cardiovascular risk factors. The RH of all cause mortality for the highest quartile 
of clopidogrel gap days was 0.83 (95% C.I.: 0.36-1.94) when compared to those in the 
lowest quartile of clopidogrel gaps days after adjustment for the same covariates.
Conclusions: Gaps in clopidogrel use increase the risk of MI in patients with stents.
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Hospital-speciﬁc 30-day all-cause readmission rates, adjusted by patient age and gender, 
were calculated for HF and non-HF diagnoses and compared against each other using 
linear regression.
Results: Of 606,196 HF hospitalizations, 23.1% were readmitted within 30d. Of 9,420,122 
non-HF hospitalizations, 15.1% were readmitted within 30d. Every absolute 1% increase 
in 30d readmission rate for non-HF diagnoses was associated with an absolute 0.5% 
increase in 30d readmission rate after HF admission (p<0.001, r-squared = 0.28).
Conclusions: Readmission rates after HF discharge is highly correlated with the 
readmission rate after discharge for all other conditions, suggesting that some of the 
variation in HF-speciﬁc readmission rate may be due to general hospital performance. 
Reducing readmissions for HF pts may require examination of general systemic issues 
within the hospital in addition to HF-speciﬁc issues.
Figure. Box-whisker plot of hospital-level HF RSRR against deciles of overall 30-day 
readmission
9:00 a.m.
0915-7 Predicting Poor Outcomes in Heart Failure
David H. Smith, Eric S. Johnson, Micah L. Thorp, Xiuhai Yang, Amanda F. Petrik, 
Robert W. Platt, Kathy A. Crispell, The Center for Health Research, Kaiser Permanente 
Northwest, Portland, OR
Background:Health plans need to stratify patients with heart failure according to 
their absolute risk of mortality and hospitalization so that they can prioritize disease 
management efforts and reduce the rate of those events. We developed a risk score to 
predict the ﬁve-year risk of mortality or hospitalization for heart failure among patients 
with heart failure.
Methods:We conducted a retrospective cohort study. Patients with heart failure were 
diagnosed and followed at Kaiser Permanente Northwest, a health maintenance 
organization. Patients had a diagnosis of heart failure and an echocardiogram between 
1999 and 2004. Patients’ ﬁrst echocardiogram deﬁned the start of follow-up. We identiﬁed 
the ﬁrst hospitalization for heart failure and death (from any cause) using the HMO’s 
databases. We predicted patients’ risk of hospitalization or death (whichever occurred 
ﬁrst) using Cox regression.
Results: We followed 4,696 patients with readable echocardiogram ﬁndings and observed 
a 56% ﬁve-year risk of hospitalization for heart failure or death (95% conﬁdence interval, 
54% to 58%). Even though the hazard ratios for echocardiograms contributed statistically 
signiﬁcantly to the model, echocardiogram ﬁndings did not improve our ability to predict 
risk accurately once we had accounted for demographic characteristics and clinical 
examination ﬁndings: hemoglobin, estimated glomerular ﬁltration rate, body mass index, 
and systolic blood pressure (c-statistic=0.67 vs. 0.68). Even a more complex model with 22 
characteristics demonstrated a modest capacity to predict risk accurately (c-statistic=0.71 
on a scale from 0.5 to 1.0). Our risk score model discriminated the highest and lowest risk 
patients (by quintile) with limited success: the observed risk was three times higher in the 
highest risk quintile compared with the lowest risk quintile.
Conclusions:Health plans need to collect and document additional prognostic 
characteristics that will help predict patients’ risk of hospitalization and mortality. In 
the interim, the current risk score may be useful for ranking patients according to their 
absolute risk to prioritize disease management efforts.
8:15 a.m.
0915-4 Comparison of Hospital Performance on Readmission 
and Mortality for Heart Failure Patients
Patricia S. Keenan, Jersey Chen, Joseph S. Ross, Elizabeth Drye, Zhenqiu Lin, Yun 
Wang, Sharon-Lise T. Normand, Harlan M. Krumholz, Yale School of Medicine, New 
Haven, CT
Background: Medicare publicly reports measures of hospital 30-day mortality rates for 
heart failure patients. Readmission is under consideration for public reporting, yet it is not 
known whether these outcomes provide information about similar or different aspects of 
hospital quality.
Methods: We estimated hospital 30-day all-cause risk standardized readmission (RSRR) 
and 30-day risk-standardized mortality rates (RSMR) for Medicare patients hospitalized 
with heart failure at all non-federal hospitals during 2006. Model discrimination at the 
patient-level was determined by the area under the ROC curve. We estimated hospital 
RSMRs and RSRRs using separate hierarchical logistic regression models. We then 
determined the correlation between the estimated RSMRs and RSRRs using weighted 
regression. We also examined the strength of the relationship by hospital characteristics.
Results: The discrimination of the patient-level risk adjustment model based on age, sex, 
and clinical comorbidities is stronger for 30-day mortality than for 30-day readmission. 
RSMRs and RSRRs in 4658 hospitals were negatively correlated (correlation coefﬁcient 
-0.084, p<0.0001). This ﬁnding was consistent regardless of safety net status and for 
hospitals in the top and bottom quartiles of in-hospital mortality rates. A similar relationship 
was present for urban (-0.12, p<0.0001), but not rural hospitals, and for high volume (-0.14, 
p<0.0001) but not low volume hospitals. Across regions the relationship ranged from -0.18 
(p<0.0001) in East North Central to 0.0131 (p=0.73) in South Atlantic. The relationship was 
not present in hospitals in the bottom and top quartiles of post-hospital mortality.
Conclusions: The difference in patient level model performance and lack of strong linear 
correlation between hospital performance measures suggests that these measures 
capture different dimensions of hospital performance. Hospital mortality rates do not bias 
the readmission rate. Studies that combine readmission and mortality as one outcome 
could obscure potentially important predictors and results.
8:30 a.m.
0915-5 The Extent of Warfarin Use and its Effectiveness 
Within Atrial Fibrillation Patients from a US Nationally 
Representative Sample
Stephen D. Sander, Catherine J. Williams, Matthew W. Reynolds, Vladimir Bogin, 
Judith J. Stephenson, Ozgur Tunceli, Gregory P. Samsa, David B. Matchar, Boehringer 
Ingelheim Pharmaceuticals, Inc., Ridgeﬁeld, CT, United BioSource Corporation, 
Lexington, MA
Background: Well-controlled warfarin therapy should lead to effective stroke prophylaxis 
in atrial ﬁbrillation (AF) patients. Clinical trials have shown that compared to no therapy, 
warfarin reduces risk of stroke by 64% in AF patients. Compared to antiplatelet therapy, 
warfarin reduces the risk of stroke 39%. However, the effectiveness of warfarin in actual 
clinical practice is not well understood. This analysis aimed to quantify the extent of 
warfarin use and evaluate the effectiveness of warfarin in actual clinical practice
Methods: Using medical claims from a nationally representative group of US managed 
care plans (from January 2001 to December 2006), we conducted a cohort study of 
patients with at least 2 diagnosis claims for AF without evidence of valvular heart disease. 
We deﬁned patients as eligible candidates for warfarin if they were at moderate to high 
risk for stroke as outlined by the American College of Chest Physicians and lacked any 
evidence of contraindication to treatment. The primary outcome was ischemic stroke 
as deﬁned by a validated method of identiﬁcation using ICD-9 codes. Adjusted risk of 
ischemic stroke was calculated using Cox proportional-hazards regression.
Results: Of the 50,072 AF patients identiﬁed (mean age=68.3 years), 44,719 (89%) were 
eligible candidates for warfarin. Among those eligible, 45% received warfarin. Overall, 
the rate of ischemic stroke was 5.8 per 100 patient-years. After adjusting for stroke risk 
factors, warfarin use was associated with an 11% reduction in ischemic stroke (hazard 
ratio=0.89; 95% CI 0.82-0.96; p=0.003) compared with eligible patients who did not 
receive warfarin.
Conclusions: These results indicate that within a large, nationally-representative 
population of insured patients, less than half of eligible candidates for anticoagulation 
received warfarin. Among those that did receive warfarin, we observed a statistically 
signiﬁcant reduction in ischemic stroke. However, the observed stroke reduction rate was 
substantially lower than the 39 to 64% range reported in clinical trials. This study reveals 
a considerable discrepancy between the effectiveness observed in clinical trials and real 
world practice.
8:45 a.m.
0915-6 Do Hospital Heart Failure Readmission Rates Reﬂect 
Disease-Speciﬁc Performance?
Jersey Chen, Yun Wang, Joseph S. Ross, Héctor Bueno, Jeptha P. Curtis, Elizabeth 
E. Drye, Patricia S. Keenan, Sharon-Lise T. Normand, Geoffrey C. Schreiner, John A. 
Spertus, Maite Vidán, Yongfei Wang, Zhenqui Lin, Harlan M. Krumholz, Yale University 
School of Medicine, New Haven, CT
Background: While hospital-level readmission rates for heart failure (HF) have been 
proposed as outcomes-based measure of HF quality of care, improving performance may 
reﬂect hospital-wide needs for quality improvement in the overall discharge processes, as 
measured by hospital-level readmission rates for all other non-HFdiagnoses .
Methods: We examined Medicare pts age >= 65 discharged alive in 2006 after 
hospitalization for HF or any other diagnosis based on principal discharge codes. 
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1046-03 Comparative Study on the Feasibility and Safety of 
Transulnar Artery Versus Transradial Artery PCI in 
Patients With Coronary Heart Disease
Xianghua Fu, Xinshun Gu, Xinwei Jia, Jing Zhang, Guozhen Hao, Weili Wu, Shiqiang Li, 
2nd Afﬁliated Hospital of Hebei Medical University, SHIJIAZHUANG, People’s Republic 
of China
Background: Although the diameter of ulnar artery and radial artery is similar, the ulnar 
artery as alternative access for PCI has not been widely used. Since we ﬁrst performed 
transulnar artery (TUA)PCI in the world in 2001, we have performed PCI via TUA approach 
for 860 patients so far. So, we summarized our work and compared the feasibility of TUA-
PCI vs. TRA-PCI (transradial artery PCI).
Methods: There were 860 CHD patients in TRA-PCI group (male 610, female 250) and 
860 CHD patients in TUA-PCI group (male 633, female 227). The PCI time for each case 
was recorded. The time of Allen’s test, lumen diameter (mm), cross area of vessel lumen 
(mm2), blood velocity (Vs max) and blood ﬂow resistance index(RI) in ulnar and radial 
artery were measured respectively, and then the approach arteries were followed up for 
6 months after PCI procedure.
Result: The puncture success rate of TUA-PCI group was 95.7%, which is equal to that of 
TRA-PCI group. The ﬁrst puncture success rate was 83.6% in TUA-PCI group and 84.2% 
in PCI-TRA group. In TUA-PCI group, 1226 lesions in 1178 vessels were intervened and 
1215 stents were implanted via 6F guiding catheter, while in PCI-TRA group 1121 lesions 
in 1077 vessels were intervened and 1012 stents were implanted. The average time that 
the guiding catheters were inserted into the ostium of target vessles, the average time 
of X ray ﬂuoroscopy and the total time of the whole procedure were not signiﬁcantly 
different between two groups ( 4.72±0.53 vs. 4.82±0.41min, 22.3±0.41 vs. 24.1±0.61min, 
58.6±11.1 vs. 54.8±13.2min; all p>0.05). No signiﬁcant changes were found in the 
approach vessels and no serious complications such as occlusion of ulnar artery and 
ulnar nerve injury were found during the follow-up period after PCI procedure.
Conclusion: TUA-PCI in CHD patients are feasibile and safe. Ulnar artery is an alternative 
approach for PCI.
9:30 a.m.
1046-04 Safety and Efﬁcacy of Drug-Eluting Versus Bare Metal 
Stents for Treating Saphenous Vein Grafts
Riem Hawi, Mehdi H. Shishehbor, E. Murat Tuzcu, Deepak Bhatt, Stephen Ellis, Samir 
Kapadia, Cleveland Clinic, Cleveland
Background: Only 1 randomized trial with 75 patients and a handful of small observational 
studies have evaluated the outcomes of DES versus BMS for treating SVG. To examine 
the safety and efﬁcacy of drug-eluting stents (DES) versus bare-metal stents (BMS) in 
patients undergoing intervention to saphenous vein grafts (SVG).
Methods: All patients undergoing percutaneous coronary intervention with a DES or 
BMS to SVG from January 1, 2000, to June 30, 2007, at a tertiary care center were 
assessed. In order to eliminate any unobserved bias regarding stent selection, we divided 
the BMS cohort into those that received a stent prior to 2003 and those that had a BMS 
after 2003 when DES were available. Two sets of multivariable Cox proportional hazard 
analysis were performed where the DES cohort was compared to before and after 2003 
BMS cohorts. The primary endpoint was all-cause mortality, myocardial infarction (MI), 
and target lesion revascularization.
Results: A total of 559 patients met our study criteria, of these 210 (38%) received a 
DES, 110 (20%) received a BMS after 2003, and 239 (42%) received a BMS before 2003. 
Drug-eluting stents were associated with lower composite endpoint of death, MI, and TLR 
(n = 86) when compared to those who received a BMS after 2003 (25% vs. 33%, adjusted 
hazard ratio, 0.55, 95 percent conﬁdence interval, 0.31-0.97; p = 0.041). However, despite 
more events (n=173), DES use was not associated with lower composite endpoint of 
death, MI, or TLR when compared to those that received a BMS before 2003 (25% vs. 
50%, adjusted hazard ratio, 0.75, 95 % CI, 0.43-1.32; p=0.32).
Conclusions: In this large cohort, DES were associated with a lower rate of primary 
endpoint when compared with those who received a BMS after 2003; however, this 
association was no longer present when DES use was compared with those who received 
a BMS prior to 2003. These results indicate that unobserved biases in observational 
registries may explain the reported beneﬁt of DES over BMS for treating SVG.
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1046-01 Efﬁcacy and Safety of Three Different Drug Eluting 
Stents: The Prospective-Randomized ENTACY Study
Henrik Schneider, Huseyin Ince, Tim C. Rehders, Kische Stephan, Akin Ibrahim, Ina 
Korte, Sabrina Leyh, Frank Weber, Christoph A. Nienaber, University of Rostock, 
Rostock, Germany, Frankenwald-Hospital, Kronach, Germany
Background: The use of drug eluting stent (DES) in PCI leads to a considerable reduction of 
In-Stent-Restenosis (ISR) and Target Vessel Revascularisation (TVR) rate. But the efﬁcacy 
and safety of different DES have not been evaluated in a prospective manner yet.
Methods: We performed a prospective, randomised and angiographic controlled all-in-
comers-study, to compare 3 DES: Cypher, Taxus and Endeavour. Primary endpoint was 
the late lumen loss (LLL) after 6 months; secondary endpoint the rate of ISR, Target lesion 
Revsacularisation (TLR), Stentthrombosis (SAT) and MACE after 6 and 12 months.
Results: 346 patients (63.8 ±10.9 years) with 390 lesions we randomized in the 3 DES-
groups. 76.6% of patients were men, 40.9% of the DES-implantations occurred in acute 
coronary syndroms, 63.9% in complex lesions (C, B2). The antithrombotic therapy with 
aspirin and clopidogrel occurred for 6-12 months. An angiographic 6 months-follow up 
was available for >90% of patients and a clinical 12 month follow-up for >95%. (Table)
Conclusions: The Cypher-stent is superior to Taxus- and Endeavour-DES in terms of LLL, 
ISR and TLR after 6 and 12 month in the randomized all-in-comers study. However the 
Cypher stent was associated with a higher rate of possible late stent thrombosis with an 
increased cardiac death rate compared with Taxus and Endeavour. The Endeavour Stent 
is inferior to the other both DES concerning LLL, ISR and TVR. On aggregate the MACE 
rate after 6 and 12 month for the 3 DES is equal in our prospective study.
Results: ENTACY study, *=signiﬁcant difference
Cypher select plus Taxus liberte Endeavor
patients (n) 111 117 118
treated stenosis (n) 132 136 122
6-month LLL (mm) 0.19 ±0.09 0.38 ±0.12* 0.56 ±0.15*
6-month ISR>50% (n,%) 10 (8.3) 15 (12.4)* 16 (15.2)*
TVR (n/N,%)
- 6 month
- 12 month
8/132 (6.1)
10/132 (7.6)
12/136 (8.8)
13/136 (9.5)
16/122 (13.1)*
17/122 (13.9)*
12 month SAT(n,%)
- deﬁnite
- probable
- possible
3 (2.7)
0
0
3 (2.7)
3 (2.6)
1 (0.9)
0
2 (1.7)
2 (1.7)
1 (0.9)
0
1 (0.9)
recurrent MI (n,%)
- 6 month
- 12 month
2 (1.8)
2 (1.8)
2 (1.7)
2 (1.7)
2 (1.7)
2 (1.7)
cardiac death (n,%)
- 6 month
- 12 month
2 (1.8)
3 (2.7)
0
2 (1.7)
0
1 (0.9)
12 month MACE (n,%) 17 (15.2) 16 (13.7) 21 (17.8)*
9:30 a.m.
1046-02 Multivessel Coronary Disease in Patients With ST-
Elevation Myocardial Infarction Undergoing Primary 
Angioplasty: Different Strategies of Treatment and 
Long-Term Outcomes
Luigi Politi, Rosario Rossi, Fabio A. Sgura, Daniel E. Monopoli, Andrea Di Girolamo, 
Elisa Guerri, Francesca Bursi, Maria Grazia Modena, Cardiology Department, Policlinico 
University Hospital, Modena, Italy
Background: In patients with ST elevation myocardial infarction (STEMI) and multivessel 
coronary disease (mCAD) few reports studied outcomes of complete compared to infarct 
related artery (IRA) only revascularization and none distinguished simultaneous treatment 
of non-IRAs from the staged approach.
Methods: 155 consecutive patients with STEMI and mCAD undergoing primary 
angioplasty were randomized to 3 different strategies: 1) culprit vessel angioplasty only 
(COR group), 2) angioplasty of IRA followed by elective procedure for other lesions 
(staged revascularization-SR), and 3) simultaneous treatment of non-IRAs (CR). After 2.2 
years of follow-up we evaluated the incidence of major adverse cardiac events (MACE) 
among the 3 groups.
Results: Throughout follow-up 61 (39.4%) patients experienced at least one MACE, 40 
(53.3%) in COR group, 9 (23.7%) in SR, and 12 (28.6%) in CR, p=0.002. The incidence 
of re-PCI and re-hospitalization was signiﬁcantly different in the 3 groups (p=0.011 and 
p=0.005 respectively), but there was no signiﬁcant difference in re-infarction and death. 
Survival free of MACE was signiﬁcantly worse in COR group compared both to CR 
(p=0.023) and SR (p=0.015), while it was similar in CR and SR groups (p=0.762).
Conclusions: Culprit vessel only angioplasty was associated with the highest rate of MACE 
as compared to multivessel treatment. Patients with staged revascularization had a similar 
rate of MACE as patients undergoing complete simultaneous treatment of non-IRAs. 
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1046-07 Intravascular Ultrasonic, Angioscopic and 
Histopathological Characterization of Heterogeneous 
Patterns of Restenosis After Sirolimus-Eluting Stent 
Implantation: Insights Into Potential Thromborestenosis 
Phenomenon
Yuji Oikawa, Junji Yajima, Ryuichi Funada, Shunsuke Matsuno, Toshiro Inaba, 
Yuya Nakagawa, Michinari Nakamura, Hajime Kirigaya, Kazuyuki Nagashima, Ken 
Ogasawara, Hitoshi Sawada, Tadanori Aizawa, The Cardiovascular Institute, Tokyo, 
Japan
Background: Tissure characterization of DES restenosis remains unclear.
Objective: The purpose is to examine restenotic tissue characteristics after sirolimus-
eluting stent (SES) and compare histological and clinical image ﬁndings with restenosis 
after bare-metal stent (BMS).
Methods: IVUS, coronary angioscopy (CAS), and DCA were performed in 21 consecutive 
patients who presented with restenosis after SES (n=13) and BMS (n=8). Histological 
analyses were performed in the atherectomy samples.
Results: Mean time from implantation to restenosis was 10.8 months in the SES versus 
7.5 months in the BMS. Typical ``black hole’’, echolucent appearance by IVUS was 
observed in 1 SES case, and corresponded to a ﬁbrin rich tissue by histology which 
appeared translucent tissue by CAS. All restenosis after BMS showed homogenous low- 
or iso-echoic appearance by IVUS. CAS did not reveal red thrombus, but showed white 
thrombus in 6 SES versus 2 BMS (46.2 % vs. 25.0 %, p=0.597). Histology demonstrated 
various patterns after SES including thrombus, ﬁbrin, inﬂammatory inﬁltrate, and collagen-
matrix rich tissue, while thrombus component was not detected in BMS. Thrombus and 
ﬁbrin deposition detected by either CAS or histopathology were observed more frequently 
in SES than in BMS group (92.3 % vs. 25.0 %, p=0.007).
Conclusions: Restenosis after SES and BMS have different clinical and histological 
patterns. SES restenosis is heterogeneous and frequently associated with thrombus 
component. 
9:30 a.m.
1046-08 Implementation of a Novel Pathway for Management 
of Acute Coronary Syndrome Improves Guidelines 
Adherence and Remarkably Decrease Mortality and 
Readmission Rates at Four Years Follow-up
Emad F. Aziz, Dan Musat, Sandeep Pulimi, Amjad Nader, Lauren Rosenberg, Deborah 
Tormey, Manpreet Singh Sabharwal, Raja Singh, Anshu Alok, Olivier Frankenberger, 
Eyal Herzog, St. Luke’s-Roosevelt Hospital center, New York City, NY
Background: Clinical guidelines for the management of acute coronary syndrome 
(ACS) have consistently shown a major gap between the national guidelines and their 
application in the actual management of patients with ACS. In 2004 a new program 
“Advanced Cardiac Admission Program” ACAP was developed and implemented at our 
Institution. The program consists of tools and strategies for implementing guidelines.
Methods: 3043 patients admitted with ACS were risk stratiﬁed on admission to one of 
the four categories according to our PAIN pathway (Priority, Advanced, Intermediate or 
Negative Risk). Implementation feasibility and clinical response were reviewed at 48 
months, and compared to the published national statistics for hospital performances.
Results: As the result of our pathway implementation over the past 4 years, ASA 
utilization rate at discharge was increased to 91.4%, B blocker utilization improved to 
87%, ACEi/ARB utilization also improved to 68% and statin usage increased to 76% 
(p<0.0001). Most importantly, the event rate post-pathway implementation at four years 
following hospital discharge shows decrease in recurrent angina from 12% to 3.1%, 
(p<0.001), decrease in re-hospitalization from 26.4% to 14.5% (p<0.001), and marked 
decrease in mortality from 8% to 1.8% (p<0.001). (Graph)
Conclusion: Implementation of a novel pathway for management of acute coronary 
syndrome improves guidelines adherence and remarkably decrease mortality and 
readmission rates at four years follow up. 
9:30 a.m.
1046-05 Myocardial Damage Following Complex Percutaneous 
Coronary Intervention, as Assessed by Cardiac 
Magnetic Resonance Imaging: Testing the Association 
Between Markers of Inﬂammation and Distal Coronary 
Embolization
Didier Locca, Chiara Buccharelli-Ducci, Giuseppe Ferrante, Alessio La Manna, Niall 
Keenan, Agata Grasso, Peter Barlis, Francesca Delfuria, Sanjay Prasad, Juan Kaski, 
Dudley Pennell, Carlo Di Mario, Royal Brompton Hospital, London, United Kingdom
Background: Myocardial magnetic resonance imaging (MRI) can identify myocardial 
damage due to distal embolization of athero-thrombotic material after percutaneous 
coronary interventions (PCI).We sought to assess whether circulating CRP and neopterin 
levels correlate with late gadolinium enhancement (LGE) in the myocardium supplied by 
the affected coronary artery.Methods:45 of 65 consecutive patients (mean age 61±12 
years, 33(73%) male) undergoing elective PCI, were recruited into the study. These did 
not show increased markers of necrosis (troponin I) or LGE in the territory supplied by 
the target vessel on the baseline MRI carried out within 24 hours before PCI. All patients 
underwent a second MRI 24 hours after PCI. where LGE areas were classiﬁed as ‘distal’ 
(> 10 mm downstream from the stented segment) or ‘adjacent’ (in close proximity to the 
stent). In 35 of the 45 pts, high sensitivity CRP and neopterin were assessed at baseline. 
Results:Troponin I elevation occurred in 26 (58%) patients, (mean 0.56 ng/ml; 0.26-
1.23 ng/ml). New areas of LGE were detected in 15 of the 45 (33%) patients,averaging 
0.83 g (0.32-1.3 g), and all had raised troponin I levels after PCI. In 7 of the 15 (47%) 
patients the new LGE areas were ‘distal’ to the stent, and the reminder (53%) ‘adjacent’. 
Myocardial damage (g of tissue) after PCI correlated with troponin levels, r = 0.64, 
p<0.001, in the overall population. Patients with new ‘distal’ LGE showed a trend towards 
higher CRP levels compared to the remaining patients [7.4 mg/L (2.5-62.9) vs 2.5 mg/L 
(0.9-6.3), p=0.08]. CRP was a weak predictor of new distal LGE (odds ratio 1.03, 95% 
conﬁdence interval (0.99-1.06, p=0.07). There was no signiﬁcant difference, however, 
regarding neopterin levels between patients with and without new ‘distal’ LGE areas [7.1 
nmol/L (6.1-8.3) vs 6.1 nmol/L (4.4-9.0), p=0.39].Conclusions: Patients who develop 
myocardial damage due to distal coronary embolization during PCI show a trend toward 
higher baseline CRP levels. This suggests that CRP may be a marker of higher friability 
of coronary plaques and/or of enhanced inﬂammatory response of the myocardium to 
embolizing particles, responsible for subsequent myocardial damage.
9:30 a.m.
1046-06 Antithrombotic Strategy During Percutaneous Coronary 
Iintervention in NSTEMI: Update From ACTION 
Registry-GWTG
Karen P. Alexander, Anita Y. Chen, Matthew T. Roe, Tracy Y. Wang, Erik M. Ohman, 
David J. Magid, Michael P. Ho, Stephen D. Wiviott, Benjamin M. Scirica, Eric D. Peterson, 
Duke Clinical Research Institute, Durham, NC
Background: A variety of antithrombotic strategies are available for NSTEMI patients 
undergoing PCI, but their use in current practice has not been described.
Methods: Antithrombotic strategies for NSTEMI pts undergoing PCI at 217 ACTION 
hospitals from Jan 1, 2007 to Dec 31, 2007 (n=11,085) were grouped as Heparin only 
(either LMWH or UF Hep), Bivalirudin only (Bival), Hep with Glycoprotein IIb/IIIa inhibitors 
(Hep/GPI), and Bival with GPI (Bival/GPI). Rates for major bleeding and death, and adj. 
OR for major bleeding (vs.Hep/GPI) are shown.
Results: The most common strategy in this setting is Hep/GPI (63%), followed by Hep 
or Bival only (~30%), then Bival/GPI (<10%). Bival only and Bival/GPI pts were often 
switched from Hep in the cath lab (77% and 81%, respectively). Hep or Bival only pts 
were older with more co-morbidity, heart failure, and lower peak troponin levels. (Table, 
p <0.0001) Rates of death were similar: Hep (1.3%), Bival (0.7%), Hep/GPI (1.3%) and 
Bival/GPI (1.3%) (p=ns). However, major bleeding was less with Hep (6.5%) and Bival 
only (5.7%) compared to Hep/GPI (8.8%) and Bival/GPI (10.7%). Adj. ORs for major 
bleeding were 0.52 (0.42, 0.65) for Hep, 0.48 (0.39, 0.60) for Bival, and 1.23 (0.98, 1.56) 
for Bival/GPI compared to Hep/GPI.
Conclusions: Hep or Bival only was used in ~30% of NSTEMI pts undergoing PCI. 
Despite being older and sicker, these pts had less bleeding and similar mortality c/w those 
given either agent with GPI conﬁrming ﬁndings from randomized trials in an unselected 
ACS population 
Heparin only Bival only Hep/GP IIb/IIIa
Bival/ GP IIb/
IIIa
Use, n (%) 1,365(12.3%)
1,771
(16.0%)
7,086
(62.9%) 863 (7.8%)
Median Age (yrs) 66.0 66.0 61.0 61.0
Age q 75 yrs (%) 30 30 18 20
Female (%) 39.1 36.6 30.0 29.4
Diabetes (%) 35.0 32.8 26.1 28.7
PVD (%) 9.7 11.0 7.0 6.8
Median eGFR by C-G (mL/
min) 74.7 75.3 88.2 87.4
Peak Tn >5x ULN 77.9 76.7 84.6 86.6
HR on admission (median 
BPM) 80 80 78 77
HF on admission (%) 14.7 14.4 9.9 12.2
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Results: Repeated measures analysis showed that over a three year study period the 
HOPS intervention Z weight scores decreased signiﬁcantly among boys (0.81 to 0.71, 
P<0.001) with a trend among girls (0.56 to 0.51, P < 0.07). Within ethnicity, a signiﬁcant 
decrease in Z weight score for Hispanics (0.66 to 0.59 P <0.01) and whites (0.62 to 0.54, 
p< 0.02) was shown. Over the same time period, FCAT math scores improved signiﬁcantly 
among girls (308 to 319, p<0.001) and reading scores improved signiﬁcantly among boys 
(299 to 307, P<0.01). Within ethnicity, Hispanics signiﬁcantly improved both their FCAT 
math (298 to 309, p<0.001) and reading (286 to 301, p<0.0001) scores.
Conclusions: School-based obesity prevention interventions that use both nutrition 
and physical activity components show promise in improving health and academic 
performance in elementary-aged children, and among Hispanics in particular.
9:30 a.m.
1046-11 Relative Risk Is a Better Discriminator Than Absolute
Risk When Estimating Ten-Year Risk of Coronary Heart
Disease in Young Adults
Geir Hirlekar, Thor Aspelund, Thorarinn Gudnason, Vilmundur Gudnason, Karl 
Andersen, Icelandic Heart Association, Kopavogur, Iceland
Background: European society of cardiology (ESC) guidlines on cardiovascular disease 
(CVD) prevention suggest the use of relative risk (RR) in young adults instead of absolute 
risk (AR) in assessing the risk of developing CVD over a 10-year period. No data is available 
comparing AR to RR in 10-year coronary heart disease (CHD) risk assessment. Our aim is 
to compare AR to RR in estimating 10-year risk of CHD in a population based study.
Methods: Data from the prospective Reykjavik study of 15763 participants without clinical 
heart disease were used to estimate the 10-year risk of CHD morbitity in Iceland. The event 
of CHD was deﬁned as having had myocardial infarct, coronary artery bypass grafting or 
coronary angioplasty. Sensitivity and speciﬁcity were used for diagnostic accurancy.
Results: A total of 188 (2%) women and 679 (9%) men experienced CHD within 10 years. 
Among women aged 34-50 years, 34 (1%) women experienced CHD within 10 years. 
Among men younger than 40 years, 21 (3%) experienced CHD within 10 years. Current 
10 year risk threshold for CHD is 10% absolute risk and has only 8% sensitivity and 98% 
speciﬁcity for women compared to 70% sensitivity and 60% speciﬁcity in men. For women 
younger than 50 years and men younger than 40 years the sensitivity is 0%. Using 3.5 in 
RR as a diagnostic threshold for women younger than 50 years results in 59% sensitivity 
and 89% speciﬁcity. Using 3.5 in RR as a diagnostic threshold for men younger than 40 
results in 57% sensitivity and 82% speciﬁcity.
Conclusions: RR is a more sensitive diagnostic method than AR in 10 year CHD risk 
assessment for women younger than 50 years and men younger than 40 years.
9:30 a.m.
1046-12 Innovative Multidisciplinary Approach to Consultative
Cardiovascular Services: A Retrospective Analysis
Comparing two Models of Care
Carolyn Lekavich, Michael Blazing, Daniel Mark, Duke Hospital, Durham, NC
Background: This study was designed to retrospectively evaluate the effect of the 
operational changes implemented to the pre operative cardiology consult clinic. This 
retrospective study will compare the practice model of medical student/Attending to NP/
PA /Attending MD on the quality, safety, patient satisfaction and ﬁnancial outcomes of 
patients evaluated in the Pre Operative Cardiology Consult Clinic.
Methods: A retrospective analysis was completed evaluating using the Duke Heart 
Database, Scheduling and Press Gainey Patient Satisfaction systems to objectively 
evaluate a. clinical safety; 30 post operative mortality, rehospitalization, MI b. patient 
satisfaction c. ﬁnance data/consult billing/downstream revenue.
Results: Clinical quality demonstrated 2 deaths not associated with consult process
Patient and Customer Satisfaction rated as excellent
Patient Volume increased 215%
Finance Billing increased 261%
Conclusions: Through a collaborative MD/NP/PA Pre Operative Consult Practice Model 
the Division of Cardiovascular Medicine was able to implement an operational change 
that signiﬁcantly improved the clinical quality, patient satisfaction and ﬁnance.
9:30 a.m.
1046-13 Use of Platelet Transfusion to Facilitate Surgery in
Patients on Clopidogrel and Aspirin Therapy After
Drug-Eluting Stent Percutaneous Coronary Intervention
Sanjiv Sharma, Brijesh Bhambi, William Nyitray, Kirit Desai, Adrian Antonescu, Tetsuo 
Ishimori, Bakersﬁeld Heart Hospital/Central Cardiology, Bakersﬁeld, CA
Background: Surgery in patients on clopidogrel and aspirin after drug-eluting stents 
(DES) is often declined by surgeons, unless clopidogrel and aspirin are witheld for 
5-7 days. The AHA/ACC/SCAI/ACS/ADA Scientiﬁc Advisory Committee recommends 
”Elective procedures for which there is signiﬁcant risk of perioperative or postoperative 
bleeding should be deferred until patients have completed an appropriate course 
of thienopyridine therapy (12 months after drug-eluting stent DES implantation).For 
patients treated with DES who are to undergo subsequent procedures that mandate 
discontinuation of thienopyridine therapy, aspirin should be continued if at all possible 
and the thienopyridine restarted as soon as possible after the procedure because of 
concerns about late-stent thrombosis.”
Methods: We tested a strategy of prophylactic single donor platelet transfusion 
immediately prior to surgery or procedures that were deemed by the surgeon as 
otherwise unacceptable to undertake without interrupting clopidogrel and aspirin in a 
group of patients who had undergone drug-eluting stent (DES) percutaneous coronary 
9:30 a.m.
1046-09 The Effect of Human Unrestricted Somatic Stem Cells
on Swine After Acute Myocardial Infarction: Insight Into
Xenogenic Model in Cell Therapy Research
Guilherme Silva, Yi Zheng, Marlos R. Fernandes, Cristiano Cardoso, Fred Baimbridge, 
Amir Gahremanpour, Maria G. Cabreira, William L. Fodor, Joseph Laning, Maria 
Giovino, Melissa White, Deborah Vela, Maximilian Buja, James T. Willerson, Emerson C. 
Perin, Texas Heart Institute, Houston, TX
Background: It is debatable if xenograft models should be used to assess safety and 
efﬁcacy of stem cell therapy. We studied the results of endocardial delivery of CD34/
CD45 negative human unrestricted somatic stem cells (USSC) into swine model of acute 
myocardial infarction (MI).
Methods:Thirty pigs underwent LAD balloon occlusion for 90 min. Ten days post MI, NOGA 
guided transendocardial injections (TE) were performed into the infarct border zone. Animals 
were randomized to receive either 302±23 x106 USSC or saline, divided in 15 injections of
0.2cc. Oral cyclosporine 7.5 to 15 mg/kg bid was used to reach serum levels of 100 to
300 ng/ml 3 days before cell injection. Angiographic LVEF, IgG and IgM human antibodies
serum titers were measured at baseline, injection , 2 , 4 and 8 weeks post injection.
Results:There were no peri-procedural complications. The rise of IgG and IgM antibody 
titers and the presence of granulomas at the injection sites conﬁrm an immune response 
to USSC (ﬁgure 1). Immunohistochemical staining with human anti-mitochonadrail 
antibody failed to detect implanted USSC, However treated pigs had signiﬁcantly higher 
LVEF at 4 weeks ($ EF: 10.9±2.6 vs -2.3±1.9 p=0.025).
Conclusions:Human USSC induced immune rejection in pig hearts even though 
immunosuppression reached therapeutic level. This may introduce confounding factors 
that in turn might lead to misinterpretation of data. The use of xenograft models might 
impair the assessment of safety and efﬁcacy of new stem cell types such as USSC. 
9:30 a.m.
1046-10 School-Based Obesity and Related Cardiovascular
Disease Prevention Intervention Effect on Weight and
Academic Performance: Three Year Results
Danielle Hollar, Sarah Messiah, T. Lucas Hollar, Gabriela Lopez-Mitnik, Arthur S. 
Agatston, Agatston Research Foundation, Miami Beach, FL
Background: Childhood onset obesity and related health consequences continue 
to be major clinical and public health issues in the US. Healthier Options for Public 
Schoolchildren (HOPS) is a school-based obesity prevention intervention with both 
nutrition and physical activity components implemented in the elementary school setting 
and targeting 6-12 year olds. The overall goal of HOPS is to reduce childhood obesity 
rates and improve overall health status using strategies that can be easily replicated and 
integrated in other public school settings.
Methods: HOPS was implemented in August, 2004 and includes approximately 
3,200 children (48% Hispanic) attending four elementary schools in central Florida. 
Demographic, anthropometric (height, weight, body mass index [BMI]) and academic 
(Florida Comprehensive Assessment Test [FCAT]) were collected during the school 
year. The HOPS intervention included modiﬁed dietary offerings, nutrition and lifestyle 
educational curricula, school gardens, and other school-based wellness projects. We 
hypothesized that the HOPS intervention would improve weight and FCAT scores in 
HOPS intervention participants.
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1046-16 Simulation of Cardiac Electrophysiology for Interactive 
ECG Training
Vassilios Hurmusiadis, Nicholas Clifford, Primal Pictures Ltd, London, United Kingdom
Background: The presented work simulates the principles of electrocardiography using 
a real-time interactive 3D simulation model of cardiac electrophysiology. The origin of the 
ECG signal is a complex spatial and temporal phenomenon, but not enough emphasis 
is commonly given to understanding its generation. Conventional teaching is based on 
identifying patterns, which are frequently memorized without much thought given to the 
underlying cause of any particular waveform.
Methods: All four cardiac chambers were equipped with cell-nodes and myocardium ﬁber 
orientations. Ventricular ﬁbers were based on a canine ﬁber dataset obtained from DT-MRI. 
Atrial ﬁbers were constructed manually under the guidance from cardiac morphologists. 
An approximate model of the heart’s conduction tree was manually constructed. Cardiac 
cell activation sequences were constructed using the Luo-Rudy model and formed the 
basis for the construction of the inter-cellular activation propagation. A cellular automaton 
was developed to simulate the propagation of electrical excitation through the 3D cell-
nodes. Each cell-node in the automaton possesses a rest state, an excitation threshold, 
and a diffusive-type coupling to its nearest neighbors. The mean electric axis is then 
calculated and displayed over a beat cycle. The simulated electric axis is projected 
onto the standard lead vectors I, II and III of the Einthoven’s triangle and the precordial 
lead vectors V1-V6, so the respective ECG signals can be displayed. Malfunctioning or 
necrotic regions have been simulated by altering the cell activation proﬁles in certain 
regions in the atria or ventricles.
Results & Conclusions: The developed application can provide real-time simulation 
of the heart’s electrophysiology. The executable is platform-independent and can be 
run both ofﬂine and online. The application demonstrates the spatial and temporal 
relationships between the heart’s function and ECG signal generation. The solution allows 
end-users (medical students, trainee cardiologists, nurses) to become intuitively aware by 
interacting with the cardiac excitation process in real-time 3D, in a bottom-up approach: 
from cardiac cell to ECG.
9:30 a.m.
1046-17 Telemonitoring of Heart Rate Effects Induced by Mitral 
Regurgitation and Atrial Pacing
Hubert Truebel, Thomas Mondritzki, Jessica Hoffmann, Werner Nickl, Ralf Sicking, 
Stefan Schaefer, Bayer HealthCare, CV-research, Wuppertal, Germany
Background: Heart failure (HF) is reﬂected by an increased heart rate (HR). A new 
experimental setup for in-vivo monitoring of HR in awake dogs was evaluated. Mitral 
regurgitation (MR) in combination with atrial pacing were used to induce HF. Effects 
of interventions were assessed by an internet-based telemonitoring (BIOTRONIK®).
Methods: MR was induced according to Kleaveland et al. (Am J Physiol 1988) in 3 
mongrels (26 - 34kg; MR+) and compared with 3 controls (MR-). Ventricular rate was 
detected (Philos® II DR-T (Biotronik)) and transmitted via a cell phone placed in the stable. 
HR-data was reviewed online in a research facility distant from the animal housing. HR 
was monitored for 2 weeks (t1) before atrial tachypacing (t2; second pacemaker (Logos®, 
Biotronik), rate 650 bpm). ß-blockade (Atenolol, 1 & 2mg/kg) was applied to test the setup.
Results: Before pacing (t1) a marked difference in HR could be detected between groups 
(MR+ vs. MR-; (mean±SD) 94±4,8 vs. 81 ±4,9, resp.; p<0,0001). At t2 this difference 
persisted (MR+ vs. MR-: 149±15,8 vs. 117±31,6, p<0,0001). Oral administration of 1 and 
2mg/kg Atenolol during t1 decreased HR in the MR- animals from 82±9,4 to 79±7,5 (n.s.) 
and 79±4,7 BPM (n.s.), resp.. In the MR+ animals the HR decreased from 100±12,2 BPM 
to 91±13,3 BPM (1mg/kg; n.s.) and to 85±8,0 BPM (2mg/kg; p<0,05), resp..Conclusion:
A dual pacemaker implantation to stimulate and monitor HR rate separately is feasible. 
This allows for continuous detection of HR under various physiological conditions (e.g. 
sleep vs. awake state) without demanding capital investment. This model is suitable for 
drug evaluation (e.g. rate control) in different disease models. Several animals can be 
interrogated simultaneously without direct animal handling.
9:30 a.m.
1046-18 Improving the Process of Care for the Management of 
Acute Aortic Dissection
Craig E. Strauss, Frazier Eales, Alan T. Hirsch, Timothy J. Kroshus, Sue Duval, Tesfaye 
D. Kebede, Gina M. Adolphson, Subbarao Inampudi, Patricia A. Mitchell, Jonathan 
D. Cohen, Barbara T. Unger, Quirino G. Orlandi, Scott Streckenbach, Christopher 
Kapsner, Thomas F. Flavin, Vibhu R. Kshettry, Timothy D. Henry, Kevin J. Graham, Kevin 
M. Harris, Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, 
Minneapolis, MN
Background: Patients with acute aortic dissection (AAD) require emergent treatment 
with coordinated interdisciplinary care. However, few standardized protocols exist for 
patients with AAD.
Methods: We designed a standardized and coordinated system (including emergency 
room education, uniform imaging, image transfer and medical therapy) for rapid treatment 
of patients with AAD. The success of protocol implementation was assessed via evaluation 
of the times from presentation to diagnosis and to deﬁnitive treatment for patients before 
(30 months prior, n= 31) and after implementation of the protocol (n=55).
Results: This dataset included 86 patients (median age 65 years, 56% male, 67% type 
A). For all patients, the median time from presentation to diagnosis decreased from 303 
minutes before to 182 minutes after implementation (p=ns). In surgical patients with type 
A, time from diagnosis to OR decreased from 147 minutes pre-, to 98 minutes post-
protocol (p=ns). Beta-blocker administration increased post-protocol (45% vs. 96%, 
intervention (PCI) within the last 12 months. The dose of clopidogrel and aspirin was 
witheld on the day prior to surgery. Patients received 10 units of single donor platelet 
transfusion immediately prior to surgery. Clopidogrel (75 mg once a day) and aspirin 
(325 mg once a day) therapy was resumed postoperative day zero.Patients were 
evaluated for major adverse cardiac events (MACE-death, myocardial infarction, stent 
thrombosis, revascularization at 30 days), post-operative bleeding and requirement for 
blood transfusion .
Results: Eighteen patients underwent elective or urgent surgery using this strategy. 
These included 7 vascular, 5 abdominal, 4 orthopaedic and 2 prostate procedures.The 
postoperative bleeding and blood transfusion requirements were within the standard as 
reported by the surgeon. There was no adverse MACE reported in the group.
Conclusions: Surgery, including elective surgery,can be safely accomplished within 12 
months after DES PCI, without interruption of clopidogrel and aspirin therapy, if platelet 
transfusion is utilized on the day of the surgery.
9:30 a.m.
1046-14 Cigarette Smoke Exposure Results in Hypertension, 
Endothelial Dysfunction, Cardiac Hypertrophy, and 
Leukocyte-Speciﬁc Reactive Oxygen Species (ROS) 
Generation in Mice
M.A. Hassan Talukder, Wesley Johnson, Saradhadevi Varadharaj, Jiarui Lian, Patrick 
Kearns, Lawrence Druhan, Xiaoping Liu, Jay Zweier, Davis Heart and Lung Institute, 
The Ohio State University, Columbus, OH
Background: Cigarette smoking is a major risk factor for atherosclerotic cardiovascular 
diseases and is the leading modiﬁable risk factor where smokers (SM) die earlier than 
nonsmokers (NSM). While the association between smoking and atherosclerosis is well-
established, the underlying mechanisms are incompletely understood partly due to the 
lack of adequate in vivo models. Here, we report an in vivo mouse model of smoking-
induced cardiovascular pathology.
Methods: Male C57BL/6 mice (8-weeks) were exposed to whole body mainstream 
cigarette smoke (CS) by the SCIREQ “InExpose” smoking system (60 min/day, 5 days/
week) for 8, 16, or 32 weeks. Mice were sacriﬁced 24-hours after the last CS exposure. 
Age-matched, air exposed mice served as controls. Blood pressure was measured in 
conscious animals and cardiac MRI was performed under light isoﬂurane anesthesia. 
In vitro vascular ring and isolated heart experiments were performed for vascular 
reactivity and cardiac contractile function, respectively. Blood from SM and NSM mice 
were investigated for nitric oxide (NO) decay rate (electrochemical analysis) and ROS 
generation (ﬂuorescent microscopy using DCF and DHE).
Results: SM mice had signiﬁcant weight loss and developed persistent hypertension after 
16-weeks CS exposure. At 32-weeks of CS exposure (n = 4-8): acetylcholine-induced 
vasorelaxation was markedly shifted to the right and downwards; left ventricular (LV) 
mass and LV end diastolic volume on MRI were signiﬁcantly larger along with increased 
heart to body-weight ratio; in vitro cardiac contractile function was slightly impaired at high 
afterloads; NO decay rate in the whole blood was increased by 15%; and white blood cells 
demonstrated signiﬁcantly higher cell-speciﬁc ROS generation.
Conclusions: The present study provides in vivo evidence that CS exposure induces 
leukocyte activation, endothelial dysfunction and hypertension leading to cardiac 
hypertrophy. This mouse CS exposure model should enable further determination of the 
molecular and cellular mechanisms of smoking induced cardiovascular diseases and help 
identify ways to prevent these processes.
9:30 a.m.
1046-15 Doing More in Less Time: Using Operations Management 
Tools to Improve Efﬁciency in the Cardiac Cath Lab
Osnat Levtzion-Korach, Arthur Reitman, Pat Jansen, Susan Madden, PatientFlow 
Technology, Inc., Boston, MA, Kennestone Hospital WellStar Health System, Marietta, GA
Background: Beginning in the fall of 2007, an innovative and comprehensive project to 
improve efﬁciency began in the cardiac catheterization lab at Kennestone Hospital, WellStar 
Health System’s 633-bed hospital, in Marietta, GA. Although door-to-balloon times for STEMI 
patients were well below the 90-minute benchmark, cardiologists at Kennestone Hospital 
were frustrated by numerous other issues that occur commonly in cath labs: scheduled cases 
being bumped or delayed by add-ons; long waits and fasting time for inpatients; and idle time 
in the lab during prime time coupled with frequent long days and overtime hours.
Methods: Three months of case level data, including patient arrival times, procedure start 
and end times, and clinical urgency were collected and analyzed. Using queuing theory - 
an operations management tool for managing random arrivals - the team determined the 
capacity needed for add-on cases. The data was also used to improve the accuracy of the 
times used for scheduling cases.
Under the plan adopted, one or two labs were set aside, depending on the day of the 
week, for urgent and semi-urgent cases (those needing to be performed within 24 
hours and 3 days respectively). The other labs were used for elective cases, which were 
scheduled and performed back-to-back.
Results: Within six months of the project start, the following results were measured:
s 7AITING TIMES FOR URGENT CASES DROPPED  FROM AN AVERAGE OF  HOURS IN $ECEMBER 
to six hours in July;
s 7AITING TIMES FOR SEMIURGENT INPATIENT CASES DROPPED BY  FROM AN AVERAGE OF  
to 23 hours;
s 4HE VOLUME OF ELECTIVE CASES ROSE BY MORE THAN  AND
s ,AB OVERTIME HOURS DECREASED BY MORE THAN  FOR ALL BUT EMERGENCY CASES
Conclusions: Queuing theory, used in private industry for decades, provides an effective 
tool for managing situations where randomly arriving cases compete with scheduled 
cases, as occurs in cardiac cath labs. As this project illustrates, it is possible to improve 
capacity and efﬁciency without the need for additional resources.
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Quality and Outcomes of PCI and Acute 
Coronary Syndromes
Tuesday, March 31, 2009, 10:30 a.m.-Noon
Orange County Convention Center, Room W307C
10:30 a.m.
0919-3 Long-Term Mortality After Percutaneous Coronary 
Intervention Versus Medical Therapy: A Meta-Analysis 
of Post Myocardial Infarction Versus Chronic Coronary 
Disease Randomized Trials
Paul Kolm, William E. Boden, John A. Spertus, David J. Maron, Koon K. Teo, George A. 
Diamond, GB John Mancini, Marcin Dada, Sanjay Kaul, Robert A. O’Rourke, William S. 
Weintraub, Christiana Care Health System, Newark, DE
Background: There is controversy surrounding the impact of percutaneous coronary 
intervention (PCI) vs. medical therapy on long-term survival of coronary disease (CAD) 
patients. Previous meta-analyses of the 16 randomized trials comparing PCI and medical 
therapy on all-cause mortality suggested a beneﬁt of PCI on mortality, but failed to distinguish 
between patients with acute coronary syndromes (ACS) and chronic stable CAD.
Methods: Random effects logistic regression was used to assess the interaction 
between treatment (PCI vs. medical) and patient type (post MI vs. chronic CAD). This was 
performed on the treatment effect from 2 x 2 tables of all-cause mortality for each study.
Results: We found a signiﬁcant treatment by patient type interaction (p = 0.019) 
indicating a difference in the odds of all-cause mortality between treatment groups related 
to whether patients were treated for ACS or stable CAD. The estimated OR for chronic 
CAD was 0.901 (95% CI = 0.745 - 1.089, p = 0.280) compared to 0.503 (95% CI =0.644 
- 0.989, p = 0.016) for post MI (Figure 1).
Conclusions: There was no evidence of a mortality beneﬁt from randomized trial data 
of PCI for patients with chronic CAD. However, there was a mortality beneﬁt from PCI in 
ACS patients. While meta-analytic methods provide a way of estimating treatment effects 
pooled from different studies, careful attention must be given to differences between 
study populations that can potentially impact results. 
10:45 a.m.
0919-4 Outcomes Following Coronary Stenting in a Linked 
NCDR and CMS Database: A National Study of Long-
Term, Real World Outcomes of Bare Metal and Drug-
Eluting Stents
Pamela S. Douglas, J Matthew Brennan, Kevin Anstrom, Eric L. Eisenstein, David Dai, 
Ghazala Haque, David F. Kong, Ralph G. Brindis, Art Sedrakyan, David B. Matcher, Eric 
D. Peterson, Duke University, Durham, NC
Background: The safety and comparative effectiveness of drug eluting coronary artery 
stents (DES) vs bare metal stents in contemporary real world populations remain a matter 
of controversy.
Methods: We studied 262,700 patients > 65 years from 650 sites enrolled in the National 
Cardiovascular Data Registry in 2004-2006 whose follow-up could be obtained by linking 
to Medicare claims data. Outcomes were compared using propensity scoring with inverse 
probability weighted estimators and Cox proportional hazards regression models.
Results: DES were implanted in 217,675 subjects; BMS in 45,025 (17%). 30-month 
unadjusted event rates per 100 patients were lower for DES vs. BMS (death: 12.9 vs. 
17.9; non-fatal MI: 7.3 vs. 10.0; repeat revascularization: 23.4 vs. 24.5). After adjustment, 
patients who received DES had signiﬁcantly lower rates of death (HR 0.75; 95% CI 0.73 to 
0.78), nonfatal MI (HR 0.76; 95% CI 0.72 to 0.80) and revascularization (HR 0.91; 95% CI, 
0.89 to 0.94) than patients who received BMS. Composite endpoints also favored DES. 
There were no clinically signiﬁcant differences in stroke (HR 0.96; 95% CI 0.88 to 1.04) 
or major bleeding (HR 0.91; 95% CI 0.85 to 0.98). Landmark analyses demonstrated no 
change in direction or reduction of hazard ratios of DES vs BMS for death or death/MI for 
up to 3 years of follow-up.
p<0.0001). Patients presenting to non-tertiary hospitals (n=66) experienced greater 
delays in median time from presentation to diagnosis (250 vs. 86 minutes, p=0.0004) and 
from diagnosis to operative repair (159 vs. 76 minutes, p=0.003) compared to patients 
presenting to a community-based tertiary care hospital (n=20).
Conclusions: An integrated system for transfer of patients with AAD reduces the time 
to diagnosis, time to deﬁnitive treatment, and promotes increased use of beta-blockers. 
The integrated system of care may be of particular value in non-tertiary hospitals, where 
signiﬁcant delays in diagnosis and treatment exist.
9:30 a.m.
1046-19 Medical Simulation Training to Improve Acute 
Myocardial Infarction Care for Rural Hospitals
Andrew J. Klein, Michael S. Kim, John M. Westfall, Frederick A. Masoudi, John S. 
Rumsfeld, John D. Carroll, Cathy L. Jaynes, John C. Messenger, University of Colorado 
Denver, Aurora, CO, Denver VA Medical Center, Denver, CO
Background:Rates of adherence for guideline-recommended treatments for acute 
myocardial infarction (AMI) care in rural healthcare settings are suboptimal. Lack of 
effective dissemination and education of rural providers may play a role in this quality 
gap. We sought to assess the feasibility and acceptability of a novel simulation training 
program aimed at improving adherence rates to guideline-recommended treatment of 
AMI in rural hospitals.
Methods:We performed on-site simulation-based training at 5 rural hospitals in Colorado. 
Multidisciplinary teams (nurses, physicians and emergency medical personnel) completed 
4 AMI simulated scenarios using the SimMan® system. Each scenario had post-test 
questions regarding guideline based AMI care. All subjects completed an assessment of 
the training program using a standardized Likert-scale questionnaire.
Results:A total of 18 teams composed of 95 healthcare professionals in 5 rural Colorado 
hospitals completed the training. The proportions of correct answers regarding AMI 
care were highly variable, ranging from 40-100%, indicating a wide disparity of baseline 
knowledge. Following training, 98% of participants strongly agreed/agreed that the 
simulated cases were realistic and engaging and could improve conﬁdence and skills 
in the treatment of AMI patients. 99% of participants strongly agreed/agreed that it was 
useful for on-site training of rural providers for AMI care.
Conclusions:An on-site simulation-based training program focusing on AMI care in rural 
hospitals is feasible and can provide a realistic and safe environment for rural healthcare 
providers to gain instruction in guideline-concordant AMI care. Such a training program 
could be implemented widely in order to improve AMI care in rural hospitals.
9:30 a.m.
1046-20 Genetic Comparison of Angiographically Normal 
Patients Versus Random Population Sample for 
Angiographic CAD Association Studies at Four 9p21 
Loci
James J. Park, Jeffrey L. Anderson, Benjamin D. Horne, Chrissa P. Mower, Heidi T. May, 
Mona S. Jahromi, Natalie Winn, John F. Carlquist, Intermountain Medical Center, Murray, 
UT, University of Utah, Salt Lake City, UT
Background: As controls for genetic association studies of coronary artery disease 
(CAD), we have used subjects shown to be disease free (<10% stenosis) by angiography 
(angio-C). Whereas angio-C have phenotypic characterization, angio-C may not be similar 
to a population control (pop-C) due to referral bias. To validate angio-C, we compared 
allele frequencies in 4, 9p21 single nucleotide polymorphisms (SNPs) between angio-C, 
pop-C, and CAD patients.
Methods: Consenting patients with angiographic CAD (n=1011) were compared with 
angiographic controls (n=482) matched for age, sex, near date of angiography, and with 
a random population sample (n=569) (pop-C). Subjects were genotyped for 4 SNPs at 
9p21, a replicated CAD risk locus. Genotyping used 5’ exonuclease (TaqMan) assay.
Results: A comparison of minor allele frequency in angio-C versus pop-C revealed no 
signiﬁcant difference for any of the 9p21 SNPs. In contrast, CAD sample vs. each control 
group showed signiﬁcant differences for all four SNPs.
Minor Allele Frequency: 
rs10757278 rs2383207 rs2383206 rs10757274
CAD (%) 51.7¶ 55.9¶ 55.2¶ 51.5¶
angio-C (%) 46.6 50.1 49.0 47.0
pop-C (%) 45.4 49.3 48.5 45.1
(p-trend angio-C vs. pop-C = ) 0.61 0.71 0.80 0.40
(p-trend CAD vs angio-C = ) 0.011 0.004 0.002 0.021
¶p<0.001 vs pop-C
Conclusion: This study found genotypic similarity between angio-C and pop-C for the 4 
9p21 SNPs. Both controls have limitations: angio-C may be subject to ascertainment bias 
with regards to other, presently untested loci, but the clinical coronary status of pop-C 
is unknown. Thus, neither sample is an ideal control; however, these ﬁndings validate 
angio-C as a control for 9p21 and suggest that the use of both controls will be useful for 
future CAD association studies.
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0919-7 Incidence of Death or Acute Coronary Syndrome After 
Stopping Clopidogrel in a Managed Care Population
Gail D. Wygant, Ole Hauch, Chun-Lan Chang, Judith J. Stephenson, Mark Cziraky, 
AstraZeneca LP, Wilmington, DE, HealthCore, Inc., Wilmington, DE
Background: Ho et al described a cluster of death or recurrent acute coronary 
syndrome (ACS) events within 90 days of clopidogrel (CL) discontinuation in a Veteran’s 
Administration ACS population. We replicated their analysis in a large national managed 
care population of ACS patients.
Methods: Retrospective claims analysis identiﬁed 22,270 ACS patients with >1 CL 
pharmacy claim during 2001 - 2006. CL claims were analyzed following index ACS event. 
Patients with adverse events (AE), deﬁned as death or recurrent ACS, during CL therapy 
were excluded from the analysis. CL discontinuation was deﬁned as date of last ﬁll plus 
days supplied. Poisson regression was used to calculate the incidence rate ratio of AE 
risk in the 1st 90 days, compared to the 2nd 90 days, after CL discontinuation.
Results: Of 9,585 ACS patients with no AE prior to CL discontinuation, 895 (9.3%) had an 
AE after CL discontinuation. Patients, medically treated during the index ACS event, had a 2.2 
times higher risk of AE in the 1st 90 days, compared to the 2nd 90 days, after CL discontinuation 
(P<0.001). Patients with bare metal stents (BMS) had a 1.6 times higher risk of AE in the 1st 90 
days, compared to the 2nd 90 days, after CL discontinuation (P=0.008). For patients with drug-
eluting stents (DES), the AE risk was 1.6 times higher in the 1st 90 days (P=0.061). Sensitivity 
analysis showed that medically treated patients with <90 days of CL therapy had a 2.3 times 
higher AE risk in the 1st 90 days, compared to the 2nd 90 days, after discontinuation (P=0.028). 
Similar results were seen for stent patients with <90 days of CL therapy. For BMS patients 
the AE risk in the 1st 90 days was 1.7 times higher (P=0.044) and for DES patients it was 2.4 
times higher (P=0.086). Among patients with 91-180 days of CL therapy, the AE risk in the 1st
90 days, compared to the 2nd 90 days, after CL discontinuation was statistically insigniﬁcant, 
regardless of whether patients were medically treated, BMS or DES.
Conclusions: ACS patients who discontinue clopidogrel therapy are at high risk of 
recurrent ACS or death in the ﬁrst 90 days following discontinuation. AE risk appears 
to be increased in patients with <90 days of clopidogrel therapy compared to those with 
>90 days of therapy.
Conclusions: In this largest study to date assessing real-world outcomes, patients 
receiving DES had signiﬁcantly lower risk of adverse outcomes, including death, MI, and 
revascularization compared with their BMS counterparts, without an associated increase in 
major bleeding or stroke. These results were consistent throughout 3 years of follow-up.
11:00 a.m.
0919-5 New Insights Into Finding Low-Risk Patients With ST-
Elevation Myocardial Infarction: The Case for Very Early 
Discharge
Padma Kaul, Christopher B. Granger, Paul Wayne Armstrong, Jeffrey A. Bakal, Christian 
W. Hamm, David R. Holmes, Jr., William W. O’Neill, Frans Van de Werf, Arnoud van’t 
Hof, Daniel B. Mark, University of Alberta, Edmonton, AB, Canada
Background: Several models have been developed to identify low-risk STEMI patients 
undergoing PCI. However, validation of these is lacking and no previous study has used 
two independent risk algorithms (each model essentially “checking” the results of the 
other) to identify truly low-risk patients presumably prime candidates for very early 
discharge (a 48 hours).
Methods: We applied the previously established Zwolle and PAMI risk scores to the APEX-
AMI STEMI patients (n= 5745). Three categories of low risk patients were identiﬁed: 1) 
Zwolle score of 0; 2) PAMI score = 0; 3) Zwolle and PAMI score of 0. We examined length 
of stay and adverse outcomes across the three groups in the overall population and in the 
subset of US patients (n=1236) enrolled in a prospective economic substudy.
Results: A combination of the risk scores proved more effective in identifying low 
risk patients than each individual score (Table). Average LOS among these low risk 
patients was 3 days in the US but almost 5 days in the overall trial. If early discharge 
of these patients had occurred, i.e. reducing LOS from 5 to 2 days it would have saved 
approximately $20 million US ($5,597 per patient per day) in the APEX-AMI cohort.
Conclusion: Use of two independent risk scores in ST elevation MI patients identiﬁed 
a core group (20%) of low risk patients potentially suitable for discharge by day 2. 
Therefore, opportunities exist for more efﬁcient use of resources in the US, but especially 
in Europe. 
Description US patients enrolled in Economic Substudy (N=1236) All patients (N=5745)
Risk Score Zwolle PAMI Z+PAMI Zwolle PAMI Z+PAMI
Number of low-risk 
patients 332 618 277 1325 2652 1154
90-day Death 1 (0.3%) 7 (1.1%) 1 (0.4%) 7(0.5%)
33
(1.3%) 7 (0.6%)
90-day death/heart 
failure/shock 11 (3.3%) 28 (4.5%) 7 (2.5%)
33
(2.5%)
98
(3.7%) 23 (2.0%)
ICU days 1.6 1.7 1.5 2.4 2.5 2.4
Total days 3.2 3.3 3.0 4.7 5.1 4.7
Costs baseline $16,933 $17,767 $16,791
Cumulative 6m costs $19,597 $20,878 $19,377
11:15 a.m.
0919-6 A Risk Score Predicts Compliance to Thienopyridines 
After Coronary Stent Implantation
Alexandre S. Quadros, Dulce Welter, Fernanda Camozzatto, Rogério Sarmento-Leite, 
Carlos A.M. Gottschall, Institute of Cardiology of Rio Grande do Sul / FUC, Porto Alegre, 
Brazil
BACKGROUND: Premature discontinuation of antiplatelet therapy after coronary stenting 
is associated with a signiﬁcant increase of stent thrombosis, myocardial infarction, and 
death. We sought to develop a risk score for thienopyridine compliance on a contemporary 
cohort of patients (pts) treated with coronary stents.
METHODS: Clinical, socioeconomic and angiographic characteristics of pts with coronary 
stent implantation between December 2007 and March 2008 were assessed. In the one-
month follow-up, all pts were asked if they have stopped thienopyridines, the reasons for 
drug discontinuation, and the Morisky Questionnaire was applicated. Multivariate analysis 
was used to identify independent predictors of thienopyridine discontinuation. Points were 
assigned to each variable according to the odds-ratios, and the c-statistic of the score 
was calculated.
RESULTS: The mean age of the 400 pts included was 60.99±10.35 years, and 66 pts 
(16.5%) stopped thienopyridines after one month. Patient reasons for drug discontinuation 
were cost (41 pts, 62%), lack of information regarding the importance of treatment (11 
pts, 17%), and recommendation to stop treatment by another doctor (10 pts, 15%). The 
risk score could range from 0 to 14 points, and the following variables were included: 
not married (1 point), acute coronary syndrome (1 point), nondiabetic (1 point), lack of 
private health insurance (4 points) and salary (0-2 minimum wages=7 points, and 2-3 
minimum wages=3 points). The risk score was strongly associated with thienopyridine 
discontinuation: 0-4 points = 0% of the pts stopped thienopyridines; 5-8 = 7%; 9-12 = 
20%; 13 or more = 37% (p<0.0001; c-statistic = 0.76). The risk score was also signiﬁcantly 
associated with complete adherence (Morisky score=0) (p<0.0001).
CONCLUSIONS: A risk score based on variables obtained before stent implantation 
accurately predicts thienopyridine discontinuation and complete treatment adherence. 
This information can be useful to enhance compliance in vulnerable subgroups of pts, 
and also aid in the decision of implanting a drug-eluting or a bare metal coronary stent in 
those at the highest risks for thienopyridine discontinuation.
